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Psoriasis and psoriatic arthritis relationship
P002
Early treatment of psoriatic arthritis is associated
with improved outcomes: findings
from the etanercept PRESTA trial
Kirkham, Bruce1; Li, Wenzhi2; Boggs, Robert2;
Nab, Henk3; Tarallo, Miriam3
1Guy’s and St Thomas’ NHS Foundation Trust, London,
UK; 2Pfizer Inc., Collegeville, PA, USA; 3Pfizer Europe,
Rome, Italy
Background: The effect of early biologic treatment has
not been well investigated in patients with psoriatic
arthritis (PsA) and psoriasis.
Objective: To compare short versus longer disease
duration in patients with PsA and moderate-to-severe
psoriasis treated with the biologic etanercept (ETN)
50 mg once weekly (QW) for 24 weeks in the PRESTA
trial [1].
Methods: Patients who received C1 dose ETN 50 mg QW
and C1 post-baseline value were evaluated. Mean
changes from baseline at Week 24 were compared in
patients with PsA B2 years versus PsA[2 years in
efficacy measures (physician global assessment [PGA]
arthritis, swollen joint count, and psoriasis area and
severity index [PASI]) and patient-reported outcomes
(PROs; joint pain, arthritis activity, Euro-Qol [EQ-5D]
utility and visual analogue score [VAS], Health
Assessment Questionnaire [HAQ], and Hospital Anxiety
and Depression Scale [HADS]) using linear regression
analysis with age and sex as covariates.
Results: At Week 24, all efficacy measures and PROs
improved significantly from baseline in both the
PsA B 2 years (n = 103) and PsA[2 years (n = 269)
groups. After controlling for age and sex, these
improvements were significantly greater in patients
with PsA B 2 years versus PsA[2 years for PGA
arthritis (-39.8 vs. -35.7; P = 0.0269), joint pain
(-42.1 vs. -34.6; P = 0.0072), arthritis activity (-41.7
vs. -34.9; P = 0.0148), EQ-5D utility (+0.30 vs. +0.24;
P = 0.0457), and EQ-5D VAS (+22.8 vs. +18.7;
P = 0.0402). Improvements from baseline at Week 24
were similar in both disease duration groups for the
swollen joint count, PASI, HAQ, and HADS scores.
Conclusions: Patients with short and longer PsA duration,
with moderate-to-severe psoriasis, responded well to
ETN 50 mg QW treatment; however patients with
shorter PsA duration had significantly greater responses
in several measures. Notably, PROs that incorporate pain
assessments (joint pain and EQ-5D utility) improved
significantly more in patients with PsA B 2 years than
PsA[2 years.
Reference: 1. Sterry W, et al. BMJ 2010;340:c147.
P003
Bone alterations in psoriatic patients: an early sign
of psoriatic arthritis?
Finzel, Stephanie1; Renner, Regina2; Englbrecht,
Matthias1; Schett, Georg1; Rech, Ju¨rgen1;
Sticherling, Michael2
1Department of Internal Medicine 3, Rheumatology
and Immunology, University Hospitals Erlangen,
Erlangen, Germany; 2Department of Dermatology,
University Hospitals Erlangen, Erlangen, Germany
Nail plate, underlying bone and entheses are anatomically
closely related. Recently, autoinflammatory processes
such as enthesitis have been addressed. However, the
exact mechanism of enthesitis spreading towards bone
still has not yet been fully clarified. Therefore the link
between psoriasis and alterations of periarticular bone
was investigated in 30 psoriatic (PSO) patients from our
Dermatology outpatient clinic (19 male, 11 female;
mean age 49.47 ± 14.01). They were examined by
two rheumatologists in addition to a micro-computed
tomography (microCT) scan of the dominant
metacarpophalangeal joints (MCPJ) 2–4. Bone erosions,
new bone formation (NBF) and surface changes (SC)
were assessed both semiquantitatively and metrically.
17/30 patients showed typical bone alterations as
described earlier by our group in psoriatic arthritis
(tPSA), 7/30 had established PSA (ePSA), 5/30 had no
specific bone alterations (healthy bone, HB). None of the
HB cohort showed bone erosions, but 6/7 ePSA (mean
number 2.43/median 1) and 7/17 tPSA (0.71/0); ePSA
score was higher (3.71/2) than in tPSA (0.59/0) as well as
width and depth bigger. NBF-involvement of digits was
D2[D3[D4. HB and tPSA did not show significant
differences in total NBF-numbers or -scores; ePSA
showed distinctly more extensive NBF than HB and
tPSA. However, detailed per-finger analysis showed more
NBF in tPSA (D2: 5.5/4; D3: 4/4.5: D4: 2.38/1.5)
compared to ePSA (3.5/3; 2.38/2; 1.13/1) and HB (2.25/
1.5; 1.63/1; 0.88/1). Interestingly, tPSA and ePSA both
showed NBF of the whole circumference of phalangeal
bases 2 and 3 whereas only ePSA also had NBF at the
ulnar and radial sides of the MCP heads. Moreover, tPSA
had distinct cortical thinning in semiquantitative
SC analysis (tPSA D2: 4.38/3, D3: 4.75/3.5, D4: 6.75/6,
ePSA: 2.38/2.5, 3.75/3.5, 3.5/2.5, HB: 1/0.5, 1.38/1.5,
1.38/1). Even in asymptomatic patients with psoriasis,
periarticular bone alterations typical for PSA can
be found by high resolution imaging technique. Our
findings suggest that early damage is present and
presumably might require early treatment. Whether
tight monitoring or immediate treatment are needed
will have to be further studied.
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P004
Effects of PUVA and narrowband UVB on adenosine
deaminase activities in plasma and tissue samples
of patients with psoriasis
Ozyurt, Kemal1; Ozturk, Perihan1; Yy´ldy´z, Sinem2;
Uksal, Umit3
1KSU Medicine Faculty, Dermatology, Kahramanmaras,
Turkey; 2Kayseri State Hospital, Dermatology, Kayseri,
Turkey; 3Taksim Alman Hospital, Dermatology,
Istanbul, Turkey
Presence of active T lymphocytes in lesions and the
response to immunosupressive agents, strongly support
the possibility that psoriasis is a immunological diseases.
Adenosine deaminase (ADA) activity is a non-specific
marker of T cell activation. ADA activity has been shown to
be increased in diseases characterized by T lymphocyte
proliferation and activation.
In this study, ADA activities were measured in plasma
and tissue samples of patients with psoriasis before and
after PUVA or narrowband UVB treatment as well as in
healthy controls. The severity of the disease was
evaluated before and after treatment according to
Psoriasis Area and Severity Index (PASI) score. Plasma
and tissue ADA levels significantly elevated in patients
with psoriasis compared to control groups. There was a
statistically significant decrease in the ADA levels after
treatment compared to pretreatment values in the same
patients. There was no correlation between ADA levels
and PASI scores.
These results support the evidence that T cell activation
is involved in the pathogenesis of psoriasis and that ADA
may be valuable in the assessment of disease activity in
psoriasis.
P005
Unilateral psoriasis: a case report
Yavuz, Cahit1; Ataseven, Arzu1; Ozturk, Perihan2
1Department of Dermatology, Konya Education and
Research Hospital, Konya, Turkey, Konya, Turkey;
2Department of Dermatology, Kahramanmaras
Sutcuy´mam University, Kahramanmaras, Turkey,
Kahramanmaras, Turkey
Psoriasis is a multifocal, common, chronic inflammatory
skin disease. Unilateral psoriasis is a rare entity. A 28-year-
old man presented with erythematosquamous lesions that
were distributed over the right side of the body. Clinical
examination and results of histopathologic studies
indicated unilateral psoriasis.
P006
Two cases of concomitant vitiligo and psoriasis
Ataseven, Arzu1; Ozturk, Perihan2;
Karaosmanoglu, Ilknur3
1Department of Dermatology, Konya Education and
Research Hospital, Konya, Turkey, Konya, Turkey;
2Department of Dermatology, Kahramanmaras
Sutcuy´mam University, Kahramanmaras, Turkey,
Kahramanmaras, Turkey; 3Department of Pathology,
Konya Education and Research Hospital, Konya,
Turkey, Konya, Turkey
Vitiligo and psoriasis are common dermatoses that occur
in 1–3 and 0.5% of the general population, respectively.
Yet the pathogenesis of the association between these
two dermatoses is still unknown but both are considered
to have an autoimmune component in their
pathogenesis. We report two very rare cases of
concomitant vitiligo and psoriasis. Case 1: is a 31-year-
old man presented with small vitiligo pathches on his
hands, legs and elbows for 10 years. Nine years after the
onset of vitiligo, psoriasis developed on his vitiligo
lesions. Case 2: is a 51-year-old man. His psoriasis and
vitiligo lesions started at the same time. Both lesions
exist on hands, knees, elbows and face. Based on clinic
and histopathologic findings; we present two cases of
concomitant vitiligo and psoriasis.
P007
The prevalence of rheumatologist-diagnosed
psoriatic arthritis in psoriasis patients in European/
North American dermatology clinics: Results
of the PREPARE study
Mease, Philip J.1; Papp, Kim A.2; Gladman, Dafna3;
Thaci, Diamant4; Northington, Robert5; Fuiman,
Joanne5; Boggs, Robert5; Alvarez, Daniel5
1Swedish Medical Center, University of Washington
School of Medicine, Seattle, WA, USA; 2Probity Medical
Research, Waterloo, Ontario, Canada; 3University of
Toronto, Toronto, Ontario, Canada; 4J. W. Goethe
University, Frankfurt, Germany; 5Pfizer Inc,
Collegeville, PA, USA
Introduction: Psoriatic arthritis (PsA) is a debilitating
inflammatory disease associated with permanent joint
damage, which may be prevented with prompt,
appropriate treatment. (1) Prevalence estimates of PsA
in psoriasis patients range from 7 to 48%. (2) Further
study is needed to confirm PsA prevalence and raise
awareness of the need for thorough PsA screening.
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Objective: To assess PsA prevalence in psoriasis patients
seen in 34 dermatology centers in Europe and North
America.
Methods: Consecutive psoriasis patients from
dermatology centers were evaluated by rheumatologists
for a clinical diagnosis of PsA with/without the aid of
laboratory tests. Dermatology centers included primary,
secondary (primary + referred patients), and tertiary
(referred only) centers.
Results: Of 949 patients evaluated, 285 (30%) had PsA
(95% CI: 27%, 33%). The highest prevalences were
observed in Denmark (n/N = 49/117; 42%), Hungary
(64/169; 38%), the US (35/98; 36%), and Germany (65/
189; 34%); the lowest in France (12/44; 27%), Belgium
(6/33; 18%), and Canada (54/299; 18%). PsA patients on
average had slightly more severe psoriasis (body surface
area, 9.6% vs. 7.7%; p = 0.015) and had slightly longer
psoriasis duration (21.7 vs. 19.1 year, p = 0.006) than
patients without PsA. The PsA diagnosis changed in only
1.2% of patients when diagnostic laboratory tests were
added. The prevalence of PsA did not differ based on
center type (primary, 31.0% [95% CI: 27.2%, 35.0%];
secondary, 24.9% [95% CI: 19.1%, 31.4%]; or tertiary,
32.9% [95% CI: 26.0%, 40.5%]; p = 0.170). Of 285
patients diagnosed with PsA, 117 (41%) had not
previously been diagnosed; 47 (7%) of 664 PsA-negative
patients had previously been diagnosed with PsA.
Conclusions: In this large, multinational prevalence
study, almost a third of psoriasis patients seen in
dermatology centers had PsA as determined by a
rheumatologist. More than a third of patients with PsA
had not previously been diagnosed. Given that untreated
PsA can lead to permanent joint damage, monitoring for
joint disease in psoriasis patients is paramount.
References: 1. Ritchlin CT et al. Ann Rheum Dis.
2009;68:1387–94. 2. Gladman DD. J Rheumatol.
2009;36(suppl 83):4–8.
P008
Epidemiology of psoriasis and psoriatic arthritis
in Scotland
McHattie, Lorna W.1; Diack, H. Lesley1; Stewart,
Derek1; Ormerod, Anthony O.2; Burden, A. David3
1Robert Gordon University, School of Pharmacy and
Life Sciences, Aberdeen, UK; 2University of Aberdeen,
Aberdeen, UK; 3Greater Glasgow and Clyde Health
Board, Department of Dermatology, Glasgow, UK
Aim: To describe the severity and prevalence of psoriasis
and psoriatic arthritis in two health board areas in
Scotland.
Background: Prevalence data were collected as part of a
large study investigating the pathway of care for people
with psoriasis and psoriatic arthritis.
Method: The Scottish Primary Care Research Network
collected data from Primary Care patient records to
measure the prevalence of psoriasis, using National
Health Service diagnostic codes. These data were used
to recruit 2,000 participants for a cross-sectional survey
investigating perceptions of and satisfaction with the
care pathway. An expected 30% response rate would
yield 77% power. Questionnaires were sent to psoriasis
patients from GP practices and returned to the Robert
Gordon University. Data were entered into SPSS and
analysed using frequencies and v, with a level of
significance p\0.05.
Results: Analysis of GP records identified psoriasis
prevalence of 2.4% in this population. The response
rate to the questionnaire was 673 (33.7%), additionally
107 responded on-line. 46.9% (366) perceived their
psoriasis to be mild, 39.6% (309) moderate and 10.9%
(85) severe. Severity was also measured by SAPASI, which
correlated to self perception of mild/moderate/severe
(Spearmans Rho, p\0.05).
19.7% (153) participants reported a diagnosis of psoriatic
arthritis (PsA): mild in 21.6% (33), moderate in 47.7%
(73) and severe in 24.8% (38). Of those NOT reporting a
diagnosis of PsA (n = 615), 17.1% (105) had symptoms
suggestive of arthritis and of these 77.3% (77) had
frequent joint pain and/or joint stiffness. For patients
with confirmed PsA, 55.6% (85) had joint swelling on
first presentation to GP. For patients WITHOUT a
diagnosis of PsA, diagnosis, but with joint stiffness/
pain 18.1% (19) reported joint swelling.
Conclusions: Most people with psoriasis had mild/
moderate symptoms (86.5%), whereas most people
with PsA had moderate/severe symptoms (75.4%). Joint
swelling could be the trigger for psoriatic patients to
discuss their arthritic symptoms. This suggests further
investigation as an indicator for earlier diagnosis and
supports the need for an annual review in Primary Care.
P009
Comparison of composite disease activity scores
in psoriatic arthritis
Helliwell, Philip1; FitzGerald, Oliver2;
Pedersen, Ronald3; Bananis, Eustratios3
1Section of Musculoskeletal Disease, University of
Leeds, Harehills Lane, Leeds, UK; 2St. Vincent’s
University Hospital, Dublin, Ireland; 3Pfizer Inc.,
Collegeville, PA, USA
In the absence of a psoriatic arthritis (PsA)-specific
composite disease activity score, rheumatoid arthritis
composite scores have predominantly been utilized
although they do not incorporate outcomes for
accurate PsA assessment. Several PsA-specific composite
measures are in development. The purpose of this
analysis is to assess the performance and relationship
between existing and novel PsA composite measures for
evidence of validation.
Observed data from the PRESTA trial, a randomized
study evaluating 2 etanercept (ETN) dose regimens in
psoriasis pts with active PsA, were analyzed. The
modified composite psoriatic disease activity index
(mCPDAI), disease activity index for PsA (DAPSA), PsA
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disease activity score (PASDAS), and arithmetic mean
desirability function (AMDF) were calculated at BL and
Wk 12 and 24 and compared between dosing regimens.
Spearman correlations, paired t-tests, and ANCOVA
models were used. mCPDAI uses 4 domains: joints (66/
68 SJC/TJC, HAQ), skin (PASI, DLQI and or PGA),
dactylitis, and enthesitis for a score of 0–12 or 0–24.
DAPSA sums pt global and joint pain VAS assessments,
66/68SJC/TJC,andCRPforascoreof0–160.PASDASutilizes
pt and physician global VAS, 66/68 SJC/TJC, CRP, predicted
physical component score, dactylitis, and enthesitis. AMDF
is calculated from pt skin, joints, and global VAS
assessments, PASI, 66/68 SJC/TJC and HAQ for a score 0–1.
All indices could distinguish response to treatment
comparing BL and 12/24-wk values. Of the 4 measures,
mCPDAI and AMDF were able to differentiate between the
dosing regimens at Wk 12 (P\0.05). Although most
measures did not correlate well at BL, all were highly
correlated at Wks 12/24. The strongest correlations at Wks
12/24 were between AMDF vs. PASDAS and DAPSA
(r[0.79). mCPDAI was correlated with all indices
(r[0.70) including other modified versions of mCPDAI
(r[0.93). Similar findings were observed with only AMDF
utilizing LOCF analysis. In addition to distinguishing
treatment responses, both AMDF and mCPDAI which
better reflect most PsA disease domains, strongly correlate
with other composite measures. Further clinical trial
analysis and validation of measures is required.
P010
High prevalence of articular involvement
in patients with severe psoriasis with poor
performance of screening questionnaires
Haroon, Muhammad1; Kirby, Brian2;
FitzGerald, Oliver1
1St Vincent’s University Hospital, Department of
Rheumatology, Dublin, Ireland; 2St Vincent’s
University Hospital, Department of Dermatology,
Dublin, Ireland
Background and objectives: Delay in diagnosis of psoriatic
arthritis (PsA) remains a significant contributor to poor
patient outcome. The objectives of this study were: (1) to
assess the prevalence of PsA among Ps patients attending
dermatology clinics; (2) to identify clinical predictors of
the development of PsA; and (3) to compare the
performance of 3 PsA screening questionnaires—PASE,
PEST, and ToPAS.
Methods: Patients were divided into two groups: group 1,
consecutive patients with skin psoriasis attending
dermatology clinics who have no known diagnosis of
inflammatory arthritis; group 2, consecutive patients
attending rheumatology clinics with a confirmed
diagnosis of PsA. The diagnosis of PsA was made using
the CASPAR criteria. In group 1, patients completed the
screening questionnaires, followed by a thorough
rheumatologic evaluation whether or not they reported
musculoskeletal symptoms.
Results: 200 patients were recruited; 100 in each group.
84% of patients in Group1 were using systemic therapy for
their skin disease, and 99% of patients in Group 2 were on
systemic immunosuppressives. InGroup 1,29%ofpatients
were diagnosed with PsA after rheumatologic evaluation.
On univariate and multivariate analysis, the only
significant positive association was noted between high
PASIs and the new diagnosis of PsA (p = 0.046), even
after adjusting for confounders such as, age, gender, use
of TNFi, duration of psoriasis and the presence of nail and
scalp disease ever in the disease course. A strikingly
different pattern of joint involvement was noted in
patients with newly diagnosed PsA versus patients with
established PsA with fewer polyarticular disease
(p = 0.0001). In Group 1, the PEST, PASE and ToPAS
had sensitivities of 27.5, 24 and 41%, and specificities of
98, 94 and 90%, respectively; however, in Group 2, the
sensitivities were 86, 62 and 83%, respectively.
Conclusions: 29% of Ps patients attending dermatology
clinics had undiagnosed PsA. Psoriasis severity was
associated with the diagnosis of PsA. Poor sensitivities
for the screening questionnaires was noted, due to
inadequate recognition of patterns of arthritis other
than that of polyarticular disease.
P011
Prevalence of psoriatic arthritis in psoriatic patients
attending dermatologists’ units in Spain:
PREVAL study
Zarco, Pedro1; Lo´pez-Estebara´nz, Jose Luis2;
Ferna´ndez-Sueiro, Jose Luis3; Garcı´a-Calvo, Carmen4
1Fundacio´n Hospital Alcorco´n, Department of
Rheumatology, Alcorco´n, Madrid, Spain; 2Fundacio´n
Hospital Alcorco´n, Department of Dermatology,
Alcorco´n, Madrid, Spain; 3Hospital Universitario Juan
Canalejo, Department of Rheumatology, A Corun˜a,
Spain; 4Pfizer Spain, Medical Department, Madrid, Spain
Background and objectives: Psoriatic patients present an
increase risk for development psoriatic arthritis (PsA).
Dermatologists may play a relevant role in the detection
of early joint symptoms. The main aim of this study was to
evaluate the prevalence of PsA in a population of psoriatic
patients attended by dermatologists and then referred to
rheumatologists’ units for PsA diagnosis confirmation.
Methods: Non-interventional, cross-sectional study
conducted in 40 hospitals in Spain in 2010–2011. A total
of 375 psoriatic patients were screened for PsA suspicion by
dermatologists. The PASE questionnaire (Psoriatic Arthritis
Screening and Evaluation Questionnaire) was used as a PsA
screening tool. All patients were referred to the
rheumatology units for PsA evaluation, accordingly to
Classification Criteria for Psoriatic Arthritis—CASPAR—
and Moll and Wright criteria; overall, 130 patients who
fulfilled criteria for PsA and other arthropathies were
evaluated for clinical activity at the rheumatologists’ units.
Results: Overall, 32.6% (n = 121) of psoriatic patients
were positively screened for PsA by dermatologists. The
prevalence of PsA resulted in 22.9% (n = 86) after
Dermatol Ther (2012) 2:10 Page S5 of S67
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confirmation by rheumatologists’ evaluation; of them,
68.6% (n = 59) patients had been suspected of PsA by
dermatologist. A total of 51.2% of patients diagnosed of
PsA by rheumatologists presented a score equal or higher
than 44 in the PASE questionnaire. Correlation between
dermatologists and rheumatologists diagnosis of PsA was
0.410; whereas correlation between CASPAR and Moll
and Wright criteria was 0.900. Overall 47 patients were
diagnosed by rheumatologists of other arthropathies
different from PsA; being osteoarthritis (51.1%; n = 24)
and non inflammatory low back pain (27.7%; n = 13)
the most frequent diagnosis.
Conclusions: The prevalence of PsA in patients attending
dermatologists’ units observed in our study was
approximately 23%. The PASE questionnaire for the
screening of PsA by dermatologists seems to have a
moderate predictive value. It was also observed a
moderate correlation between dermatologists and
rheumatologists at the time of diagnosing PsA. Study
promoted by Pfizer Spain, S.L.U.
Genetics
P012
Search and exploration candidate genes and their
role in pathogenesis of psoriasis
Sobolev, Vladimir1; Soboleva, Anna2;
Mezentsev, Alexandre2; Bruskin, Sergey2
1Institute of General Genetics, Functional Genomics;
2Institute of General Genetics, Functional Genomics,
Moscow, Russian Federation; 3Gubkina Street, room
302, Moscow, Russian Federation
Purpose of this study was to conduct a search for
candidate genes as well as identify and characterize
one of the molecular mechanisms standing behind the
development of psoriatic skin lesions.
Results: We performed a bioinformatics analysis of gene
expression (GEO dataset GSE6710) in uninvolved and
lesional psoriatic skin as well as gene ontology and
networking analyses. This analysis revealed a signaling
pathway leading from IL-17 to the target genes such as
matrix metalloproteases through the transcription
factors (AP-1 and NF-kB). Metalloproteases are one of
the key in the development of pathological process in
psoriasis. Comparing gene expression in uninvolved and
lesional epidermis by qPCR we found elevated levels of
matrix metalloproteinases—MMP-1, -9, -12 as well as
proinflammatory cytokine, IL-17, and decreased levels of
C-JUN, JUN-B, JUN-D and C-FOS, which are four major
components of the transcription factor, AP-1. We also
discovered that treatment of the patients with laser
radiation of low intensity (k = 1.27 nm) or interference
therapy normalized expression of these genes and also
accompanied by remission of the disease suggesting an
important role of these genes in pathogenesis of
psoriasis. Moreover, we found that induction of
primary or immortalized keratinocytes by interleukin
IL-17 in vitro also activated expression of MMP-1, -9, -12,
while Inhibition of interleukin-17 pathway dramatically
decreased their expression.
In conclusion, our data indicate on a direct link between
IL-17 and activation of metalloproteases in psoriasis.
This mechanism correlates with flow of the disease and
involves the transcription factor, AP1, primarily four
components of this heterodimeric complex, C-JUN,
JUN-B, JUN-D and C-FOS.
P013
Risk variants for psoriasis in a large case–control
collection and association with clinical
subphenotypes
Julia`, Antonio1; Tortosa, Rau¨l1; Hernanz, Jose´
Manuel2; Can˜ete, Juan D3; Fonseca, Eduardo4;
Ferra´ndiz, Carlos5; Unamuno, Pablo6; Puig, Lluı´s7;
Ferna´ndez-Sueiro, Jose´ Luı´s4; Sanmartı´, Raimon3;
Rodrı´guez, Jesu´s8; Grataco´s, Jordi9; Dauden,
Esteban10; Sa´nchez-Carazo, Jose´ Luı´s11; Lo´pez-
Estebaranz, Jose´ Luı´s12; Moreno-Ramı´rez, David13;
Queiro´, Rube´n14; Montilla, Carlos15; Torre-Alonso,
Juan Carlos16; Pe´rez-Venegas, Jose´ Javier17;
Vanaclocha, Francisco18; Herrera, Enrique19; Mun˜oz-
Ferna´ndez, Santiago20; Gonza´lez, Carlos2; Roig,
Daniel21; Erra, Alba22; Acosta, Isabel1; Ferna´ndez-
Nebro, Antonio23; Zarco, Pedro12; Alonso, Arnald1;
Lo´pez-Lasanta, Marı´a1; Garcı´a-Montero, Andre´s24;
Gelpı´, Josep Lluı´s25; Absher, Devin26; Marsal, Sara1
1Vall d’Hebron Hospital Research Institute, Barcelona,
Spain; 2Hospital Universitario Gregorio Maran˜o´n,
Madrid, Spain; 3Hospital Clı´nic de Barcelona,
Barcelona, Spain; 4Complejo Hospitalario Juan
Canalejo, A Corun˜a, Spain; 5Hospital Universitari
Germans Trias i Pujol, Barcelona, Spain; 6Hospital
Universitario de Salamanca, Salamanca, Spain;
7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;
8Hospital Universitari de Bellvitge, Barcelona, Spain;
9Hospital Parc Taulı´, Sabadell, Spain; 10Hospital
Universitario La Princesa, Madrid, Spain; 11Hospital
General Universitario de Valencia, Valencia, Spain;
12Hospital Universitario Fundacio´n Alcorco´n, Madrid,
Spain; 13Hospital Universitario Virgen Macarena,
Sevilla, Spain; 14Hospital Universitario Central de
Asturias, Oviedo, Spain; 15Hospital Virgen de la Vega,
Salamanca, Spain; 16Hospital Monte Naranco, Oviedo,
Spain; 17Hospital de Jerez de la Frontera, Ca´diz, Spain;
18Hospital Universitario 12 de Octubre, Madrid, Spain;
19Hospital Universitario Virgen de la Victoria, Ma´laga,
Spain; 20Hospital Universitario Infanta Sofı´a, Madrid,
Spain; 21Centre d’Atencio´ Especialitzada de Cornella`,
Barcelona, Spain; 22Hospital Sant Rafael, Barcelona,
Spain; 23Hospital Regional Universitario Carlos Haya,
Ma´laga, Spain; 24Universidad de Salamanca,
Salamanca, Spain; 25Barcelona Supercomputing
Centre, Barcelona, Spain; 26HudsonAlpha Institute for
Biotechnology, Huntsville, USA
Background: Psoriatic Arthritis (PsA) is a complex disease
with a substantial genetic risk component (first-degree
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relative risk *55). Recently, Genomewide Association
Studies (GWAS) have expanded the number of risk loci
for Psoriasis (Ps) in[20 new loci.
Objectives: We have studied the association of Ps risk loci
in PsA and purely cutaneous Ps (PsC). We have also
analyzed the genetic association with several
subphenotypes of clinical relevance.
Methods: Loci showing the strongest statistical evidence
of association to Ps were selected (n = 32). The SNP
having the highest statistical evidence was genotyped
using Taqman technology in a cohort of n = 955 PsA,
1,050 PsC and 1,497 hypernormal controls of the
Spanish population. According to each subphenotype
variable, the genetic association was performed using
the Chi-square test, logistic regression or linear
regression.
Results: We have replicated the association to COG6 and
SERPINB8 loci with Ps for the first time in a Caucasian
population. We have identified, for the first time, an
association of PsA with variation at IFIH1 (P = 0.00023),
DPP6 (P = 0.0027) and COG6 (P = 0.0072). Analyzing
the association with other clinically relevant
subphenotypes we have identified a strong association
of LCE3D locus with the severity of cutaneous affection
(P = 1.8 9 10E - 5). We have also found a significant
association of IL1RN gene with nail disease (P = 0.0028).
We replicated the previously described interaction of
HLA-C and ERAP1 in the PsC cohort but not in the PsA
cohort. We identified, for the first time, a significative
epistatic association between HLA-C and SERPINB8
(P = 0.014). In PsA, no statistically significant
interactions where identified with variation at HLA-C.
However, 6 of the studied genes showed a significant
(P\0.05) association with HLA-B27 positivity.
Conclusions: Our findings show that common genetic
variants associated to a complex phenotype like PsV
influence PsA as well as different subphenotypes of high
clinical relevance.
P014
Influence of VEGF gene polymorphisms on clinical
features of psoriatic arthritis and SAPHO syndrome
Przepiera-Bedzak, Hanna1; Ciechanowicz, Andrzej2;
Brzosko, Iwona1; Brzosko, Marek1
1Pomeranian Medical University in Szczecin,
Department of Rheumatology and Internal Diseases,
Szczecin, Poland; 2Pomeranian Medical University in
Szczecin, Department of Laboratory Diagnostics and
Molecular Medicine, Szczecin, Poland
Aim of the study: To investigate the role of
polymorphisms of the vascular endothelial growth
factor (VEGF) gene C(-2578)A in PsA and SAPHO
syndrome and its relationship to clinical features.
Materials and methods: We studied 61 PsA patients and 16
SAPHO syndrome patients. The following data were
recorded: age, sex, disease duration, presence of
peripheral joint involvement, radiological changes,
spinal anterior and lateral flexion. Skin changes in PsA
patients were assessed according Psoriatic Arthritis Skin
Index (PASI) score. Clinical activity of the disease was
assessed according following indexes: Clinical activity
of the disease was assessed according following
indexes: BASMI, BASFI, BASDAI, BASG, HAQ score
and SF-36 score. We assessed ESR, CRP, platelets
level (PLT), hemoglobin level, leukocyte level. Serum
VEGF levels were determinate using ELISA method.
The polymorphisms C(-2578)A was genotyped by
polymerase chain reaction restriction fragment length
polymorphism PCR–RFLP.
Results: The mean age of PsA patients was
49.9 ± 12.6 years. The mean disease duration was
5.1 ± 4.7 years. The mean value of VEGF serum levels
in PsA group was 371.2 ± 286.1 pg/ml. The mean age of
SAPHO patients was 51.8 ± 10.9 years. The mean disease
duration was 2.8 ± 1.7 years. The mean value of VEGF
serum levels in SAPHO group was 363.7 ± 203.9 pg/ml.
Clinical features were analysed for the three genotypes:
AA, CA, CC. The genotype AA was present in 26.2% PsA
patients and 43.8% SAPHO patients. The genotype CA
was present in 45.9% PsA patients and 43.8% SAPHO
patients. The genotype CC was present in 27.9%
PsA patients and 12.4% SAPHO patients. In group with
active disease increased ESR was connected with
genotype CA in 39.3% of PsA patients. In group
with active disease increased CRP was connected with
genotype CC in 38.5% of PsA patients. In PsA the
peripheral joint involvement was connected with
genotype CA.
Conclusions: We conclude that VEGF gene
polymorphisms influence on clinical features of
psoriatic arthritis. Genotype CA is connected with
peripheral course of the disease and increased disease
activity in PsA patients.
P015
Association of HLA class I and II alleles
with psoriasis in Pakistani population
Munir, Saeeda1; Rahman, Simeen Ber2; Saba, Nusrat1;
Mazhar, Kehkashan1; Ahmad, Wasim3;
Rehman, Sadia1
1Institute of Biomedical and Genetic Engineering,
Islamabad, Pakistan; 2Simeen’s Skin and Laser Centre,
Peshawar Road, Rawalpindi, Pakistan; 3Quaid-i-Azam
University, Islamabad, Pakistan
Introduction: Psoriasis is a complex inflammatory
disorder characterized by sharply demarcated
erythematous papules and plaques with abundant
silvery white scales. The etiology of psoriasis is not
completely known. However it is clear that both genetic
and environmental factors play role in the pathogenesis
of psoriasis. The prevalence of psoriasis varies with
ethnic groups and geographical locations, with an
overall prevalence of approximately 2% of the world’s
population. The association of Human Leukocyte
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Antigen (HLA) alleles with psoriasis is well documented
in several population based studies. Numerous HLA class
I and II alleles have been reported to be associated with
psoriasis. Among these, the HLA class I alleles HLA-
Cw*06 and B*57 have been reported consistently
worldwide.
Objectives: The main aim of this study is to screen
Pakistani psoriasis patients and healthy controls for HLA
class I and II alleles as there is no data reported so far
regarding the association of HLA alleles with Pakistani
psoriasis patients.
Methodology: Our study included 290 patients (216 males
and 74 females) and 183 healthy ethnically matched
control samples. HLA alleles were typed using sequence-
specific PCR. The distribution of HLA allelic frequencies
were further analyzed according to different phenotypes
and age of onset. The data was analyzed using statistical
programme like SPSS ver 10.0 and Arlequin 3.0.
Results: This study is the first to be reported on Pakistani
psoriasis patients and we found some allelic associations
that were already reported and also found some novel
associations. In case of HLA class I A*01, B*57, B*37 and
Cw*0602 allelic frequencies were found to be higher in
patients whereas A*33, B*51, Cw*0702, Cw*15 allelic
frequencies were higher in control samples. In case of
HLA class II DRB1*0701 and DQB1*03032 allelic
frequencies were higher in patients and DRB1*03 and
DQB1*02 allelic frequencies were higher in control
group.
Conclusion: This study will give an insight about the role
of HLA alleles in the prognosis of psoriasis and will help
in future diagnosis and treatment of the disease.
P016
Different genetic background separates prepubertal
and postpubertal onset of psoriasis
Lysell, Josefin1; Padyukov, Leonid2; Kockum, Ingrid3;
Nikamo, Pernilla4; Stahle, Mona4
1Department of Medicine, Unit of Dermatology and
Venereology, Stockholm, Sweden; 2Department of
Medicine, Unit of Rheumatology, Stockholm, Sweden;
3Department of Clinical neuroscience, Stockholm,
Sweden; 4Institution of Medicine, Unit of Dermatology
and Venereology, Stockholm, Sweden
The genetic background of psoriasis is strong and several
susceptibility genes have been identified with HLA-
Cw*0602 remaining the strongest candidate. Precisely
how HLA-C contributes to psoriasis is however unclear.
Evidence for an interaction between HLA-C and
endoplasmic reticulum aminopeptidase 1, ERAP1,
confined to individuals carrying the HLA-C risk allele
was recently presented. ERAP1 plays a crucial role in
MHC class I peptide processing and is involved in cell
surface shedding of proinflammatory cytokine receptors,
altogether suggestive of a potential involvement in
psoriasis pathogenesis. Psoriasis displays wide clinical
variation and genetic heterogeneity likely contributes
substantially to clinical diversity. Therefore, stringent
stratification for sub-phenotypes may be crucial in
genetic analyses. Age of onset is an obvious phenotype
and separating psoriasis into type I (onset\40 years of
age) and Type II ([40 years of age) has been useful. To
sharpen the age—dependant phenotype, we performed a
more detailed stratification comparing genotypes for
ERAP1 and HLA-Cw*0602 in four age groups: disease
onset below 10 years, between 10 and 20, 20 and 40 and
above 40 years. Herein we confirm association to ERAP1
in patients with disease onset between 10 and 20 years,
but lack of association in other groups including those
with onset before 10 years. The latter group also displays
a significant lower association to HLA-Cw*0602 than
children with onset between 10 and 20 years but
comparable to those with disease onset between 20
and 40 years of age.
P017
A qualitative analysis of digitopalmar
dermatoglyphics in 400 psoriasis and psoriatic
artrhritis patients from Croatia
Jajiæ, Zrinka
University Department of Physical Medicine, Sestre
Milosrdnice University Hospital, Zagreb, Croatia
Objective: By one of very simple and inexpensive genetic
method, we were analysed dermograms of hands in 140
psoriatic patients (70 males and 70 females), and 260
psoriatic arthritis patients (130 males and 130 females),
with a view to differential diagnostics between psoriasis
and psoriatic arthritis from the one side and among five
psoriatic arthritis clinical subgroups, from the other side.
Namely, between 14th and 25th week of intrauterine
dermatoglyphics development on hands, there is certain
possibility that this early period, the simultaneous
pathogenetic mechanism operated on dermatoglyphic
drawing, and on group of genes responsible for psoriasis
and psoriatic arthritis. Dermatoglyphics stay
unchangeable to the end of life, and always were
available for analysis after delivery. The data obtained
were compared with those recorded in a control group of
400 (200 males and 200 females) pairs of imprints of
phenotipycally helathy adults from the Zagreb area.
Palm and finger prints were taken onto the adhesive
transparent tape by silver powder, used in criminalistics.
Statistically significant differences were found in male
psoriatics to control in 10, female psoriatics to control in
5 variables, male psoritatic arthritis patients to control in
7 variables, and female psoriatic arthritis patients to
control in 5 variables. Then, in male psoriatics to male
psoriatic arthritis patients in 10 variables, and female
psoriatics to psoriatic arthritis patients in 9 variables.
Statistically significant differences were found to control
among male psoriatic arthritis in 35 variables, and
among female psoriatic arthritis to control in 40
variables. Then, among five clinical subgroups of male
psoriatic arthritis patients in 87 variables and among
Page S8 of S67 Dermatol Ther (2012) 2:10
123
five clinical subgroups of female psoriatic patients in
65 variables. In conclusion we could say that
dermatoglyphics came to existence as an important
tool for genetics in psoriasis and psoriatic arthritis, and
in their differential diagnostics.
In conclusion we could say that dermatoglyphics came
to existence as an important tool for genetics in psoriasis
and psoriatic arthritis, and in their different diagnostic.
P018
Time to event and progressive multi-state analyses
confirm the association between human leukocyte
antigen alleles and the development of arthritis
mutilans in patients with psoriatic arthritis
Chandran, Vinod1; Cook, Richard2;
Thavaneswaran, Arane3; Lee, Ker-Ai2;
Fawnda, Pellett3; Gladman, Dafna3
1Toronto Western Hospital, Division of Rheumatology,
1E416, 399 Bathurst Street, Toronto, Canada;
2University of Waterloo, Department of Statistics and
Actuarial Science, Waterloo, Canada; 3Toronto
Western Hospital, Division of Rheumatology, Toronto,
Canada
Objective: To identify HLA alleles associated with
development of Arthritis Mutilans (AM), the most
severe form of psoriatic arthritis (PsA).
Methods: Radiographs of hands and feet were obtained at
baseline and at 2-yearly intervals from a large cohort.
AM was defined as C5 joints with grade 4 damage using
the modified Steinbrocker method. The time when
joints with grade 4 damage was first observed was
obtained on 610 Caucasian subjects. Parametric
survival analyses were carried out using a Weibull
regression model, adjusted for age at diagnosis of PsA
and sex, to identify HLA alleles associated with the
interval-censored time to development of AM. This
analysis ignores the information provided by time of
development of grade 4 damage in the first 4 joints.
Multi-state analysis modeling the transition from no
grade 4 damage to 1, 2, 3, 4 and finally C5 joints with
grade 4 damage was therefore conducted.
Results: 610 subjects (58% males, age at diagnosis
36 years, duration of PsA 7 years at first visit) had a
median of 3 radiographs during a median follow up of
6.3 years. 97 (16%) subjects developed AM. Univariate
survival analyses showed that HLA-B*27 and -DQB1*02
alleles are associated with an increased hazard of
developing AM whereas HLA-A*11 and -C*04 are
associated with a reduced hazard. Multivariate analysis
showed that HLA-B*27 (HR 2.14, p\0.01) and
-DQB1*02 (HR 1.80, p\0.01) are independently
associated with increased risk whereas HLA-A*11 (HR
0.36, p = 0.03) and -A*29 (HR 0.22, p = 0.04) are
associated with lower risk. Univariate multi-state
transition analyses showed that HLA-C*01, -B*08,
-B*27, -DQB1*02 increases risk of transition through
each state whereas HLA-A*11, -C*03, -C*04 and -B*60
decreases risk. Multivariate multi-state transition
analysis using a reduced common effects model
confirmed that HLA-B*27 (RR 1.50, p = 0.001) and
C¨DQB1*02 (1.42, p = 0.001) increases risk and HLA-
C*03 (0.77, p = 0.013) decreases risk.
Conclusion: Time to event and progressive multi-state
analyses suggest that HLA-B*27 and -DQB1*02 are
associated with increased risk of developing AM in PsA.
Pathophysiology and immunobiology
P019
Anti-inflammatory potential of bacterial
components
Zakostelska, Zuzana1; Kverka, Miloslav1; Klimesova,
Klara1; Rossmann, Pavel1; van der Zee, Ruurd2;
van Eden, Willem2; Tlaskalova-Hogenova, Helena1
1Institute of Microbiology AS CR, Department of
Immunology and Gnotobiology, Prague, Czech
Republic; 2Utrecht University, Faculty of Vererinary
Medicine, Department of Infectious diseases and
Immunology, Utrecht, Netherlands
Uncontrolled activation of macrophages could be
involved in the development of chronic inflammatory
diseases, such as psoriasis, rheumatoid and psoriatic
arthritis and inflammatory bowel disease. Recently, it
was demonstrated that activities of macrophages can be
modulated either negatively or positively by bacterial
components. The aim of our study was to evaluate the
immunomodulatory effect of selected bacterial
components in the process of macrophage activation.
Macrophage cell line RAW 264.7 was activated by
lipopolysacharide and cultivated with various
concentrations of bacterial lysates prepared from
Lactobacillus casei DN-114-001 (Lc), Lactobacillus
plantarum (Lp), Parabacteroides distasonis (Pd) and
recombinant mycobacterial heat shock proteins 60, 70
(HSP) for 24 h at 37 C and 5% CO2 in DMEM. After
cultivation, the concentration of cytokines in the
supernatants was measured by ELISA (TNF-a) and
cytokine antibody arrays. NFjB assay kit was used to
detect changes in the binding activity of subunit p65 in
NFjB pathway. Macrophage viability and polarization to
M1 or M2 stage was performed by FACS analysis.
We found that bacterial components obtained from Lc,
Pd, and HSP significantly decrease the production of
TNF-a in LPS-activated RAW 264.7 cells in dose
dependent manner, while similarly prepared Lp did
not. Lc, Pd and HSP significantly decreased the NF-jB/
DNA binding activity of p65 subunit as compared to the
LPS-only or Lp + LPS treated macrophages. Additionally,
we found that M2 phenotype marker, the mannose
receptor CD206 was significantly upregulated and M1
phenotype marker IL-7R downregulated in LPS + Lc
treated macrophages as compared to either LPS or
LPS + Lp treated macrophages. Therefore, Lc seems to
counteract the LPS mediated M1 polarization.
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These results suggests that some bacterial components
exert beneficial immunomodulatory activity and could
be considered as a powerful tool in the treatment of
inflammatory disorders.
P020
The role of human microRNA-31 in psoriasis
Xu, Ning; Meisgen, Florian; Sta˚hle, Mona;
Sonkoly, Eniko¨; Pivarcsi, Andor
Karolinska Institutet, Unit of Dermatology,
Department of Medicine, Stockholm, Sweden
MicroRNAs (miRNA) are *22 nucleotides single-
stranded noncoding RNAs, which play important roles
in gene regulation. We previously identified a specific
miRNA expression profile in psoriasis, distinct from that
of healthy skin. One of the miRNAs upregulated in
psoriasis skin was miRNA-31 (miR-31). By in situ
hybridization we showed that the major cell type
responsible for increased miR-31 levels in psoriasis
lesions was keratinocytes. We found that TGF-b1, a
cytokine highly expressed in the epidermis and serum of
psoriatic patients, up-regulated miR-31 expression in
keratinocytes both in vitro and in vivo. To explore the
role of miR-31 on cellular functions, we transfected miR-
31 inhibitor oligonucleotides into primary human
keratinocytes. Interestingly, inhibition of endogenous
miR-31 decreased keratinocyte proliferation rate and
suppressed the production of several chemokines
playing key roles in psoriasis, such as CXCL1, CXCL5
and CXCL8. Furthermore, we identified genes regulated
by miR-31 in keratinocytes by microarray expression
profiling. Among these genes, we identified serine/
threonine kinase 40 (STK40), a modulator of NF-jB
signalling, as a direct target for miR-31 by luciferase
reporter assays. Inhibition of STK40 by siRNA rescued
the suppressive effect of miR-31 inhibitors on
chemokine expression indicating that miR-31 regulates
chemokine expression by targeting STK40 in
keratinocytes. Taken together, our results demonstrate
a role for miR-31 in regulating keratinocyte proliferation
and chemokine expression. MiR-31 may become a novel
target for psoriasis therapeutic intervention.
P021
Langerhans cells in psoriasis
Wike´n, Maria; Cheuk, Stanley; Bergh, Kerstin;
Sta˚hle, Mona; Eidsmo, Liv
Karolinska Institutet, Medicine, Stockholm, Sweden
Introduction: Psoriasis is a chronic inflammatory disorder,
in which a vigorous infiltration of T cells, neutrophils
and dendritic cells (DCs) occurs in the skin. DCs is a
heterogeneous cell population that exhibit a wide
complexity in inflamed skin and little known of their
role in psoriasis. Human DCs residing in healthy
epidermis, i.e. Langerhans cells (LCs), are characterized
by Langerin, CD1a, EpCAM and HLA-DR expression.
Upon antigen uptake they migrate to regional lymph
nodes. The exact role of LCs in infection and
inflammation is not known despite excessive studies in
human and mice. Impaired epidermal LC mobilization
has been shown in non-lesional psoriatic skin and we
have found Langerin expressing DCs in lesional dermis.
This study aims at elucidating if LCs have a local
immune-modulatory role in inflamed skin.
Materials and methods: Skin biopsies were collected from
lesional and non-lesional areas of untreated plaque
psoriasis patients, and from healthy subjects. Epidermis
was separated from underlying dermis and
inflammatory genes were studied in FACS-sorted DC
subsets, using realtime-PCR. Electron microscopy
was used to detect the LC-specific intracytoplasmic
organelle, i.e. Birbeck granule, within dermal Langerin
expressing cells.
Results: LCs were the main cytokine producers in
epidermis, expressing both pro- and anti-inflammatory
genes, whereas DCs expressed higher levels in dermis.
Epidermal LCs of lesional skin displayed a more
pronounced pro-inflammatory phenotype than LCs of
control skin. Our data indicated that dermal LCs
secreted more pro-inflammatory cytokines than
epidermal LCs. Epidermal, as well as dermal LCs, but
not other DCs, contained Birbeck granules.
Conclusion: The activated LC phenotype in lesional
psoriatic skin indicates that they participate in the
local activation of inflammatory cells, e.g. T cells, in
the skin, thus contributing to the ongoing
inflammation. Detection of Birbeck granules within the
dermal Langerin expressing cells together with
expression of EpCAM and CD1a suggests that these
cells are true LCs originating from the epidermis.
P022
Obesity and psoriasis: vaspin as a possible link?
Vester, Katharina1; Saalbach, Anja1; Tremel, Jenny1;
Anderegg, Ulf1; Averbeck, Marco1; Bodendorf, Marc1;
Ziemer, Mirjana1; Beck-Sickinger, Annette G.2;
Bluher, Matthias3; Simon, Jan C.1
1University of Leipzig, Department of Dermatology,
Venerology and Allergology, Leipzig, Germany;
2University of Leipzig, Institute of Biochemistry,
Faculty of Life Sciences, Pharmacy; LIFE –Leipzig
Research Center for Civilization Diseases, Leipzig,
Germany; 3University of Leipzig, Department of
Medicine, Medical Faculty; LIFE –Leipzig Research
Center for Civilization Diseases, Leipzig, Germany
The link of psoriasis with obesity and the serum levels of
certain adipokines is actually discussed. Vaspin, a
suggested serine proteinase inhibitor of the serpin
family, was originally isolated from visceral adipose
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tissue of obese rats. In humans it is detectable partially in
human white adipose tissue of obese patients and in
human placenta. Because the impact of vaspin on
inflammatory skin diseases such as psoriasis is still
unknown, the expression of vaspin in healthy and
psoriatic skin was investigated by analyzing vaspin
mRNA by RT-PCR and protein expression by
immunohistochemistry.
Keratinocytes could be identified as the major cell type
expressing vaspin mRNA, whereas dermal fibroblasts or
endothelial cells were vaspin-negative in vitro as well as
in vivo.
To study whether the expression of vaspin is altered in
psoriasis the expression level of vaspin in psoriatic skin
biopsies of lesional psoriatic skin and non-lesional skin
from the same localisation of the same patient were
analyzed. In healthy skin vaspin is mainly expressed in
the Str. granulosum, whereas in non-lesional psoriatic
skin a uniform expression of vaspin in all epidermal
layers was observed. By contrast in lesional psoriatic skin
from the same patient a clear staining in the Str.
spinosum was found, whereas vaspin was rarely
detectable in the Str. granulosum. Quantification of
vaspin mRNA expression in lesional psoriatic skin and
uninvolved skin of the same patient confirmed
significant decrease in vaspin expression in lesional
psoriatic skin.
We hypothesize that altered expression of vaspin—the
suggested inhibitor of serine proteases—might
contribute to the maintenance of psoriasis by
disturbing the balance of proteases and inhibitors
involved in the in the regulation of inflammation as
well as in the desquamation process.
P023
Anti-TNF-a therapy alters serum miRNA expression
profiles in psoriasis patients
Pivarcsi, Andor; Meisgen, Florian; Xu, Ning;
Sta˚hle, Mona; Sonkoly, Eniko¨
Departmnet of Medicine, Dermatology and
Venereology Unit, Karolinska Institutet, Stockholm,
Sweden
MicroRNAs (miRNAs) are endogenous, non-protein-
coding, regulatory RNAs with important roles in health
and disease. Interestingly, miRNAs are present in the
circulation in a stable form and may serve as disease
biomarkers. We aimed to investigate the effect of anti-
TNF-a therapy on serum miRNA levels in psoriasis
patients. To this end, we performed miRNA expression
profiling on serum samples from patients with chronic
plaque psoriasis before and 12 weeks after the initiation
of treatment with the TNF-a-inhibitor etanercept. We
identified a panel of 38 miRNAs whose level significantly
changed after treatment and confirmed down-regulation
of six selected miRNAs by qPCR: miR-17, miR-106b,
miR-26b, miR-142-3p, miR-223 and miR-126. Several
miRNAs regulated by etanercept have previously been
implicated in inflammation and autoimmunity.
Interestingly, none of the identified etanercept-
regulated miRNAs changed in serum of psoriasis
patients treated with methotrexate for 12 weeks,
suggesting that the observed changes are specific for
anti-TNF-a treatment. Our results suggest the
involvement of miRNAs in pathways affected by anti-
TNF-a therapy and warrant for further investigation of
serum miRNAs as potential biomarkers for therapy
response in psoriasis.
P024
Skin equivalent as an experimental model to study
psoriasis
Soboleva, Anna; Mezentsev, Alexandre;
Sobolev, Vladimir; Bruskin, Sergey
Vavilov Institute of General Genetics, Functional
Genomics, Moscow, Russian Federation
Introduction: Psoriasis is a common inflammatory skin
disorder of unknown etiology, for which there is no cure.
Pathology is clinically characterized by prominent
epidermal hyperplasia and a distinct inflammatory
infiltrate. Crosstalk between immunocytes and
keratinocytes, which results in the production of
cytokines, chemokines and growth factors, is thought
to mediate the disease. Most of the known antipsoriatic
drugs either reduce proliferation of keratinocytes or
prevent activation of the immune cells. Artificially
produced skin equivalent obtained from human
keratinocytes in a controlled manner can become a
useful tool for analysis of key factors contributing to
development of the disease and help to assess efficacy of
new drugs.
Aim of this study was to develop a three dimensional
skin model that would allow us to screen anti-psoriatic
drugs in a controlled manner and be a model in the
study of the disease.
Methods: Human skin equivalent was generated from
normal human adult keratinocytes grown on the de-
epidermized dermis after an air exposure. The prepared
skin equivalent was fixed and stained with hematoxylin
and eosin to verify tissue morphology.
Results: We found that adult normal human
keratinocytes cultured grown on the de-epidermized
dermis at an air–liquid interface formed a structure
similar to the normal human epidermis if two growth
factors, EGF and KGF were added to the culture medium.
Contrary, addition of proinflammatory cytokines such
as IL-17 led to psoriasis-like appearance of the skin
equivalent with dense stratified layer, increased
thickness and hyperkeratosis.
Conclusion: We obtained 3-dimensional skin that
phenotype was sensitive to the presence of
proinflammatory growth factors and reproduced
characteristic features of psoriasis. Thus, this model can be
used to study physiological effects of the cytokines and
pathology of the disease.
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P025
Small intestine microflora at psoriasis: its possible
role in pathogenesis
Peslyak, Mikhail1; Gumayunova, Natalia2;
Nesterov, Alex2; Potaturkina-Nesterova, Natalia2
1Kudits, Izmailovsky prospekt 93-1, app.54, Moscow,
Russian Federation; 2Ulyanovsk State University,
Ulyanovsk, Russian Federation
For the first time researches of transient microflora of
proximal small intestine at 121 psoriatic patients
(PASI C 20) are conducted. Control group consists of
43 healthy persons.
Level SIBO (small intestinal bacterial overgrowth) more
than 105 CFU/ml (TBC[5) was found at 95 psoriatic
patients (78.5%). TBC (total bacterial count) for psoriatic
patients has made—on average 3 9 106 CFU/ml that is
much more than in the control group—on average
1.1 9 103 CFU/ml.
The correlation between SIBO level and PASI (R = 0.46),
between SIBO level and duration of psoriasis disease
(R = 0.43) has been found.
At 93% of psoriatic patients Bifidobacterium spp. was
found—on average 2 9 105 CFU/ml (in the control
group at 40%, on average 250 CFU/ml).
At 84% of psoriatic patients Lactobacillus spp. was
found—on average 4.6 9 104 CFU/ml (in the control
group at 19%, on average 350 CFU/ml).
At 79 of 121 psoriatic patients (65%) Enterococcus spp.
was found—on average 2 9 105 CFU/ml.
Enterococcus spp. are not found in the control group at
all.
At part of psoriatic patients Str.pyogenes (9%) and
Str.viridans (30%) were found (not found in the control
group).
It is supposed that increased colonization of small
intestine by Str.pyogenes and others Gram + bacteria
with similar peptidoglycan interpeptide bridges
(in particular E.faecalis and Str.viridans), and also by
Gram (-) bacteria can play important role in psoriasis
pathogenesis.
The fragments of bacterial products of these bacteria
contain PAMP (LPS and specific PG). These fragments get
to systemic blood flow, form chronically increased both
PAMP-level and PAMP-load on blood phagocytes
(neutrophils, monocytes and dendritic cells). It
provides functioning of systemic psoriatic process SPP.
Details about SPP are in report:  Psoriasis as skin
reaction to systemic psoriatic process SPP. Y-model of
pathogenesis. www.psorias.info.
P026
Differential scanning calorimetry analysis
of human plasma in different psoriasis stages
Moezzi, Mehdi1; Fekecs, Tamas2; Zapf, Istva´n3;
Ferencz, Andrea4; Lorinczy, Denes5
1Medical University of Pecs, Dermatology, Pecs,
Hungary; 2University of Pe´cs, Medical School,
Dermatology, Pecs, Hungary; 3University of Pe´cs,
Medical School, Surgery, Pecs, Hungary; 4Semmelweis
University, Medical School, Surgery, Budapest,
Hungary; 5University of Pe´cs, Medical School,
Biophysics, Pecs, Hungary
Psoriasis vulgaris is a chronic autoimmune,
inflammatory, proliferative skin disease. Recently, there
is a need for new methods to detect and diagnosis of
psoriasis in the early stages. The application of
Differential Scanning Calorimetry (DSC) should be as a
new diagnostic method for psoriasis detection and
monitoring using human plasma. We aimed to detect
liquid plasma components with DSC in psoriasis
patients. The study included 18 white adults (8 men
and 10 women; median age 55.7 years) who had
underwent a full skin examination for psoriasis and
completed a standardized questionnaire. The Psoriasis
Area Severity Index (PASI) is an index used to express the
severity of psoriasis. It combines the severity (erythema,
induration and desquamation) and percentage of
affected area. Taking in consideration the severity of
symptoms, we stratified them in 3 groups based on the
above scoring system PASI: 0 (symptomless), PASI: 1–10
(minimal symptom), PASI: above 11 (symptom).
Peripheral blood samples were collected from these
patients and from healthy controls. Human blood
plasma components were analyzed by DSC technique.
In this preliminary study we observed that thermal
changes (Tm, calorimetric enthalpy) in blood plasma
showed closed correlation with psorasis stages. Further
studies are needed to elucidate these relationships, but
our application of the DSC method has provided a
potential new tool for the early diagnosis and
monitoring of psoriasis patients.
P027
The role of miR-146a in innate immunity
of keratinocytes
Meisgen, Florian1; Xu, Ning2; Sta˚hle, Mona2;
Sonkoly, Eniko¨2; Pivarcsi, Andor2
1Karolinska Institutet, Department of Medicine Solna,
Unit of Dermatology and Venereology, Stockholm,
Sweden; 2Karolinska Institutet, Department of
Medicine Solna, Stockholm, Sweden
Previously, our group performed a genome-wide screen
for microRNAs in psoriasis skin, and showed a distinct
pattern of deregulated microRNA expression. However,
the specific role of the deregulated miRNAs in the
complex cellular context of psoriasis is not fully
understood.
In this study we focused on miR-146a, which was one of
the microRNAs we found to be deregulated in psoriasis
skin. This miRNA plays a vital role in innate immunity
and acts as a gatekeeper of autoimmunity. However
nothing is known about its role in keratinocytes.
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Therefore, we aimed to study the regulation and
function of miR-146a in keratinocytes. First, we tested
the effect of different Toll-like receptor (TLR) ligands in
keratinocytes. We found that Zymosan, quickly induced
expression of miR-146a in keratinocytes already 1 h after
treatment in a TLR2-dependent manner. Interestingly,
while the production of TNF-alpha, IL-1beta, IL-8,
CCL20 and beta-Defensin 2, which were all induced by
Zymosan, was diminished 24 h after stimulation, the
expression of miR-146a remained at a continuously high
level for several days (up to 96 h) upon stimulation.
Overexpression of miR-146a in keratinocytes effectively
decreased both base-line and TLR-ligand-induced
production of cytokines and chemokines and could
thus block the effects of Zymosan stimulation. In
accordance, the specific inhibition of miR-146a led to
an increased production of cytokines and chemokines in
unstimulated keratinocytes. These results suggest that
miR-146a provides a negative feedback of NF-kB
signaling in keratinocytes and thus helps to dampen
inflammation. Altogether our data provide evidence that
miR-146a regulates the production of inflammatory
mediators in keratinocytes and thus might be an
interesting target for therapeutic approaches.
P028
FC gamma receptors in active psoriatic arthritis
Matt, Johann Peter1; Lindqvist, Ulla Ruth Kristina2;
Kleinau, Sandra3
1Department of medical sciences, Rheumatology,
Uppsala university, University hospital ent 30, 6th
floor, Uppsala, Sweden; 2Department of medical
sciences, Rheumatology, Uppsala university, Uppsala,
Sweden; 3Department of Cell and Molecular Biology,
Biomedical Center, Uppsala University, Uppsala,
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Introduction: In autoantibody inflammatory rheumatic
diseases an important role of Fc receptors has been
proposed but not fully clarified. In psoriatic arthritis
(PsA) multiple disease-phenotypes are known, but our
knowledge of Fc receptor function and the interplay
between the humoral and adaptive immunity is limited.
The aim of this study was to characterize Fc receptors in
active PsA.
Methods: Peripheral blood was collected from 23 patients
with active polyarticular PsA and 33 healthy blood donors.
Immunoglobulin, autoantibody levels and C-reactive
protein (CRP) were analyzed. Disease activities were
characterized with DAS28, HAQ, stiffness-VAS, pain-VAS
and PASI. Fc alpha (CD89) and Fc gamma (CD16,
CD32a + b, CD64) receptor status as well as cell bound
IgG on CD14 + blood monocytes were studied using
flow cytometry. Monocyte subpopulations were
characterized for degree of CD14 and CD16 expression.
IgG immune complex binding and IgG-stimulated TNF-
alpha production in MACS purified monocytes were
analyzed using a rosetting technique and a sandwich-
TNF-ELISA.
Results: IgG1-, IgG2-, IgG3-levels were increased in the
PsA patients. The proportion of CD14 + monocytes
correlated positively with DAS28, CRP and total serum
IgG in the patients. CD64 + monocytes were more
abundant in PsA patients and displayed increased
cell-surface bound IgG. The CD16 + monocyte
subpopulation was decreased in compared to healthy
controls. IgG3 stimulated TNF-production in monocytes
from patients was decreased, especially in patients on
immunosuppressive medications. Immune complex
handling correlated with tender joint count, patient
reported stiffness/pain and DAS 28CRP.
Conclusions: Alternations in monocytic Fc gamma
receptors is observed in active PsA and these could be
used as markers for characterization of disease activity.
Handling of immunocomplexes via these receptors is
probably affected due to occupancy with increased
amount of IgG. This study shows a possible interaction
between humoral and adaptive immunity in PsA.
P029
Evaluation of cardio-protective role of methotrexate
in psoriasis
Malhotra, Suresh1; Dhaliwal, Gurinder1;
Puri, Karanjit1; Mahajan, Mridula2
1Govt medical collage, Dermatology, Amritsar, India;
2Govt medical collage, Biochemistry, Amritsar, India
Introduction: Psoriasis is a chronic inflammatory skin
disease that affects 1–3% of population The underlying
pathogenesis of psoriasis is characterized by T cell
activation and subsequent immune/inflammatory cell
trafficking within the skin, promoting keratinocyte
proliferation and epidermal hyperplasia leading to
psoriatic plaque formation.
Suppression of inflammatory process with treatment
may reduce cardiovascular risk in patients with psoriasis
and rheumatoid arthritis. The presence of comorbid
conditions in patients with psoriasis affects the clinical
management of the disease. As psoriasis and its
associated comorbidities share common inflammatory
mechanisms, thus suggesting that therapies targeting
underlying inflammation may be effective in treating
both psoriasis and these comorbidities.
Aims: To evaluate the cardioprotective role of
methotrexate in psoriasis.
Materials and Methods: 60 patients of moderate to severe
psoriasis having BSAI[10% and PASI[10 were studied.
Serum cholesterol, triglycerides, plasma glucose, serum
C-Reactive protein (CRP) were analysed along with
recording of electrocardiogram (ECG) which were
repeated after 8 weeks of methotrexate therapy. Metabolic
syndrome was diagnosed by the presence of three or more
criteria of the modified version of National Cholesterol
Education Programme’s Adult Panel III (ATP III).
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Results: CRP was reactive in 10 (16.6%), ischemic heart
disease (IHD) in 6 (10%) and septal hypertrophy in 1
(1.6%) patient. After 8 weeks of MTX therapy, serum
CRP became non-reactive in 4 (40%) whereas ischemic
changes on ECG were reversed to normal in 3 (50%)
patients.
Conclusions: Methotrexate was found to be
cardioprotective in 50% of psoriasis patients having
associated IHD in our study. So the cardioprotective role
of methotrexate should be kept in mind while selecting
treatment modalities in psoriasis patients associated
with IHD.
P030
Immune regulation at the border of psoriatic lesions
Keijsers, Romy1; van Erp, Piet1; de Boer-van Huizen,
Roelie1; Joosten, Irma2; Koenen, Hans2;
van de Kerkhof, Peter1
1Radboud University Nijmegen Medical Centre,
Department of Dermatology, Nijmegen, Netherlands;
2Radboud University Nijmegen Medical Centre,
Laboratory of Medical Immunology, Nijmegen,
Netherlands
Background: Psoriasis is strongly associated with CD4 + T
helper 17 (Th17) cells. Th17 cells are highly pro-
inflammatory T cells and produce IL-17.
CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) play
an important role in maintaining immune tolerance and
preventing autoimmunity.
Objectives: We performed a descriptive study using the
border of a psoriatic lesion as an approach to study
cellular infiltrates in the different phases of psoriasis,
with the emphasis on IL-17 producing cells and Tregs.
Methods: From nine patients with mild-to-moderate
chronic plaque psoriasis 3 mm punch biopsies were
obtained from the centre and the margin of the lesion,
perilesional skin and distant uninvolved skin. The
tissues were processed for immunohistochemistry and
immunofluorescence using several markers.
Results: In the transition from clinically uninvolved to
lesional skin, we found a marked increase in the
presence of CD3, CD4 and Foxp3 expressing cells,
while IL-17 producing cells only slightly increased.
Moreover, we found standard levels of IL-17, present in
the perilesional and distant uninvolved skin. Regardless
of biopsy location, a minority of IL-17 was related to
CD4 + cells and neutrophils, while most of the IL-17
expression was related to mast cells.
Conclusions: We found a discrepancy in trends of CD3+,
CD4+ and Foxp3+ T cells versus IL-17 producing cells in
the transition from clinically uninvolved to lesional
psoriatic skin. While CD3, CD4 and Foxp3 expression
was higher in the perilesional skin compared to the
distant uninvolved skin, IL-17 expression did not differ
between the two biopsy locations. Although IL-17
production is supposed to be an important driver in
the psoriatic process, it does not act as a marker for a
specific phase in the pathogenesis of psoriasis. Moreover,
most of the IL-17 expression was related to mast cells,
while a minority was related to T cells and neutrophils.
Further studies are necessary, to assess the role of IL-17
producing T cells versus mast cells in the pathogenic
process of psoriasis.
P031
Comparison between involved and uninvolved
psoriatic skin in a pathological skin model
produced with the self-assembly approach
Jean, Jessica1; Duque-Fernandez, Alexandra1;
Bernard, Genevie`ve1; Soucy, Jacques2;
Pouliot, Roxane1
1Faculte´ de Pharmacie, Universite´ Laval, Que´bec,
Canada, Centre LOEX de l’Universite´ Laval, Ge´nie
tissulaire et re´ge´ne´ration, Que´bec, Canada;
2De´partement de Dermatologie, Hoˆpital de l’Enfant-
Je´sus, Que´bec, Canada
Current research on psoriasis suggests that uninvolved
psoriatic skin could demonstrate characteristics
associated with both normal or involved psoriatic
skins. However, the triggering factor allowing the
conversion of uninvolved skin into a psoriatic plaque
is not fully understood. This work strives to develop and
characterize a psoriatic skin model produced with
involved or uninvolved cells, in order to reach a better
understanding of the differences between these psoriatic
skins regarding several characteristics such as histology
as well as lipid organization and permeability of the
stratum corneum. The self-assembly approach were used
for the production of normal, involved and uninvolved
psoriatic skin substitutes. Skin biopsies were taken and
histological, physico-chemical and permeability
analyses were performed. Results showed that involved
substitutes had a thicker epidermis as well as a more
permeable and disorganized stratum corneum compared
with normal substitutes. Results obtained with
uninvolved cells showed two different profiles: profile
1 in which substitutes mimicked those produced with
normal cells and profile 2 in which substitutes shared
characteristics with those produced with involved
cells. In brief, uninvolved substitutes of profile 1 had
a thin and well-organized epidermis such as observed
with normal substitutes, while uninvolved substitutes
of profile 2 showed an inverse trend i.e. a thicker
epidermis as well as a more disorganized and
more permeable stratum corneum such as observed
with involved substitutes. The results suggest
that uninvolved substitutes could demonstrate
characteristics associated with both normal or
involved psoriatic skins. It is interesting to note that
the self-assembly approach lies in the possibility of
dissecting step by step the contribution of each
different cell type involved in such a complex
pathology as psoriasis. Even today, the exact cause of
psoriasis is still unknown, but we believe that
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uninvolved cells could give us some very interesting
clues on the development of this complex pathology
and that our psoriatic skin substitute model could
become a powerful tool in making these discoveries
possible.
P032
Clinical and immunological response to treatment
of psoriasis in the Blue Lagoon compared
with narrow-band UVB monotherapy
Eysteinsdottir, JH1; Olafsson, JH2; Davidsson, S3;
Brynjolfsdottir, A4; Sigurgeirsson, B3;
Ludviksson, BR5
1Sahlgrenska University Hospital, Department of
Dermatology and Venereology, Gothenburg, Sweden;
2University Hospital of Iceland, Department of
Dermatology and Venereology, Reykjavik, Iceland;
3University of Iceland, Faculty of Medicine, Reykjavik,
Iceland; 4Blue Lagoon inc, Grindavik, Iceland;
5University Hospital of Iceland, Department of
Immunology, Reykjavik, Iceland
Introduction: The Blue Lagoon is a geothermal lagoon
located in Iceland. Blue Lagoon based psoriasis treatment,
that includes bathing in the lagoon combined with UVB
phototherapy, has proven to be highly effective but its
mechanism of action remains unclear. In this study the
therapeutic and immunological effect of psoriasis
treatment in the Blue Lagoon was evaluated and
compared to traditional UVB phototherapy.
Materials and Methods: Seventy patients with psoriasis
were randomized into three therapeutic arms. (1) (n = 22)
received out-patient treatment for 6 weeks in the Blue
Lagoon (BL out-patient group), (2) (n = 24) received in-
patient treatment for 2 weeks in the Blue Lagoon followed
by maintenance UVB phototherapy three times/week for
4 weeks (BL in-patient group), and (3) (n = 24) received
out-patient UVB phototherapy treatment for 6 weeks (UVB
group). Disease severity (Psoriasis Area and Severity Index;
PASI) was recorded and blood samples obtained before,
during and after treatment. Circulating T cells were
evaluated for several important inflammatory adhesion-,
receptors- and secretory mediators.
Results: There was a significant decrease in the frequency
of circulating T cells that co-expressed the skin-homing
molecule CLA, the chemokine receptor 4 (CCR4) and the
CD103 integrin. A significant reduction of the
Th17 + (Th17: CD4 +/IL-17 +/IL-22 +) and Tc17
phenotype (Tc17: CD8 +/IL-17 +/IL-22 +) was also
observed in both BL treatment groups, but not in UVB
phototherapy group. This anti-inflammatory response in
the blood was reflected in the clinical evaluation after
6 weeks of treatment, where more patients receiving in-
and out-patient treatment in the Blue Lagoon achieved
PASI 75 (20/26 and 15/22) compared to UVB phototherapy
alone (4/24) (p\0.05). In addition, more patients
achieved PASI 90 in in-patient Blue Lagoon group (11/26)
compared to both of the other groups (p\0.01).
Conclusion: Treatment in the Blue Lagoon is a
highly efficacious treatment for psoriasis and its
beneficial therapeutic effect is directed at potentially
pathogenic Th17 and Tc17 inflammatory T cells in this
disease.
P033
Systemically elevated Th1-, Th2- and Th17-
associated chemokines in psoriasis
Ekman, Anna-Karin1; Sigurdardottir,
Gunnthorunn1; Carlstro¨m, Maria1; Kartul, Natalja1;
Jenmalm, Maria2; Enerba¨ck, Charlotta1
1Department of Clinical and Experimental medicine,
Division of Cell biology and Dermatology, Linko¨ping
University, Linko¨ping, Sweden; 2Department of
Clinical and Experimental medicine, Division of
Clinical immunology, Linko¨ping University,
Linko¨ping, Sweden
Introduction: Psoriasis is a Th1/Th17-characterized
immune disease. In psoriasis there is an infiltration of
T cells to the skin and a local secretion of cytokines,
chemokines and growth factors. While the disease
manifests in the skin, there is also a systemic
inflammation which may explain the increased risk for
co-morbidities in psoriasis patients. The aim was to
investigate circulating chemokines in psoriasis patients
and to study how they are affected by narrowband
ultraviolet (UV)B treatment.
Method: The chemokines CXCL8, CXCL9, CXCL10,
CXCL11, CCL17, CCL20 and CCL22 were measured in
plasma from 27 patients and matched controls using a
multiplex assay. 15 patients were followed-up after 6 and
12 weeks of narrowband UVB treatment. Peripheral
blood mononuclear cells (PBMCs) were isolated from
the 10 patients with the highest PASI and were
stimulated with LPS or anti-CD3/anti-CD28 antibodies
to activate antigen-presenting cells (APCs) and T cells,
respectively, to study the systemic levels of cytokines up-
stream of the chemokine production.
Results: Analysis of plasma levels of chemokines revealed
an increased expression of CXCL9, CXCL10, CCL17,
CCL20 and CCL22 in psoriasis patients. CCL20
correlated with disease severity. Narrowband UVB
therapy reduced skin symptoms, but did not affect
plasma levels of the chemokines. Anti-CD3/anti-CD28-
mediated activation of PBMCs gave rise to a higher
secretion of the Th2 cytokine IL-13 by PBMCs from
psoriasis patients than from healthy controls. The
cytokine release by activated PBMCs was not affected
by narrowband UVB treatment.
Discussion: Analysis of plasma chemokines revealed an
elevated expression of the Th1-associated CXCL9 and -10,
Th2-associated CCL17 and -22, and the Th17-associated
CCL20. Narrowband UVB therapy reduced skin symptoms,
but did not affect the levels of chemokines in plasma, nor
did it affect the cytokine release by activated T cells or
activated APCs. These results suggest that the effect of UVB
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may be more focused on local inflammation rather than
the systemic, and that the reduction in skin symptoms is
not primarily due to altered systemic APC and T cell
activation.
P034
Characterization of skin resident T cells in psoriasis
treated with UVB or anti-TNFalpha therapy
Cheuk, Stanley; Wike´n, Maria; Sta˚hle, Mona;
Eidsmo, Liv
Karolinska Institutet, Department of Medicine Solna,
Stockholm, Sweden
Psoriasis is characterized by massive infiltration of T cells
into the skin. The pathogenic role of skin infiltrating T cells
in psoriasis has been shown in both clinical and
experimental settings. In a xenotransplant model of
psoriasis, the entry of VLA-1 expressing T cells into
epidermis has been shown to drive the development of
psoriasis. We propose that pathogenic T cells remain in the
skin after treatment and drive recurrent disease in
previously inflamed areas of the skin. The focus of our
current work is characterization of skin resident T cells in
successfully treated lesions under different treatment
regimes. Patients undergoing systemic anti-TNFalpha
(aTNFa, n = 4) treatment or UVB treatment (n = 7) in
combination with topical vitamin D analogues/
corticosteroid were recruited and compared to healthy
controls (n = 10). T cells derived from enzymatically
treated punch biopsies were analyzed using flow
cytometry. Preliminary results suggest that a population
of T cells remains in successfully treated lesions as
compared to healthy controls and nonlesional skin
regardless of the treatment regime. This population of T
cells is predominantly found in the epidermal
compartment of the skin and express VLA-1. These
results may suggest that T cells from UVB or aTNFa-
treated lesions may exhibit different functionality as
compared to healthy skin.
Epidemiology
P035
Psoriasis and psoriatic arthritis among natives
and mestizos from the Andean mountains region
of Peru
Toloza, Sergio1; Vega-Hinojosa, Oscar2; Chandran,
Vinod3; Valle-On˜ate, Rafael4; Espinoza, Luis R.5
1Hospital San Juan Bautista, Medicine, Dr. Julio Herrera
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Juliaca, Peru; 3University of Toronto, Medicine,
Toronto, Canada; 4Universidad de La Sabana,
Medicine, Bogota´, Colombia; 5Louisiana State
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Background: Previous epidemiological studies described
that both Psoriasis (Ps) and Psoriatic Arthritis (PsA) are
diseases with negligible prevalence among Natives from
the Andean mountains of Peru. We herein first report
the presence of Ps and PsA as well as the clinical status of
Peruvian Natives and Mestizos with psoriatic disease.
Objectives: Our purpose was to describe the most salient
demographic and clinical features of Peruvian Natives
and Mestizos with Ps and PsA from Juliaca, Puno in the
Andean mountains region of Peru.
Methods: During October 1st 2008 to December 31st
2010 consecutive patients attending the rheumatology
clinic at the Hospital III in Juliaca, Puno (Southern Peru)
at 3,824 meters above sea level were carefully assessed
for the presence of PsA satisfying the CASPAR
classification criteria. The diagnosis of Ps was
confirmed by a dermatologist. Descriptive statistics
were used to describe the study population.
Results: Twelve patients with a mean (SD) age of 49.3
(10.7) years fullfilling CASPAR classification criteria were
identified. There were 7 (58%) men and 5 (42%) women.
7 PsA patients were Natives of Quechua Ancestry and 5
Mestizos of European and Quechua mix. At the time of
first clinical visit all Natives with PsA had no family
history of both Ps and PsA and exhibited an established
disease (ranging from 12–72 months), were more likely
to have a polyarticular disease, and a more severe disease
phenotype evidenced by the presence of radiographic
damage than Mestizos with PsA. Methotrexate exposure
(dose ranging from 15–20 mg/wk) was almost universal
in both Natives and Mestizos as was the absence of
exposure to biological agents in spite of radiographic
damage.
Conclusions: We first report Ps and PsA in the absence of
a family history among Natives of the Andean
Mountains of Peru in whom the CASPAR criteria was
successfully applied to classify PsA patients. At the time
of first visit PsA among the indigenous appeared to be
chronic and more severe as most of these patients had
radiographic damage.
P036
The Swedish Early Psoriatic Arthritis (SwePsA)
registry. 5-year follow-up: Worse outcomes
for women compared to men
Theander, Elke1; Husmark, Tomas2; Alenius,
Gerd-Marie3; Larsson, Per T4; Telemark, Annika5;
Geijer, Mats6; Lindquist, Ulla RC7
1Ska˚ne University Hospital, Rheumatology, Malmo¨,
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3Umea˚ University Hospital, Public Health and Clinical
Medicine, Umea˚, Sweden; 4Karolinska University
Hospital, Rheumatology, Stockholm, Sweden;
5Spenshult Rheumatological Hospital, Rheumatology,
Oskarstro¨m, Sweden; 6Ska˚nes University Hospital,
Radiology, Lund, Sweden; 7Uppsala University
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Objective: SwePsA intends to describe the course of early
psoriatic arthritis (PsA) in a real life clinical setting in
Sweden.
Method: In 6 centres patients with signs suggestive of
PsA were included in the registry within 2 years from
symptom onset. Two-hundred and eight patients
fulfilling CASPAR (1) or ASAS (2) criteria had passed
the 5-year follow-up. Disease activity was measured by
DAS-28 and DAPSA (3). Remission and Minimal
Disease Activity (MDA) (4) were used as outcome
measures.
Results: Mean age at baseline was 46 years, younger in
male than female patients (43 vs. 48 years).
Mean DAS-28 values were 3.4 at baseline and 2.6 at
follow-up, significantly higher in women (3.7 and 2.9)
than in men (3.0 and 2.1) at both visits. Likewise DAPSA
scores were significantly higher in women. The degree of
improvement (delta DAS-28, delta DAPSA) was similar.
More men achieved MDA or remission (50 vs. 31%, 24
vs. 12% respectively). While women had significantly
more polyarthritis at baseline (52 vs. 33%) and after
5 years (21 vs. 15%), axial or mono/oligoarticular disease
predominated in men.
Independent predictors of MDA at 5-year follow-up were
male gender, axial disease, shorter symptom duration at
inclusion and low baseline HAQ. Despite the higher
disease activity in women, there was a trend towards less
DMARD treatment in women.
Conclusion: In early PsA male gender, axial disease, short
delay between symptom onset and diagnosis, as well as
preserved function at diagnosis are predictors of
favourable outcome at 5-year follow-up. Early
recognition of PsA and active treatment may be
important particularly in women with polyarticular
disease.
P037
Latent tuberculosis infection or tuberculin
hiperergy? A three-year retrospective study
on patients with psoriasis in an endemic area
Solovan, Caius1; Chiticariu, Elena2;
Stoia Dejka, Irina3
1University of Medicine and Pharmacy ‘‘Victor Babes’’,
Dermatology Department, Timisoara, Romania;
2County Hospital, Dermatology Clinic, Timisoara,
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Timisoara, Romania
Background: The introduction of anti TNF-alpha agents
has intensified the screening for tuberculosis infection
before biologic therapy.
Aims: The aim of this study was to determine the
prevalence of positive tuberculin skin test (TST) in
psoriatic patients, compared with other groups.
Materials and methods: We screened268 subjects for latent
tuberculosis infection (LTBI) in a 3-year retrospective
study. The screening included epidemiological studies,
history of Bacillus Calmette-Guerin vaccination, and TST
with 2 units of purified protein derivate. The cutoff for a
positive skin test was accepted as an area of induration
of more than 5 mm. For statistical analysis, we used the
ANOVA test and was performed with the InStat
software of GraphPad. P value\0.05 was considered
statistically significant.
Results: We enrolled 68 patients (mean age: 50 years)
with moderate-to-severe psoriasis (PASI, BSA[10) and
200 patients without psoriasis, tuberculosis suspects or
subjects with close contact with infected individuals:
100 adults (mean age: 50.3 years) and 100 children
(mean age: 12.7 years). Positive TST results were
observed in 70.5% (48/68) of patients with psoriasis
(TST mean value: 9.6 mm), higher than those
observed in subjects with suspicion of tuberculosis
or with close contact with infected individuals: 51%
(51/100) in adults group (TST mean value: 6.4 mm)
and 30% (30/100) in children group (TST mean value:
4 mm).
Conclusions: The incidence of LTBI evaluated with TST in
psoriatic group is higher than the general rate described
in control groups. These results support the possibility of
false positive TSTs in psoriatic patients. The tuberculin
hyperergy is common in psoriatic patients, possibly due
to subjacent immunological mechanisms.
Keywords: Psoriasis, Tuberculin skin test, Latent
Tuberculosis.
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PSOLAR: Global update of a multicentre, open
registry of psoriasis patients
Papp, Kim1; Strober, Bruce2; Ho, V3; Binder, C4;
Calabro, Steve5; Langholff, Wayne6;
Chevrier, Marc5
1Probity Research, Waterloo, Canada; 2University of
Connecticut, Department of Dermatology,
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Vancouver, Canada; 4Janssen Inc, Toronto, Canada;
5Janssen Services, LLC, Horsham, USA; 6Janssen
Research and Development, LLC, Horsham, USA
Objective: To determine the baseline characteristics of
Canadian participants in the PSOLAR registry for
patients with psoriasis who are candidates for systemic
treatment. Baseline demographics of the enrolled cohort
are presented here.
Methods/Results: PSOLAR (PSOriasis Longitudinal
Assessment Registry) is a multicenter, prospective,
longitudinal, 8+ years, observational study in academic
and community-based settings. Eligible patients are
aged C18 years, have a diagnosis of psoriasis and are
currently receiving or are candidates to receive systemic
therapies for psoriasis. Demographics and medical/
family history are collected at enrollment. Collections
at 6 month intervals include: adverse events, disease
activity, quality of life, economic status, healthcare
utilization and interval therapies. International sites in
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North America and Europe recruited 9,495 patients as of
23 August 2011. The baseline characteristics were as
follows: median age: 49.0 (range 18–100 years), 61.8% of
patients C45 years, 54.5.0% male, 82.4% white, mean
BMI 31.1 (SD 7.3), disease duration of 17.4 years (SD 13.6
years) since diagnosis. Medical history includes: 38.8%
cardiovascular disorders, 14.9% pulmonary disorders,
21.0% psychiatric disorders, 19.0% endocrine disorders,
and 6.4% skin cancer. Infections requiring treatment in
the last 3yrs occurred in 26.0% of which 23.1% were
bacterial infections. Mean BSA coverage at enrollment
was 12.5% (SD 18.0%), mean PGA 2 (SD 1.2); 96.8% of
patients presented with plaque type psoriasis.
Medication (current and historical) included topicals
(97.3%), phototherapy (54.8%), systemic steroids
(24.6%), immunomodulators (46.2%), and biologics
(78.7%).
Conclusions: As a disease directed registry, PSOLAR offers
the ability to collect disease activity/outcomes associated
with many therapies in actual clinical practice.
P039
Genital involvement in Indian patients
with psoriasis
Muthu, Sendhil Kumaran; Mahajan, Rahul;
Dogra, Sunil; Narang, Tarun; Handa, Sanjeev
Postgraduate Institute of Medical Education and
Research, Dermatology, Venerology, Leprology,
Chandigarh, India
Background: Genital involvement in psoriasis can have
significant physical and psychosocial morbidities;
however there is little data available on burden of
disease from Indian subcontinent.
Aim: To analyse the genital involvement in psoriasis at
our centre.
Materials and methods: All consecutive patients attending
the psoriasis clinic past 6 months were screened for
genital involvement due to disease. Data regarding
demography, body surface area, psoriasis area and
severity index (PASI) and morphology of genital lesions
was recorded. The severity of genital involvement was
graded as mild, moderate and severe.
Results: Among 852 cases screened, 100 had genital
psoriasis, giving a prevalence of 11.7%. The mean age
was 37.09 ± 13.46 years; male to female ratio being 3:1.
The average duration genital involvement was
19.3 ± 40.91 months. The genital involvement was the
initial site of presentation in 3.8% patients. Itching or
burning sensation in genital lesions noted in 67.5%
patients. The commonest site affected was scrotum
(37.5%) followed by glans/labia/prepuce (22.3%) and
corona (16.3%). Erythematous scaly plaques were
commonest type of lesions seen in 87.6%, associated
fissuring was observed in 53.1% of these lesions and thin
non scaly plaques commonly described in genital
psoriasis was seen in only 8.8% of patients. Unusual
lesions like erythematous pin-point papular eruption
were seen in 6 patients. Less common variants observed
were pseudo circinate balanitis, annular psoriasis and
pustular psoriasis in 1.3% patients each. Associated
flexural and nail disease was seen in 22.5 and 48.8%
respectively. Chronic smoking, alcoholism was present
in 17.6% of patients. There was no significant
correlation of genital involvement with PASI.
Conclusion: The prevalence of genital psoriasis in our
patients was 11.7% usually associated with nail and
flexural disease having no significant correlation to
severity of disease. Larger studies involving more
number of subjects will shower some light over this
poorly reported side of psoriasis.
P040
Advanced cardiometabolic phenotyping
in psoriasis: links between psoriasis
and cardiovascular disease?
Mehta, Nehal1; Reilly, Muredach2; Rader, Daniel2;
Mohler, Emile2; VanVoorhees, Abby3;
Gelfand, Joel3
1University of Pennsylvania, Cardiovascular Medicine,
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Pennsylvania, Cardiovascular Medicine, Philadelphia,
USA; 3University of Pennsylvania, Dermatology,
Philadelphia, USA
Psoriasis is a Th-1/17 inflammatory disease associated
with increased risk of major adverse cardiac events
(MACE), however, the mechanisms underlying this
association remain poorly understood. Systemic
inflammation has been implicated in: (1) metabolic
and adipokine derangement leading to an insulin
resistant (IR) state; (2) lipoprotein particle dysfunction;
(3) increased generation of cell membrane vesicles, or
microparticles (MP) which are predictive of MACE. We
sought to determine if modulation of these pathways
implicated in atherosclerosis may provide a link between
psoriasis and MACE. We prospectively enrolled a
consecutive sample of patients with psoriasis (n = 122)
and compared these cardiometabolic risk factors with
health controls (n = 129). We performed metabolic
assessment for IR and adiposity (n = 122), lipid
particles by NMR spectroscopy (n = 122), HDL efflux
by a J774 macrophage system (n = 78) and
microparticles for endothelial cells, T cells and platelets
after fluorescent labeling and characterization by flow
cytometry (n = 51). In fully adjusted models, psoriasis
patients demonstrated more insulin resistance (HOMA-
IR: 3.5 (2.3–6.6) vs. 1.4 (.94–2.1), p\0.001), lower
adiponectin [7.1 (4.9–11.3) vs. 14.5 (8.4–24.2),
p\0.001], a more adverse lipid particle profile by NMR
(increased LDL particle number [1,271 (±413) vs. 1,139
(±328), p = 0.002], decreased LDL size [20 (±0.7) vs. 21
(±0.7), p\0.001] and HDL size [8.9 (±0.6) vs. 9.1 (±0.3),
p = 0.01]), decreased HDL function by cholesterol efflux
(0.86 ± 0.13 vs. 1.18 ± 0.11; p = 0.002) and higher
absolute MP levels (2.6-fold; p\0.01) and MP
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concentration (per lL, 50-fold; p = 0.01).
Characterization of these MPs revealed a predominance
of endothelial-, platelet-, and T lymphocyte-derived
MPs, all present in higher absolute levels in psoriasis
patients (p\0.05). We demonstrate that assessment of
established and novel CV biomarkers reveals a more
atherogenic profile in psoriasis, a finding which
persisted after adjustment for traditional MACE risk
factors and BMI. These findings may provide links
between the association of psoriasis and MACE.
P041
Prevalence of doctor-diagnosed psoriasis
and psoriatic arthritis in southern Sweden
Lo¨fvendahl, Sofia1; Theander, Elke2; A˚ke, Svensson3;
Martin, Englund1; Aleksandra, Turkiewicz1;
Petersson, Ingemar F1
1Clinical Sciences, Lund University, Lund, Department
of Orthopedics, Lund, Sweden; 2Ska˚ne University
Hospital, Malmo¨, Department of Rheumatology,
Malmo¨, Sweden; 3Ska˚ne University Hospital, Malmo¨,
Department of Dermatology, Malmo¨, Sweden
The prevalence of psoriasis (PSO) and psoriatic arthritis
(PsA) leading to a doctor consultation needs to be more
described in detail with up-to-date information. This
study estimates the prevalence of doctor-diagnosed PSO
and PsA in southern Sweden, using a health care register
covering the entire population in the region.
In the Ska˚ne Health Care Register (SHCR) (covering 1/8
of the total Swedish population), information on all
primary health care and specialized outpatient and
inpatient care are continuously collected for
individuals living in the county of Ska˚ne with personal
identification number (PIN), age, sex, health care
provider, date of visit and ICD-10 diagnosis codes.
From the SHCR, we selected individuals who at any
time during the period Jan. 1, 1998 and Dec. 31, 2010
had consulted a doctor and at that time received an ICD-
10 diagnosis code (L40.0, L40.1, L40.4, L40.5, L40.8,
L40.9) consistent with PSO. From this group we selected
those with any of the following PsA diagnosis codes:
M07.0, M07.1, M07.2, M07.3 and M09.0. Those
diagnosed using code L40.5 or a combination of a PSO
and a PsA diagnosis code were defined as having PsA. By
cross-referencing with PIN from the Population Register
(total pop. in southern Sweden Dec. 31,
2010 = 1,242,669) individuals who were deceased or
had relocated out of the county by Dec. 31, 2010 were
excluded. Hence, we calculated the point prevalence
estimates for both PSO and PsA by Dec. 31, 2010.
During 1998–2010, we identified 20,625 individuals who
fulfilled the inclusion criteria for PSO and were still alive
and resident in the county. This means a doctor-
diagnosed PSO prevalence estimate of 1.95% (95% CI
1.93–1.98) in the population of southern Sweden. Out of
the individuals diagnosed with PSO, 3,596 (13.5%)
individuals were identified as having PsA, yielding a
prevalence of doctor-diagnosed PsA of 0.34% (95% CI
0.33–0.35) by the end of 2010.
In this study we have demonstrated how a register of
true health care consumption can be used to estimate
the prevalence of PSO and PsA. This information is of
particular interest in further studies on the burden of the
disease and costs associated with PSO and PsA.
P042
Nail psoriasis: epidemiology and the burden
of disease.
Klaassen, Karlijn1; Pasch, Marcel2;
van de Kerkhof, Peter2
1Radboud University Nijmegen Medical Centre,
Dermatology, Rene Descartesdreef 1, Nijmegen,
Netherlands; 2Radboud University Nijmegen Medical
Centre, Dermatology, Nijmegen, Netherlands
Background: Nail manifestations in psoriasis are an often
overlooked symptom of the disease. The documented
prevalence of nail disease among psoriasis patients varies
between 15 and 79%, with an estimated lifetime
incidence of 80–90%. The aim of this investigation was
to gain knowledge about the epidemiology of nail
psoriasis and the burden of disease.
Methods: A structured self-administered questionnaire
was distributed to all members (n = 5,400) of the Dutch
Psoriasis Association. The questionnaire enquired about
socio-demographic patient characteristics and psoriasis-
related data. Patients reported their nail manifestations
after instruction with photographs. The questionnaire
included validated instruments concerning quality of
life (Dermatology Life Quality Index; DLQI) and
psoriasis severity (Self Administered Psoriasis Area and
Severity Index; SAPASI). Patients with nail psoriasis were
compared with patients without nail psoriasis with
regard to former mentioned items.
Results: A total of 1,479 (27.0%) questionnaires were
returned and included. Of all respondents, 66.0% was
diagnosed with nail psoriasis. The most frequent
observed psoriatic nail manifestation was pitting
(65.4%). The group of patients with nail involvement
had more severe psoriasis (SAPASI score 6.6 vs. 5.3),
longer disease duration (32.4 vs. 30.3 year) and younger
age at diagnosis (24.4 vs. 28.3 year) compared to the
patients without nail involvement. Patients with both
nail bed and nail matrix manifestations showed a
significant worse quality of life and more severe
psoriasis compared with patients with either nail bed
or nail matrix involvement (DLQI: 5.3 vs. 4.3 and 4.3;
SAPASI 7.2 vs. 5.6 and 5.8). Sixteen percent of patients
received treatment for their nail psoriasis.
Discussion: Nail psoriasis is a relevant manifestation of
psoriasis. Psoriasis severity and quality of life are
influenced by nail psoriasis. Combination of nail bed
and nail matrix manifestations is related to a higher
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severity of psoriasis and inferior quality of life.
Management of psoriasis should include a focus on
nail involvement to improve quality of life in psoriasis
patients.
P043
Comparative analysis of the cohorts with early
and established psoriatic arthritis (PsA)
Khraishi, Majed1; Aslanov, Rana2
1NEXUS Clinical Research, St. John’s, Canada;
2Memorial University of Newfoundland, St. John’s,
NL, Canada
Aim: Early PsA diagnosis/management could prevent
disease progression, associated with destructive joint
damage, disability, and increased cardiovascular risk.
The aim of this study was to analyze the differences in
clinical presentation and patient quality of life (QoL) in
early (EPsA) versus established PsA, defined as\2
and C2 years from diagnosis, respectively.
Methods: PsA patients (CASPAR criteria) were recruited
from a rheumatology clinic specializing in PsA and
followed prospectively. Clinical assessment included
TJC, SJC, standard joint radiography, blood tests,
number of involved entheses, PASI, PASQ, HAQ, and
DAS28. QoL was assessed with the SF-36 and EQ-5D (EQ-
VAS) questionnaires.
Results: A total of 196 patients were included, among
whom 84 (42.9%) and 112 (57.1%) belonged to the early
and established cohort, respectively. Gender distribution
(52.4 vs. 48.2% females) and age (48.0 vs. 49.7 years)
were comparable. EPsA patients were older at Psoriasis
(38.7 vs. 34.1; P = 0.030) and PsA (47.9 vs. 44.3;
P = 0.037) onset; they also had a significantly higher
incidence of DIP involvement (OR = 1.78, 95% CI
1.00–3.15; P = 0.049). Mean TJC and SJC did not differ
significantly. The Established PsA cohort had a
significantly higher number of abnormal, clinically
relevant changes in almost all joints compared to EPsA.
EPsA patients had significantly higher PASQ score (11.3
vs. 6.2; P\0.001), DAS28-3 (CRP) (3.8 vs. 3.3;
P = 0.011), and Pain VAS (33.2 vs. 23.8; P = 0.017). At
baseline, NSAID use was non-significantly higher in
EPsA patients (81.0 vs. 71.4%), while patients with
Established PsA were more frequently treated with
MTX (46.4 vs. 31.0%; P = 0.039), sulfasalazine,
adalimumab, etanercept, and infliximab. Significant
between-group differences were observed in QoL with
EPsA patients reporting improved physical (PCS 57.2 vs.
42.6; P = 0.003) and mental functioning (MCS 62.1 vs.
46.2; P\0.001), as well as General Health Status (EQ-
VAS 65.7 vs. 50.2; P\0.001).
Conclusions: The results of our study suggest that early
diagnosis and management of PsA can effectively help in
reducing the burden of disease, preventing the
permanent joint damage and improving the patients
QoL.
P044
Biologic therapies in the treatment of psoriasis: their
association with the development of specific
inflammatory comorbid conditions among a cohort
of the Newfoundland and Labrador population
Gulliver, Wayne1; Gladney, Neil2; Collins, Kayla2;
Morrissey, Andrea2; MacDonald, Don2
1Memorial University of Newfoundland, Faculty of
Medicine, 300 Prince Phillip Drive, St. John’s, NL,
Canada; 2Newfoundland and Labrador Centre for
Health Information, St. John’s, NL, Canada
This is a retrospective cohort study investigating the
association between particular inflammatory conditions
including uveitis, ankylosing spondylitis, psoriatic
arthritis, Crohn’s disease, ulcerative colitis, myocardial
infarction and stroke and treatment type received
(biologics versus non-biologics). We hypothesize that
a decreased frequency of such inflammatory conditions
will be seen in psoriasis patients receiving biologic
therapy. Such a hypothesis stems from the
rationalization that biologics target important aspects
of the immune system including T lymphocytes and
cytokines which cause the inflammatory aspects of
psoriasis. Because biologics are targeted to reduce
chronic inflammation of psoriasis, it follows that they
might also have an impact on inflammation in the eye,
joints, bowel and coronary arteries. A retrospective
cohort study linking medical records of over 10,000
confirmed cases of psoriasis who have received either
biologic or non biologic treatment. Cases come from a
private dermatology clinic in St. John’s (NewLab Life
Sciences Inc.), as well as administrative health
databases of the Newfoundland and Labrador Centre
for Health Information, St. John’s, Newfoundland and
Labrador. The following data sources will be linked
through a multi-step data linkage process.
1. The NewLab Psoriasis Clinical Database (1989–2011)
2. The NewLab Biologics Treatment Database
(1999–2011)
3. The Clinical Database Management System (CDMS;
hospital separation database) (1995/96–2009/10)
4. The Newfoundland and Labrador Medical Care Plan
(MCP) fee-for-service physician claims database (FFS)
(1995/96–2009/10)
Descriptive statistics will be generated to describe the
distribution of psoriasis patients by treatment type,
demographic and prognostic. Analyses will be performed
to determine if there is a difference in the occurrence of
specific inflammatory comorbidities between treatment
groups. Analyses will be performed to investigate possible
associations between inflammatory conditions and
treatment type (biologics or non-biologics).
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P045
An examination of biologic treatment groups
of psoriasis patients in a cohort
of the Newfoundland and Labrador population
Gulliver, Wayne1; Morrissey, Andrea2; Gladney,
Neil2; Dowden, Jeffrey2; Collins, Kayla2;
Alaghehbandan, Reza2; MacDonald, Don2
1Memorial University of Newfoundland, Faculty of
Medicine, 300 Prince Phillip Drive, St. John’s, NL,
Canada; 2Newfoundland and Labrador Centre for
Health Information, St. John’s, NL, Canada
Research regarding biologics treatment for psoriasis is
quite limited given that biologics treatments were
introduced to the market only within the past
10 years. In this study, the distribution of psoriasis
patients by biologic treatment type, demographic factors
and prognostic factors was examined. Health service
utilization (hospital and physician visits) and
comorbidities among psoriasis patients by biologic
treatment type was also described. The odds of
developing particular comorbid conditions was
examined based on whether or not a patient received
biologics treatment. Preliminary findings suggest the
majority of patients receiving biologics treatment had
moderate/severe psoriasis. Signs and ill-defined
conditions, skin/sub-cutaneous diseases, respiratory
disease, nervous system/sense organs disease and
musculoskeletal/connective tissue diseases were some
of the most common comorbidities found across all
biologic classes. Among biologics patients, 63.7% had at
least one unique hospital separation, and 96.3% had at
least one physician visit. The Charlson Comorbidity
Index (CCI) which predicts 1 year mortality for patients
with many comorbid conditions was significantly higher
in female patients (2.37) as compared to male patients
(1.93) p\0.05 on biologics. Of the biologics patients
whose Psoriasis Area and Severity Index (PASI) scores
were available, 86.1% saw improvements after biologics
treatment. An important limitation of this study is its
design as a cross-sectional, descriptive study looks only
at a snapshot of a population at a particular time.
P046
PSOLAR: Canadian update of a multicentre, open
registry of psoriasis patients
Poulin, Y1; Bissonnette, R2; Gulliver, W3;
Guenther, L4; Lynde, C5; Ho, V6; Papp, Kim7;
Binder, C8; Langholff, Wayne9; Chevrier, Marc9
1Centre Dermatologique du Quebec Metropolitain,
Quebec City, Canada; 2Innovaderm, Montreal,
Canada; 3Memorial University of Newfoundland,
NewLab Clinical Research Inc, St. John’s, Canada;
4Guenther Dermatology Research Centre, London,
Canada; 5Lynde Dermatology, Markham, Canada;
6University of British Columbia, Department of
Dermatology and Skin Science, Vancouver, Canada;
7Probity Medical Research, Waterloo, Canada; 8Janssen
Inc, Toronto, Canada; 9Janssen Services, LLC,
Horsham, USA
Objective: To determine baseline characteristics
of Canadian participants in PSOLAR (PSOriasis
Longitudinal Assessment Registry) for patients (pts) with
PsO who are candidates for systemic treatment. Baseline
demographics of the enrolled cohort are presented.
Methods/Results: PSOLAR is a multicenter, prospective,
longitudinal, 8 + years, observational study in academic
and community-based settings. Eligible pts are
aged C18 years, have a diagnosis of PsO and are
currently receiving (or are candidates for) systemic
therapies for PsO. Demographics and medical/family
history are collected at enrollment. Collections at
6 month intervals include: adverse events, disease
activity, quality of life, economic status, healthcare
utilization and interval therapies. 35 Canadian sites
recruited 1,366 pts (representing 14.4% of the total
global population) as of August 23, 2011. Number of pts
discontinuing to date is 38 (2.8%) with reason of
‘‘withdrawal of consent’’ [15 (1.1%)] and ‘‘presumed
lost to follow-up’’ [16 (1.2%)] documented as the top 2
reasons. The baseline characteristics were: mean age:
49.2 (SD 12.1), 28.0% of pts C45 years, 62.5% male,
90.7% white, mean BMI 31.5 (SD 6.9), 73.4% in a
committed relationship, 55.0% with college/university
education, disease duration is 11–20 years in 30.1%, and
21–30 years in 27.1%. Medical histories reported
[category (% patients)]: cardiovascular (43.2%),
pulmonary (11.2%), psychiatric (22.8%), skin cancer
(2.8%), endocrine (20.4%). Infections requiring
treatment (during the past 3 years) occurred in 19.2,
16.9% of which were bacterial infections. Mean disease
activity (peak historical disease activity and disease
activity at entry) were: BSA 24.5% (SD 18.5) and 8.1%
(SD 12.7); PGA 3.4 (SD 0.7) and 2 (SD 1.2);. mean
baseline PASI was 5.9 (SD 6.8). 99.1% of pts presented
with plaque type PsO. Medication (current and history)
included (not mutually exclusive) topical (97.2%),
phototherapy (73.7%), systemic steroids (9.6%),
immunomodulators (56.0%), and biologics (87.0%).
Conclusions: As a disease directed registry, PSOLAR offers
the ability to capture multiple features of pts using (or
eligible to use) systemic therapies.
P047
Psoriatic arthritis mutilans in the Nordic countries;
demographics and disease status
Gudbjornsson, Bjorn1; Leif, Ejstrup2; Jan Tore, Gran3;
Lars, Iversen4; Ulla, Lindqvist5; Leena, Paimela6;
Thomas, Ternowitz7; Mona, Sta˚hle8
1University Hospital, Center for Rheumatology
Research, Reykjavik, Iceland; 2Odense University
Hospital, Department of Rheumatology, Odense,
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Denmark; 3Oslo University Hospitals, Department of
Rheumatology, Oslo, Norway; 4Aarhus University
Hospital, Department of Dermatology, Aarhus,
Denmark; 5Uppsala University, Department of Medical
Sciences, Uppsala, Sweden; 6Helsinki University
Central Hospital, Department of Rheumatology,
Helsinki, Finland; 7Stavanger University Hospital,
Department of Dermatology, Stavanger, Norway;
8Dermatology Unit, Department of Medicine,
Karolinska Institutet Stockholm, Stockholm, Sweden
Objectives: Determine the prevalence and demographics of
psoriatic arthritis mutilans (PAM) in the Nordic countries
based on initiative and guardianship of the Nordic
Psoriasis Associations Cooperation Group, NORDPSO.
Methods: Patients with PAM 18 years of age or older,
living in four Nordic countries (Denmark, Norway,
Iceland and Sweden), were located in collaboration
with dermatologic and rheumatologic departments in
four Nordic countries. 59 patients were identified and
examined for verification of their skin and joint disease
according standardized procedures.
Results: Prevalence of PAM in the adult Nordic population
was estimated to be 4.48 per 1,000,000 inhabitants (95%CI
1.14–8.81). The female to male ratio 1:1. The mean age of
skin disease onset was 25 years of age and 30 years for the
onset of joint disease. Onset of skin disease was 2 years
earlier among female patients. Mean duration of arthritis
formalewas27 ± 11and33 ± 11 years for femalepatients.
The PAM was most frequently seen in the DIP joints of the
toes, followed by the IP joint of the thumb and DIP-joint of
the little finger. Evaluation of the peripheral joints
demonstrated that 32 patients (54%) had painful joint on
palpation and 28 patients (47%) had swelling over their
joints at the time of evaluation. Enthesitis was found in 19
patients (32%), while 38 patients (64%) had a history of
dactylitis, whereas no patient was found to have active
dactylitis on the time of clinical evaluation. 23 of these 38
patients (61%) had dactylitis in the same finger/toe as they
had their PAM.
At the time of inclusion, 45% of the patients were found
to have clear or almost clear skin, 35% had mild to mild-
moderate skin involvement and only 11% of the
patients had moderate to severe skin involvement
according to assessment by the physician.
The majority of the patients (61%) had a familiar history
of psoriasis, but fewer had family history of PsA (24%),
among their first-degree family members.
Conclusions: PAM in the Nordic countries has a low
prevalence, or only three cases per million inhabitants.
Further studies, e.g. on genetics, bone markers, quality
of live and imaging are in progress.
P048
Psoriasis–epidemiology characteristics and patients’
quality of life; Palestine 2011
Nazzal, Zaher; Arda, Hisham; Elaf, Abuzarour
An-Najah National University, Nablus, Palestinian
Territory
Background: Psoriasis is a multifactorial, complex,
disfiguring, chronic inflammatory skin disease with a
worldwide distribution. It is well known to be associated
with psychological morbidity. The database on this
aspect from developing countries is limited. The aim of
this work is to describe the epidemiological
characteristic of psoriatic patients and to assess the
quality of life (QOL) among a group of them.
Methods: This study is a retrospective descriptive survey
of patients seen at a general dermatology clinic in North
Palestine during a 5 years period; from Jan 2006 to Dec
2011. It presents the epidemiological and clinical
characteristics of all psoriatic patients. For the purpose
of assessing quality of life, a cross sectional study was
conducted on 46 psoriatic patients using the
Dermatology Life Quality Index (DLQI) questionnaire.
Results: During the above mentioned period, a total of
29,155 patients were treated for dermatologic
conditions, among them 772 patients were diagnosed
with Psoriasis; 2.6% occurrence rate. Files of theses
psoriatic patients were studied; 51% of the patients were
male, 56.2% of the patients were B30 years of age, and
11.2% had family history of psoriasis. Plaque Psoriasis
was the most frequent type and the scalp and trunk were
the most affected body sites. Psoriasis affects the life of
about 90% of the patients, most of whom reported
moderate effect on their QOL; mostly due to feeling and
symptoms of the diseases. Other affected aspects of life
were work, leisure, and social relations.
Conclusion: Psoriasis is a common disease among
patients attending dermatology clinics in Palestine. It
is equally distributed between both genders and most of
patients are young. On the other hand, Psoriasis is not
just a cosmetic nuisance; it also has a negative impact on
QOL among Palestinian patients.
P049
Natural course of psoriasis: a preliminary study
Alpsoy, Erkan1; Donmez, Levent2; Nazlim, Berna3;
Ozkesici, Birgul3; Akman-Karakas, Ayse3;
Yilmaz, Ertan3
1Akdeniz University, Dermatology and Venerology,
Akdeniz University, Dept. of Dermatology and
Venerology, Antalya, Turkey; 2Akdeniz University,
Public Health, Antalya, Turkey; 3Akdeniz University,
Dermatology and Venerology, Antalya, Turkey
Objective: The natural course of psoriasis is not fully
known. In this preliminary study, we aimed to
determine the occurrence of the clinical presentations
and individual symptoms retrospectively in chronologic
order in psoriasis patients.
Patients and Methods: A total of 54 patients (35 female,
19 male; aged, 40.24 ± 2.18 years) were involved in the
study. Clinical presentations and individual symptoms
of the disease were recorded in the time order of the
manifestations per patient retrospectively. Kaplan–
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Meier survival analysis was used for obtaining the mean
occurrence duration of each clinical presentation.
Results: Skin was the most common onset area (n:52;
96.2%) followed by nails (n:4; 7.4%) and joints (n:1;
1.8%). Plaque psoriasis was the most commonly
observed clinical subtype (n:51; 94.4%). Additionally,
1 guttate psoriasis, 1 inverse psoriasis and 1
palmoplantar pustular psoriasis were seen. Change in
clinical morphology has been obtained in 14 patients
(11 guttate psoriasis, 1 plaque psoriasis, 1 generalized
pustular psoriasis, 1 guttate and inverse psoriasis). Scalp
(n:12; 22.2%) was the most commonly affected skin area
at onset of the disease, followed by knee and elbow
(n:11; 20.3%), and arm, leg and palms (n:5; 9.2%). The
duration between the occurrence of the first symptom
and the diagnosis of psoriasis was found to be
2.39 ± 0.48 (mean ± SE) years. In survival analysis,
average time period between the appearance of the
first symptom and skin involvement, nail involvement,
and articular involvement was calculated to be
0.21 ± 0.11, 25.41 ± 3.25 and 43.99 ± 1.17 (mean ± SE)
years, respectively.
Conclusions: Our study indicates that at onset, skin is far
more frequently affected area than nails and joints. Plaque
psoriasis is the most commonly observed clinical subtype,
and scalp, knee and elbow are the most commonly affected
skin area at onset of the disease. During the natural course,
although attacks of the disease are generally similar to
original clinical subtype, guttate psoriasis was the most
frequently observed change in clinical morphology.
P050
Childhood psoriasis: characteristics of the disease
among Saudi population
Alajlan, Abdulmajeed1; Alsuwaidan, Sami2
1King Khalid University Hospital, Dermatology, P.O
Box 7805 Dermatology, KKUH-Dermatology, Saudi
Arabia; 2King Saud University, Dermatology, Riyadh,
Saudi Arabia
Psoriasis is a chronic inflammatory, immunologically
mediated disorder in which one-third of patients suffer
under the 18 years of age (childhood psoriasis). In this
study, we present our experiences with 36 children having
psoriasis who visited the dermatology and phototherapy
unit from January 2000 to December 2005. Of the 36
children with psoriasis, 12 (33.33%) had the generalized
(plaque type) psoriasis, 8 (22.22%) had the guttate
psoriasis, 4 (11.11%) had the mixed guttate and plaque
type; while 6 (16.67%) had the localized lesions on elbows
and knees, 4 (11.11%) had the localized pustular lesions on
hands and feet and 1 (2.77%) had localized lesions on the
scalp. The age of children was ranging from 8 months to
18 years (mean = 11.27 years). The duration of the disease
was ranging from 2 months to 11 years (mean = 3.04
years). The number of malepatients was 15 and the females
were 21, hence the male and female ratio was 1:1.4. The
familyhistorywaspositive in10children(27.78%).Mostof
patients were treated with topical medications
(corticosteroid, vitamin D derivatives and tacrolimus)
and/or narrow-band ultraviolet-B phototherapy
treatment with reasonable control. Two of the cases with
guttate psoriasis developed plaque psoriasis later. One
child was given etanercept with good response and
minimal side effect. Psoriatic arthritis was not noticed in
our group of children. We conclude that childhood
psoriasis is more common in girls and plaque type
psoriasis is the commonest in our community. Psoriatic
arthritis has not been documented in our group. At
present, topical therapy (corticosteroid, vitamin D
derivatives and tacrolimus) the narrow-band ultraviolet-B
phototherapy are sufficient for most of the children and
showed decent safety and efficacy.
Comorbidities
P051
Atherosclerosis in patients with psoriasis:
role of systemic inflammation
Yeung, Chi Keung1; Yiu, KH1; Zhao, CT1; Siu, CW1;
Tam, Sydney2; Wong, CS3; Yan, GH3; Yue, WS2;
Khong, PL3; Chan, Henry1; Tse, HF1
1The University of Hong Kong, Medicine, Hong Kong,
Hong Kong; 2The University of Hong Kong, Clinical
Biochemistry, Hong Kong, Hong Kong; 3The University
of Hong Kong, Diagnostic Radiology, Hong Kong,
Hong Kong
Introduction: Patients with psoriasis are prone to premature
atherosclerosis; nonetheless the prevalence and extent of
atherosclerosis in the coronary and carotid arteries in
relation to systemic inflammation are unknown.
Methods: The prevalence and extent of coronary and
carotid arterial atherosclerosis in 70 patients with
psoriasis (46 ± 9 years, 71% male) without known
cardiovascular diseases was compared with 51 age-and
gender-matched controls (45 ± 7 years, 71% male).
Coronary arterial atherosclerosis was determined by
the coronary calcium score (CCS) measured by multi-
detector computed tomography. Carotid atherosclerosis
was assessed by high-resolution ultrasound derived
carotid intima media thickness (cIMT).
Results: Patients with psoriasis had a significantly higher
prevalence of CCS[0 as compared to controls (28.6 vs.
3.9%, p\0.01). Moreover the degree of coronary
atherosclerosis estimated by the mean CCS was more
severe inpatientswithpsoriasis (67.4 ± 349.2vs. 0.5 ± 3.0,
P\0.05). Carotid atherosclerosis was greater in patients
with psoriasis (cIMT 0.73 ± 0.11 mm vs. 0.67 ± 0.08 mm,
p\0.01). Importantly, the presence of significant
coronary atherosclerosis defined by CCS[10 was
independently associated with hs-CRP. In contrast, only
age was independently associated with increased cIMT.
Conclusion: The present results demonstrated that
patients with psoriasis had early onset, diffuse arterial
atherosclerosis over coronary and carotid arteries as
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compared to age-and-gender matched controls.
Importantly, hs-CRP was independently predictive of
significant coronary atherosclerosis, suggesting a link
between systemic inflammation and subclinical
atherosclerosis in patients with psoriasis.
P052
Considerations in the study of TNF-alpha inhibitor
and methotrexate therapy on metabolic factors
in psoriasis/psoriatic arthritis and rheumatoid
arthritis patients
Wu, Jashin1; Rowan, Christopher2; Poon, Kwun-Yee3;
Anthony, Mary4; Xiang, Anny3
1Kaiser Permanente Los Angeles Medical Center,
Dermatology, 1515 North Vermont Avenue, 5th Floor,
Los Angeles, USA; 2Outcome, A Quintiles Company,
Cambridge, USA; 3Kaiser Permanente Southern
California, Department of Research and Evaluation,
Pasadena, USA; 4Amgen Inc., Center for Observational
Research, Thousand Oaks, USA
Objective: To understand the impact of treatment with a
TNF inhibitor (TNFi) or methotrexate (MTX) on
metabolic factors in psoriasis (PsO), psoriatic arthritis
(PsA), and rheumatoid arthritis (RA) patients.
Methods: The study population consists of adult patients
diagnosed with prevalent or incident PsO/PsA/RA between
January 1, 2002 and July 31, 2011 from a large HMO.
Patients exposed to a TNFi (etanercept, adalimumab,
infliximab, golimumab, and certolizumab pegol) ± MTX
exposure comprised the TNFi group. Patients in the TNFi
group were matched to patients exposed to MTX but not a
TNFi (MTX group). Drug exposure status was determined
based on exposure status within 15–45 days prior to the lab
measurements. The groups were matched on
inflammatory condition (PsO/PsA/RA), diabetes status,
and the date of TNFi initiation/prevalent MTX exposure
(index date). All patients had metabolic factor
measurements within 1-year before and after the index
date. Unadjusted mean percent change from baseline and
95% confidence intervals (CI) in HbA1C, fasting glucose
(FG), and triglycerides (TG) was determined in both
exposure groups.
Results: The study population had a mean age of
62 + 12 years (SD), about 27% were male, 22% had
PsO, 12% PsA and 86% RA. For HbA1c, 78% of those
with this measure had diabetes mellitus type 2 (DM).
The HbA1c mean percent change was +0.8% in TNFi (CI:
-0.4, 2.0, n = 550) and +2.0% in MTX (CI:1.4, 2.7,
n = 1,979). For FG, 31% had DM. The FG mean percent
change was +4.2% in TNFi (CI: 2.2, 6.1, n = 644) and
+3.5% in MTX (CI: 2.7, 4.3, n = 3,944). For TG, 24% had
DM. The TG mean percent change was +10.2% in TNFi
(CI: 7.4, 12.9, n = 983) and +5.5% in MTX (CI: 4.2, 6.8,
n = 4,194). Analysis of other metabolic factors and
comparisons between treatment groups while accounting
for differences in medications and demographic and
clinical factors are in process.
Conclusion: TG and FG significantly increased in TNFi
and MTX groups and HbA1c significantly increased in
the MTX group. Further analyses will provide
information on the contributions of TNFi and MTX
therapy and other patient characteristics and treatments
on changes in these and other metabolic factors.
P054
Do TNF alpha-blockers influence male fertility?




Fertility of male psoriasis patients is rarely addressed and
included in therapeutic decisions. However, with this
regard young patients are often uncomfortable about
short and long term consequences of systemic treatment
of their disease. Apparently, TNF alpha plays a major role
in male fertility as motility and apoptosis are negatively
influenced. Conversely, therapeutic TNF blockage may
exert positive effects. Clinical studies on this aspect are,
however, not available. In patients aged 18–50 years
with psoriasis several fertility parameters were examined
before and during a 52 week treatment with TNF
blockers and fumaric acids (number of spermatocytes,
apoptosis, biochemical parameters like fructose and
citrate). Exclusion criteria were concomitant drug
treatment with possible effects on male fertility or
known decrease or loss of fertility. Two consecutive
spermiograms within 2 weeks were performed per date
at weeks 0, 12, 24, 38 und 48. 10 patients, four on
etanercept were included with no relevant changes of
spermatocyte numbers, motility and acrosomal reaction
over 24 weeks. Though undulation of the examined
parameters over time were found, no relevant
deterioration nor improvement of male fertility were
found. Accordingly, parameters seem grossly unchanged
by therapy.
P055
Ophthalmic manifestations in psoriatic patients
in a Brazilian referral center
Santos Paim de Oliveira, Maria de Fa´tima1;
de Oliveira Rocha, Bruno2; Simas Yamakawa Boeira,
Vanessa Lys2; Abreu Azevedo Fraga, Naiara2; Follador,
Ivonise2; Pedreira de Almeida Reˆgo, Vito´ria Regina2;
de Oliveira Chagas, Ricardo Danilo3
1Federal University of Bahia, Dermatology, Augusto
Viana Street, Canela, Salvador, Brazil; 2Federal
University of Bahia, Dermatology, Salvador, Brazil;
3Federal University of Bahia, Ophthalmology,
Salvador, Brazil
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Background: Psoriasis is a chronic inflammatory systemic
disease that affect about 1–3% of the world population.
Ocular manifestations in psoriasis are poorly reported in
the literature. The purpose of this study was to identify
the prevalence of ophthalmic manifestations in psoriatic
patients treated at a referral outpatient clinic in Salvador
(Bahia/Brazil).
Materials and methods: It was conducted an analytical
cross-sectional study, including 43 patients (24 males
and 19 females). A dermatologic evaluation included
measurement of the PASI and registration of the
topography of the lesions. The ophthalmological
examination included Schirmer-I test, the Rose Bengal
test and slit lam examination. The results were analyzed
by Fisher’s exact test and associations were considered
significant when the p value\0.05. Informed consent
was obtained from all subjects.
Results: Ocular abnormalities were detected in 36
(83.72%) patients, and the most frequent was Meibom
gland dysfunction, in 31 (72.09%) patients. Only 2
patients (4.65%) reported no ocular symptoms. There
was a statistically significant correlation between the
presence of lesions on the face and the occurrence of
Meibom gland dysfunction (p = 0.046).
Discussion: Data from this study certainly are the first
reports of the prevalence of eye diseases in psoriasis in
Brazil. The frequency of Meibom gland dysfunction in
the general population is 3.5%, suggesting that psoriatic
patients are more likely to have that. Studies with
animal models and other inflammatory diseases suggest
that this correlation is probably due to both
hyperkeratinization along the duct of the Meibom
gland and exacerbated Th17 immune response.
However, in agreement with previous studies, it can be
hypothesized that psoriasis is itself a risk factor other eye
diseases. Further investigation is required to elucidate
the prevalence and nature of the ophthalmologic
manifestation in patients with psoriasis.
P056
Vitamin D, body fat composition and parameters
of atherogenesis and inflammation in psoriatic
patients treated with narrow-band UVB
Romanı´, Jorge1; Caixa´s, Assumpta2; Ceperuelo,
Victoria3; Carrascosa, Jose´ M.4; Ribera, Miquel5;
Rigla, Mercedes2; Vendrell, Joan3; Luelmo, Jesu´s5
1Hospital Parc Taulı´, Dermatology, Parc Taulı´ S/N,
Sabadell Barcelona, Spain; 2Hospital Parc Taulı´,
Endocrinology, Sabadell Barcelona, Spain; 3Hospital
Joan XXIII, Endocrinology, Tarragona, Spain; 4Hospital
Germans Trias i Pujol, Dermatology, Badalona, Spain;
5Hospital Parc Taulı´, Dermatology, Sabadell Barcelona,
Spain
Introduction: Psoriasis is a chronic inflammatory skin
disease that has been related to metabolic syndrome.
Objectives: The objectives included the evaluation of
anthropometric and laboratory markers of metabolic
syndrome in psoriatic patients and matched controls,
and their modification after narrow-band UVB
phototherapy.
Materials and methods: We compared 50 psoriatic
patients with 50 sex, body mass index and age-
matched controls without psoriasis in a cross-sectional
study. Additionally, we evaluated the effect of narrow-
band UVB over the studied parameters. Patients eligible
for narrow-band UVB phototherapy were recruited
excluding the months of high solar irradiance.
Controls without psoriasis were matched to the
patients’ characteristics. Patients with psoriatic arthritis
were excluded, along with patients and controls with a
list of chronic inflammatory diseases. The evaluation
was performed at baseline in controls and patients, and
after phototherapy in patients, and included a panel of
laboratory and anthropometric determinations.
Results: With an identical body mass index, psoriatic
patients showed a higher body fat content as calculated
by electric bioimpedance, which correlated positively
with waist circumference, and higher plasma
concentrations of LDL-cholesterol, leptin and apo-B.
Vitamin D was low both in patients and controls, and
increased in the patients and the end of the
phototherapy course. No correlation of its increase
with PASI improvement was noted. At the end of the
treatment a decrease in ferritin levels was noted, and it
was correlated with total cumulative UVB dose.
Conclusions: We identified a different metabolic and
anthropometric profile in psoriatic patients without
arthritis when compared to matched controls. Both
patients and controls had vitamin D insufficiency. The
increase in vitamin D levels after phototherapy did not
correlate with PASI improvement.
P057
Adipocytokine expression and correlation
with atherogenesis and inflammation markers
in psoriatic patients treated with narrow-band UVB
phototherapy
Romanı´, Jorge1; Caixa´s, Assumpta2; Ceperuelo,
Victoria3; Carrascosa, Jose´ M.4; Ribera, Miquel5; Rigla,
Mercedes2; Luelmo, Jesu´s5
1Hospital Parc Taulı´, Dermatology, Parc Taulı´ S/N,
Sabadell Barcelona, Spain; 2Hospital Parc Taulı´,
Endocrinology, Sabadell Barcelona, Spain; 3Hospital
Joan XXIII, Endocrinology, Tarragona, Spain; 4Hospital
Germans Trias i Pujol, Dermatology, Badalona, Spain;
5Hospital Parc Taulı´, Dermatology, Sabadell Barcelona,
Spain
Introduction: Psoriasis is a chronic inflammatory skin
disease that has been related to metabolic syndrome.
Objectives: We evaluated several parameters related to
metabolic syndrome and the expression of
adipocytokines related to cutaneous and systemic
inflammation in psoriatic patients, and their changes
after a course of narrow-band UVB phototherapy.
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Materials and methods: We compared 50 psoriatic
patients with 50 age, sex and body mass index-
matched controls in a cross-sectional study.
Additionally, we evaluated the changes related to a
course of narrow-band UVB phototherapy in a
longitudinal study. Patients eligible for narrow-band
UVB phototherapy were recruited excluding the months
of high solar irradiance. Controls without psoriasis were
matched to the patients’ characteristics. Patients with
psoriatic arthritis were excluded, along with patients and
controls with a list of chronic inflammatory diseases.
The evaluation was performed at baseline in controls
and patients, and after phototherapy in patients. It
included the determination of leptin, resistin, omentin,
Il-6, Il-17, S-TNFR, and the lipocalins A-FABP, RBP-4 and
lipocalin-2. The multivariant study included a principal
components analysis, in order to understand the
relationships between the study variables.
Results: Patients showed increased serum concentrations
of leptin, RBP-4, lipocalin-2 and S-TNFR when compared
to controls. These adipocytokines correlated with several
parameters of inflammation and atherogenesis. Initial
PASI correlated with basal concentrations of RBP-4 and
lipocalin-2, and with high sensitivity C-reactive protein.
At the end of the phototherapy course patients
experimented a decrease in Il-6 levels. Principal
components analysis yielded a component with a
protective action over metabolic syndrome in controls,
but not in patients. Psoriatic patients showed, when
compared to healthy controls, a different positioning of
omentin, lipocalin-2, resistin and RBP4 in the principal
components’ factorial
map.
Conclusion: Our results contribute to ascertain the
function of several adipocytokines in the genesis of
inflammatory and metabolic abnormalities in psoriasis.
P058
Prevalence of metabolic syndrome in psoriatic
patients
Ravella Mateu, Anna1; Albareda, M.2; Castello´, M.2;
Saborit, S.2; Roque´, M.2; Peramiquel, L.3;
Smandia, J.A.4; Vila, L.L.5
1Hospital Dos De Maig, Dermatology, Dos De Maig
301, Barcelona, Spain; 2Hospital Moises Broggi,
Endocrinology, S. Joan Despi, Spain; 3Hospital Moises
Broggi, Dermatology, S. Joan Despi, Spain; 4Hospital
Dos de Maig, Dermatology, Barcelona, Spain; 5Moises
Broggi, Endocrinology, S. Joan Despi, Spain
Introduction: Psoriasis is a chronic inflammatory skin
disease, that affects 2% of the general population. It has
been stated that there is a higher prevalence of
metabolic syndrome (MS) and obesity in psoriatic
patients than in the general population.
Objective: To assess the prevalence of metabolic
syndrome (MS) and its components in the psoriatic
patients compared with a control population with the
same age, sex and body mass index (BMI).
Patients and methodology: We examined an ‘‘n’’ of 102
patients in each group, both psoriatic and control (with
a 6% of accuracy), estimating a prevalence of about 30%
of MS in the psoriatic patients. Both the psoriatic
patients and the controls were matched in age, sex and
body mass index.
Study protocol: Anamnesis: Diabetes mellitus records,
Blood pressure, Dyslipidemia and Psoriasis: (age of onset,
duration, type and severity according to the PASI index)
Lifestyle: Diet, Smoking, and Exercise Physical
examination: Weight, Body mass index (BMI), Blood
pressure, Waist circumference. Blood Test: Lipid profile,
Glucose tolerance test (75 g/OGT), level of Insulin
(according to the Homa index). Classification of MS
based on the 2009 Consensus criteria.
Results: 102 psoriatic patients participated in this study (55
men/47women) withanaverage age of 49.32 ± 13.47 years
and BMI 27.7 kg/m2 (18.9–41.79), and 102 control subjects
(55 men/47 women) with an average age of
48.71 ± 13.84 years and BMI 27.36 kg/m2 (18.24–40.5).
The psoriatic patients had higher systolic blood pressure
and a greater Insulin resistance, additional to a higher
frequency of known Diabetes mellitus (13.7 vs. 3.4%,
p = 0.024). Metabolic syndrome prevalence was also
higher (52 vs. 34.3%, p = 0.016). The multivariate analysis
showed that age (RR 1.086), BMI (RR 1.375), sex (RR 2.714)
and psoriasis (RR 3.73) are independent markers of MS.
Conclusion: Psoriasis can be associated with a higher
prevalence of Metabolic Syndrome and this association
is independent from the presence of obesity.
P059
Use of brachial-ankle index for assessing
cardiovascular risk in patients with psoriatic
arthritis, psoriasis alone and controls: a pilot study
Magro-Checa, Ce´sar1; Rosales-Alexander, Jose´ Luis2;
Orgaz-Molina, Jacinto3; Salvatierra, Juan2;
Arias-Santiago, Salvador3; Cantero-Hinojosa, Jesu´s2;
Ruiz-Carrascosa, Jose´ Carlos3; Raya-A´lvarez, Enrique2
1San Cecilio University Hospital, Rheumatology,
Avenida Doctor Olo´riz 16, Granada, Spain; 2San Cecilio
University Hospital, Rheumatology, Granada, Spain;
3San Cecilio University Hospital, Psoriasis Unit,
Dermatology, Granada, Spain
Background: Patients with psoriatic arthritis (PsA) and
with chronic plaque psoriasis (PS) have a higher
prevalence of cardiovascular (CV) risk factors and
atherosclerosis. The Ankle-Brachial pressure Index
(ABPI), a non-invasive and inexpensive tool for the
assessment of CV risk, can be used to identify individuals
who are at high CV risk. An ABPI\0.90 suggests high
risk of developing CV disease.
Objective: To determine the prevalence of an abnormal
ABPI in patients with PsA, PS and healthy controls and
to correlate with clinical and serological parameters.
Methods: This study included 63 consecutive patients
who fulfilled the CASPAR criteria, compared to 63
Page S26 of S67 Dermatol Ther (2012) 2:10
123
patients with cutaneous PS alone and 63 age and sex
matched controls. Patients with a previous CV event and
diabetics were excluded. The ABPI was measured using a
Mini Doppler. A ratio of\0.90 was considered abnormal.
Multivariate regression analysis was used to adjust for
the following variables: sex, age, body mass index,
classic CV risk factors, lipid profile, time since
diagnosis, clinical patterns, treatment, disease activity,
and inflammatory markers (p\0.05 was considered
significant).
Results: The mean age of all the patients was
48.73 ± 10.98 (mean ± SD). The ABPI in the group of
PsA patients was 0.94 ± 0.09, and 13 patients (22.22%)
had an abnormal index (\0.90), three of them (4.76%)
were mildly symptomatic (ABPI\0.80). The mean for
the ABPI calculated in PS patients was 0.93 ± 0.1, and 12
patients (19.04%) were reclassified below the threshold
(\0.90), four of them (6.34%)\0.80. In the group of
controls, the mean was 1.03 ± 0.14, with 5 patients
(7.93%) below the threshold, none of them\0.80.
Multivariate regression analysis showed that the most
important prognostic factor for predicting the ABPI was
the age (p\0.05) followed by a sedentary lifestyle
(p\0.05). Clinical patterns of the PsA and Psoriasis,
treatment and activity of the disease were not associated
with atherosclerosis.
Conclusions: PsA and PS patients present an increased
prevalence of an abnormal ABPI comparing with
controls implying an increased risk of CV disease.
P060
Cardiovascular risk assessment in patients
with psoriatic arthritis: comparison of European
SCORE and two calibrated national guidelines
Magro-Checa, Ce´sar1; Rosales-Alexander,
Jose´ Luis2; Salvatierra, Juan2; Cantero-Hinojosa,
Jesu´s2; Sa´nchez-Parera, Ricardo2; Montes-Garcı´a,
Silvia2; Gonza´lez-Domı´nguez, Jose´2; Raya-A´lvarez,
Enrique2
1San Cecilio University Hospital, Rheumatology,
Avenida Doctor Olo´riz 16, Granada, Spain; 2San Cecilio
University Hospital, Rheumatology, Granada, Spain
Background/Purpose: EULAR task force recommendations
in the cardiovascular (CV) risk in patients with
inflammatory arthritis were published in 2010. EULAR
recommends the use of the SCORE when no local
guidelines are available. In our country, two charts have
been calibrated, the SCORE table (cSCORE), and the
Framingham-Wilson score known as REGICOR scale.
Objective: To assess the CV risk in Psoriatic Arthriths
(PsA) patients using the SCORE for low risk European
countries (eSCORE) and compare it with the cSCORE
and REGICOR. To analyzed the correlation of several
clinical and serological variables with these SCOREs
indexes and the % of patients that received adequate
therapy for the management of CV risk.
Methods: We included 147 consecutive pts who fulfilled
the CASPAR criteria. The following data were recorded
for analysis: sex, age, BMI, classic CV risk factors, lipid
profile, time since diagnosis, clinical patterns of the PsA,
treatment, and inflammatory markers. The three guides
were calculated and concordance (Kappa Index) between
them was compared.
Results: The mean eSCORE was 1.36 ± 2.25%
(mean ± SD) and 18 pts (11.4%) were above the
threshold of high or very high CV risk (C5%). The
mean cSCORE was 2.23 ± 3.48% and REGICOR was
4 ± 3.4%. Therefore, 34 pts (21.5%) and 20 pts (12.7%)
were reclassified above the threshold of high and very
high CV risk respectively. The most important
prognostic factor for predicting the cSCORE was the
age (p = 0.000) followed by systolic blood pressure. Of
notice, the ESR was also a prognostic factor of the
SCORE. Both eSCORE and REGICOR showed a bad
concordance (Kappa Index 0.63 and 0.55 respectively)
with cSCORE. Analyzing the % of high and very high
risk pts that received adequate therapy for the
management of CV risk (antihypertensive and lipid-
lowering therapy): according to the eSCORE 75 and
85%, with cSCORE 65.21 and 35.29%, and with
REGICOR 55.55 and 22.22% respectively.
Conclusions: eSCORE and REGICOR lead to an
underestimation of the CV risk comparing with
cSCORE, which have an impact on the correct
management of these pts. Sustained inflammation
could play a role in the increase of CV risk.
P061
Psoriasis and psoriatic arthritis: large waist
circumference and severity assessment
Kogan, Nora1; Gusis, Simon2; Veira, Rosana1;
Crespo, Alejandra1; Chaparro, Elena1; Amabile,
Pilar1; Kreimer, Jennifer1; Castelli, Andrea2;
Montoya, Sandra2; Kerzberg, Eduardo2
1Ramos Mejia Hospital, Dermatology, Buenos Aires,
Argentina; 2Ramos Mejia Hospital, Rheumatology,
Buenos Aires, Argentina
Introduction: The large waist circumference is a very
important risk factor for metabolic syndrome in Psoriasis
(28%).
Objective: To assess correlation between large waist
circumference and severity assessment in Psoriasis
patients with or without arthritis.
Materials and methods: In 185 patients with Psoriasis: 132
without arthritis (67 female and 65 male) and 53 with
arthritis (33 female and 20 male) we evaluated the
degree of severity of psoriasis with or without arthritis
(Mild Mi, Moderate Mo, Severe Se) and the large waist
circumference. We considered four groups: females (up
to 59.9; 60–79.9; 80–87.9; 88 or more) and males (up to
68.9; 69–93.9; 94–101.9; 102 or more. We used Chi
Square test (Yates correction).
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Results: In 67 females without arthritis there were: up to
59.9: 0; 60–79.9 (Mi 1 Mo 7 Se 0); 80–87.9 (Mi 2 Mo 8 Se 2);
88 or more (Mi 8 Mo 17 Se 22).
In 65 males without arthritis there were: up to 68, 9: 0;
69–93.9 (Mi 2 Mo 9 Se 6); 94–101.9 (Mi 1 Mo 6 Se 3); 102
or more (Mi 3 Mo 14 Se 21).
In 33 females with arthritis there were: up to 59, 9: 0;
60–79.9 (Mi 2 Mo 0 Se 1); 80–87.9 (Mi 4 Mo 1 Se 0); 88 or
more (Mi 15 Mo 6 Se 4).
In 20 males there were: up to 68.9: 0; 69–93.9 (Mi 3 Mo 2
Se 1); 94–101.9 (Mi 5 Mo 2 Se 0); 102 or more (Mi 4 Mo 3
Se 0).
There was no correlation between the large waist
circumference and a greater degree of severity in
patients with Psoriasis without arthritis (p[0.05) and
Psoriatic arthritis (p[0.05).
Conclusions: There was no correlation between the large
waist circumference and a greater degree of severity in
patients with Psoriasis without arthritis (p[0.05) and
Psoriatic arthritis.
P062
Psoriasis and psoriatic arthritis: body mass index
and severity assessment
Kogan, Nora1; Gusis, Simon2; Veira, Rosana1;
Crespo, Alejandra1; Chaparro, Elena1; Amabile, Pilar1;
Kreimer, Jennifer1; Castelli, Andrea2;
Montoya, Sandra2; Kerzberg, Eduardo2
1Ramos Mejia Hospital, Dermatology, Buenos Aires,
Argentina; 2Ramos Mejia Hospital, Rheumatology,
Buenos Aires, Argentina
Introduction: Overweight or obesity is a frequent
comorbidity in psoriasis (32%).
Objective: To assess correlation between body mass index
(BMI) and severity assessment in patients with psoriasis
with or without arthritis.
Materials and methods: In 185 patients with Psoriasis: 132
without arthritis and 53 with arthritis we evaluated the
degree of severity (Mild Mi, Moderate Mo, Severe Se) and
body mass index (BMI). We considered low weight:\20,
normal weight: 20–24.9; overweight 25–29.9 and obese
30 or more. We used Chi Square test (Yates correction).
Results: In 132 patients with cutaneous psoriasis there
were: 4 low weight (Mo:3, Se:1); 26 normal weight (Mi:4,
Mo:19, Se:3), 55 overweight (Mi:7, Mo:26, Se:22); 47
obese (Mi:6, Mo:13, Se:28).
There was correlation between greater BMI and greater
degree of severity in patients with psoriasis without
arthritis (p\0.01).
In 53 patients with Psoriatic arthritis there were: 0 low
weight; 9 normal weight (Le:5, Mo:2, Se:2), 22 overweight
(Le:4, Mo:12, Se:6); 22 obese (Le:7, Mo:12, Se:3).
There was no correlation between greater BMI and
greater degree of severity in patients with psoriatic
arthritis (p[0.05).
Conclusions: There was correlation between greater BMI
and greater degree of severity in patients with psoriasis
without arthritis and there was no correlation in patients
with psoriatic arthritis.
P063
Psoriasis and cardiovascular screening rates
in the United States
Gustafson, Cheryl; Alamdari, Habibollah;
Davis, Scott; Huang, William; Feldman, Steve
Wake Forest University, Department of Dermatology,
Winston-Salem, USA
Background: Guidelines to screen for cardiovascular (CV)
risk factors in psoriasis patients have been established.
However, the frequency with which dermatologists and
non-dermatologists screen psoriasis patients for CV risk
factors is not well characterized.
Purpose: To determine how frequently psoriasis patients
are screened for CV risk factors in the outpatient setting.
To identify factors affecting screening rates.
Methods: Data from the 2005–2009 National Ambulatory
Medical Care Survey (NAMCS) were analyzed to
determine screening rates for blood pressure, glucose,
cholesterol, and body mass index. The probability of a
patient having at least 1 of the 4 risk factors screened was
determined and termed the ‘‘composite’’ score.
Screening rates were assessed by physician specialty,
patient demographics and clinical practice
characteristics.
Results: There were an estimated 11.4 million psoriasis
visits from 2005 to 2009. Blood pressure, glucose,
cholesterol, and body mass index were evaluated at
32.2, 5.9, 9.0, and 26.0% of psoriasis visits, respectively,
with a composite score of 41.2%. Patients without
psoriasis were screened for these CV risk factors at
59.0, 6.0, 8.0, and 38.1% of outpatient visits,
respectively, with a composite score of 66.3%. Psoriasis
had a statistically significant negative association with
CV risk screening rates. Screening rates were relatively
equal across age groups. Screening rates were higher if
the patient was of male gender, African American race,
or non-Hispanic ethnicity. Higher screening rates were
associated with the following clinical practice
characteristics: primary care specialties; faculty
practices; community health clinics with contracted
physicians; and clinics that utilized Electronic Medical
Recorders. Limitations: NAMCS data is cross-sectional
permitting assessment of screening rates based on visits
but not on patients.
Conclusions: Screening for high blood pressure, diabetes,
hypercholesterolemia and obesity are not performed at
most outpatient visits for psoriasis. Care should be taken
to ensure patients receive appropriate screening for
comorbidities associated with psoriasis.
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Association of renal cancer in a psoriasis cohort
from the Newfoundland and Labrador founder
population
Gulliver, Wayne1; Gladney, Neil2; Collins, Kayla2;
Morrissey, Andrea2; MacDonald, Don2
1Memorial University of Newfoundland, Faculty of
Medicine, 300 Prince Phillip Drive, St. John’s, NL,
Canada; 2Newfoundland and Labrador Centre for
Health Information, St. John’s, NL, Canada
Psoriasis is a common chronic immune-mediated
inflammatory disorder of the skin which has several
associated comorbidities. Recently a number of patients
with psoriasis have also been diagnosed with renal
cancer. A cross section observational study investigated
hospital-coded comorbidities associated with psoriasis in
comparison to the general Newfoundland and Labrador
hospital population. Patients with psoriasis died
significantly younger than the general population,
with patients having early onset of psoriasis (\25 years)
dying almost 12 years younger than those of a later age
of onset ([25 years). The mean age of death was 59.3
versus 71.2 (P = 0.001). Psoriasis patients were
hospitalized more frequently for severe systemic
disorders than the general population. Neoplasm was
the underlying cause of death in 37.5% in psoriasis
patients versus 27.6% in the general population
(P = 0.015). Recently in a cohort of 3,500 patients five
patients have been diagnosed with renal cancer (140/
100,000) versus 90 renal cancers in a population of
525,000 in Newfoundland and Labrador (17/100,000).
This study reports possible association between certain
malignancies, including renal carcinoma.
P065
Risk of developing cancer among psoriasis patients
as compared to non-psoriasis patients
Gulliver, Wayne1; Gladney, Neil2; Collins, Kayla2;
Morrissey, Andrea2; MacDonald, Don2
1Memorial University of Newfoundland, Faculty of
Medicine, 300 Prince Phillip Drive, St. John’s, NL,
Canada; 2Newfoundland and Labrador Centre for
Health Information, St. John’s, NL, Canada
In this descriptive study, we assessed whether or not
there is an increased risk of developing cancer among
psoriasis patients as compared to non-psoriasis patients.
We did this by assessing psoriasis patients’ health care
utilization in terms of hospital visits and fee-for-service
physician visits, and compared such with non-psoriasis
patients (controls).
In addition, we assessed whether or not psoriasis
patients receiving biologics treatment specifically have
an increased risk of developing cancer as compared to
psoriasis patients not receiving biologics treatment.
Research also indicates age, gender and psoriasis severity
have an impact on risk of cancer; therefore, we will
provide descriptive analysis with such demographic
factors. Descriptive study involved linking medical
records of 10,000 confirmed cases of psoriasis who
have received either biologic or non biologic
treatment. Data obtained from a private dermatology
clinic as well as administrative data bases using the
unique identifier, Newfoundland and Labrador Medical
Care Plan (MCP). A number of the following sources
were linked through multi step data linkage process.
1. The NewLab Psoriasis Clinical Database (1989–2011)
2. The NewLab Biologics Treatment Database
(1999–2011)
3. the Clinical Database Management System (CDMS;
hospital separation database) (1995/1996–2009/
2010)
4. the Newfoundland and Labrador Medical Care Plan
(MCP) fee-for-service physician claims database (FFS)
(1995/96–2009/10)
Initial data indicates that neoplasm was an underlying
cause of death in 37.9% of psoriasis patients versus
27.6% in the general population (P = 0.015).
P066
Association between pediatric psoriasis
and the metabolic syndrome
Goldminz BA, Ari1; Au MD, Shiu-Chung1; Kim MD,
Noori1; Loo MD, Daniel1; Dumont, Nicole1; Levine
MD, Danielle1; Lizzul MD PhD MBA MPH, Paul1; Volf
MD, Eva1; Michelon MD, Melissa1; Wang MD,
Andrew1; Yaniv BA, Shimrat1; Kerensky MD, Todd1;
Brown MD, Mary2; Kulig MD MPH, John2; Lopez-
Benitez MD, Jorge2; Natter MD, Mark2; Miller MD,
Laurie2; Pelajo MD MSc, Christina2; Davis MD,
Trevor2; Gottlieb MD PhD, Alice1
1Tufts Medical Center, Dermatology, Boston, USA;
2Tufts Medical Center, Pediatrics, Boston, USA
The increased risk of cardiovascular disease and the
metabolic syndrome (MetS) in adults with psoriasis has
been demonstrated in numerous studies, yet limited data
is available assessing cardiovascular risk factors in the
pediatric psoriasis population. We designed an assessor-
blinded study to determine if children with psoriasis or
psoriatic arthritis have an increased prevalence of the
MetS. Twenty subjects between 9- and 17-years-old with
moderate-to-severe psoriasis (C5% body surface area,
current or by documented history) or psoriatic arthritis
were enrolled, and a control group of 1,563 subjects was
created using the NHANES 2007–2008 database. The
MetS was defined by the presence of at least three of the
following: triglycerides C100 mg/dl, HDL-C\50 mg/dl
for females or\45 mg/dl for males, fasting blood
glucose C110 mg/dl, waist circumference[75th
percentile for age and gender, systolic or diastolic blood
pressure[90th percentile for age, gender, and height. Six
of the 20 psoriasis subjects (30%) were found to have the
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MetS compared to 115 of 1,563 (7.4%) NHANES control
subjects (p = 0.045). No statistically significant
difference was found between mean BMIs for the
psoriasis and NHANES cohorts, 22.7 and 22.3,
respectively (p = 0.74). Our data indicate that the MetS
occurs more frequently in children with psoriasis despite
no statistically significant increases in BMI compared to
controls. While larger studies should be performed to
substantiate our findings, a more aggressive approach
toward primary prevention of cardiovascular disease in
children with psoriasis may be warranted.
P067
Coronary risk estimation and other cardiovascular
comorbidities in moderate to severe psoriasis
patients in Spain: RECOR study
Garcı´a-Calvo, Carmen
Pfizer Espan˜a, S.L.U, Medical Department,
Avd. de Europa 20B. Alcobendas, Madrid, Spain
Background and objectives: Psoriasis (PsO) is a chronic
immune mediated skin disease. There are several risk
factor frequently associated with the appearance and
progression of the disease, including obesity, smoking and
alcohol consumption. Moreover, PsO is often associated
with other systemic diseases as type-2 diabetes,
dyslipidemia, hypertension and metabolic syndrome.
The objective of the study was to assess the prevalence
of cardiovascular risk factors, including metabolic
syndrome, as well as other comorbidities in a population
of patients with moderate to severe PsO, when comparing
with a control population including patients with
dermatological diseases different from PsO. The main
objective of the study was to estimate the 10-years
moderate to severe coronary heart disease (CHD) risk
using the calibrated Framingham function and SCORE.
Methods: Non-interventional, cross-sectional study
conducted in 81 dermatological units in Spain in
2010–2011. A total of 477 patients were included in the
analysis; of them, 238 (44.9%) were patients with moderate
to severe PsO (cases) and 239 (50.1%) were controls.
Results: Psoriatic patients presented, when comparing
with controls, a significant higher prevalence of
coronary risk factor, such as obesity, body mass index,
smoking and alcohol consumption, as well as
significantly higher levels of triglycerides, LDL-c and
HDL-C (p\0.05, all determinations).. A significant
higher percentage of PsO patients presented a 10-years
moderate to severe CHD as assessed by the Framingham
function (38.5 vs. 23.4%, cases and controls,
respectively) (p\0.05). Though no overall significant
differences between groups were observed in the
prevalence of metabolic syndrome, PsO patients with
moderate to severe CHD risk presented a significant
higher prevalence of metabolic syndrome, when
comparing with PsO patients with low CHD risk (47.9
vs. 13.6%, respectively) (p\0.05).
Conclusions: Psoriatic patients presented in our study,
when comparing with a dermatological control
population, a significant increase in the overall
10-years moderate to severe coronary heart risk. Study
promoted by Pfizer Spain, S.L.U
P068
Association between systemic anti-psoriatic drugs
and cardiovascular risk in patients with psoriasis
and psoriatic arthritis: a nationwide cohort study
Chen, Yi-Ju1; Chang, Yun-Ting2; Shen, Jui-Lung3;
Chen, Tzu-Ting3; Wang, Chang-Bi4;
Chen, Chuan-Mu5; Wu, Chun-Ying2
1Taichung Veterans General Hospital, Department of
Dermatology, Taichung, Taiwan; 2National Yang-Ming
University, Taipei, Taiwan; 3Taichung Veterans
General Hospital, Taichung, Taiwan; 4China Medical
University, Taichung, Taiwan; 5National Chung-Hsing
University, Taichung, Taiwan
Objectives: Psoriasis is associated with ischemic heart
diseases (IHD). Prior studies suggest that methotrexate
(MTX) may improve vascular disease in psoriasis and
rheumatoid arthritis. The aim of this study was to
compare the risk of new ischemic heart diseases (IHDs)
among patients of psoriasis taking MTX and other
nonbiologic anti-psoriatic drugs.
Methods: A retrospective cohort study among 179,200
patients with a diagnosis of psoriasis or psoriatic arthritis
on at least 3 visits. We conducted the analyses by using
the National Health Insurance Research Database of
Taiwan. The risk of new IHD hospitalizations was
compared between psoriasis patients taking MTX
monotherapy (MTX cohort) and those taking
nonbiologic anti-psoriatic drugs other than MTX
(reference cohort). Additional adjustments were made
for cardiovascular risk factors, number of hospital visits,
Charlson score and use of other anti-inflammatory
drugs. The study cohorts consisted of 6,578 patients in
MTX cohort and 5,471 subjects in reference cohort
between January 1996 and December 2008.
Results: The incidence rates of IHDs were 666 and 830
cases per 100,000 person-years in MTX-treated cohort
and reference cohort, respectively (p = 0.027,
unadjusted). Increasing age, males, hypertension,
diabetes, and use of phototherapies were independent
risk factors for new IHD hospitalizations in study
cohorts. However, the multivariate adjusted hazard
ratio for hospitalized IHD was 0.97 (95% confidence
interval 0.79–1.19) for MTX, in comparison with other
nonbiologic anti-psoriatic drugs after adjustment of age,
gender, comorbidity index, hospital visits and
treatments of psoriasis.
Conclusions: Among patients with psoriasis and psoriatic
arthritis, the adjusted risk of hospitalized IHD for
individuals starting MTX was comparable with those
starting with other nonbiologic anti-psoriatic drugs.
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The use of ustekinumab in a patient with severe
psoriasis and positive HBV serology
Steglich, Raquel1; Carvalho, Andre´ VE1; Cheinquer,
Hugo2; Meneghello, Luana1; Mu¨ller, Fernanda1
1Irmandade da Santa Casa de Miserico´rdia de Porto
Alegre, Dermatology, Porto Alegre, Brazil; 2Irmandade
da Santa Casa de Miserico´rdia de Porto Alegre,
Hepatology, Porto Alegre, Brazil
Objectives: Psoriasis is a chronic, immune-mediated,
inflammatory skin disorder. The biologic therapy have
been shown to improve the lives of many patients with
psoriasis. Issues concerning the potential risks of
reactivating chronic hepatitis B virus (HBV) arise when
the use of biologics agents is imperative in patients with
concurrent psoriasis and HBV infection.
Method: We report a 53-years-old man that presented
with a 27-years history of recalcitrant severe psoriasis.
With a PASI 61.2/BSA 81%, poor quality of live and
history of inefficacy, intolerance or toxicity with
standard systemic treatment for psoriasis it was
indicated ustekinumab. Pretests HBV serology
revealed the following results: anti-HBc positivity;
low titer anti-HBs (2 mIU/ml), and negativity for
anti-HBc IgM, HBsAg, HBeAg and anti-HBe. Before
starting the biologic therapy he was vaccinated against
HBV, achieving anti-HBs positivity. Lamivudine 75 mg
per day was started at the same day of the
ustekinumab.
Results: The treatment significantly improved the
lesions. In 1 year follow up he keeps a PASI 3.8/BSA
13%, normal liver tests and no adverse effects.
Conclusions: We presented a patient that probably
developed immunity to HBV after the contact with
HBV. It is known that the HBV integrates with the host
genome and is able to remain indefinitely in the nucleus
of hepatocytes in the form of ccc-DNA. There are several
reports of HBV reactivation after immune suppression.
Psoriasis treatment ustekinumab did not reactivate HBV
in this patient possibly because his HBsAg was negative,
his anti-HBs titers were increased before treatment and
an antiviral with activity against HBV replication was
initiated concomitantly. To date we haven’t find on the
literature an association between anti-IL-12/23 and
reactivation of occult hepatitis B, however there are
reports with other drugs such as rituximab and
infliximab. Given the high prevalence of chronic viral
infections in patients who are candidates for biologic
therapy, and given the potential for these agents to
reactivate viral illness, randomized controlled studies are
needed to assess the risks and benefits of such therapy in
these populations.
P070
Prevalence of overweight/obesity in psoriasis
population and its therapeutic consequences
in clinical setting: experience from biobadaderm
Carrascosa, Jose-Manuel1; Vilavella, Marta2; Garcı´a-
Doval, Ignacio3; Ferrandiz, Carlos1; Rivera, Raquel4;
Carretero, Gregorio5; Dauden, Esteban6; Herrera,
Enrique7; Alsina, Merce8; Ferran, Marta9; Lopez-
Estebaranz, Jose-Luis10; Gomez, Francisco11; Hernanz,
Jose-Manuel12; Vanaclocha, Francisco4; Biobadaderm,
group13
1Hospital Universitari Germans trias i pujol,
Dermatology, Badalona, Spain; 2Hospital Germans
Trias i Pujol, Dermatology, Badalona, Spain; 3Unidad
de Investigacio´n Academia Espan˜ola de Dermatologı´a,
Madrid, Spain; 4Hospital 12 de Octubre, Dermatology,
Madrid, Spain; 5Hospital Juan Negrin, Dermatology,
Las Palmas, Spain; 6Hospital de la Princesa,
Dermatology, Madrid, Spain; 7Hospital Universitario
de Ma´laga, Dermatology, Ma´laga, Spain; 8Hospital
Clı´nic i Provincial, Dermatology, Barcelona, Spain;
9Hospital del Mar, Dermatology, Barcelona, Spain;
10Hospital Infanta Leonor, Dermatology, Madrid,
Spain; 11Hospital Universitario Reina Sofia,
Dermatology, Cordoba, Spain; 12Hospital Alcorcon,
Dermatology, Madrid, Spain; 13AEDV, Madrid, Spain
It has been suggested from clinical trials that BMI (Body
Max Index) may condition both the severity of psoriasis
and the response to treatment. However, information
about the prevalence of overweight/obesity in psoriasis
population as well as its therapeutic consequences in
clinical setting is scarce. To describe the prevalence of
overweight/obesity in patients with moderate to severe
psoriasis included in Biobaderm database-Spanish
registry of moderate to severe psoriatic patients on
classic/biologic systemic therapy. Furthermore, the
relationship between BMI and survival of biological
treatments was evaluated. A total of 1,162 patients on
systemic treatment registered in Biobadaderm until
November 2011 were included. 31.73% had a normal
weight, overweight was detected in 39.50 and 28.72%
were obese (BMI[30).
When compared with general Spanish population (Data
Instituto Nacional de Estadistica 2009), significant
differences were only detected regarding obese patients
(29 vs. 16% p\0.001). No significant differences were
observed in the percentage of patients receiving
biologics or classical systemic therapies for different
subgroups of BMI, (p = 0.58). Patients receiving
infliximab (mean BMI: 29.1) and ustekinumab (mean
BMI: 28.8) had a significantly higher BMI with respect to
patients treated with classical systemic therapies (mean
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BMI: 27.8). While the risk of cessation by remission
(efficacy) was not associated with BMI—univariate
analysis, we detected a linear trend of decreasing
survival related to increased BMI in those who stopped
biologic therapy due to adverse events and lack/loss of
efficacy. However, after matching patients by age and
biologic drug in a multivariated analysis, the decreasing
survival related to increased BMI was only kept for
cessation of biologic therapy due to lack/loss of efficacy
(effect by 5 units of BMI: 1.09 (95% CI:1.01–1.17).
Patients with moderate to severe psoriasis in our
environment have a significantly higher prevalence of
obesity when compared with the Spanish general
population.
Increased BMI is associated with an increased risk of
discontinuation of biological treatment due to lack of
efficacy or loss of efficacy.
Current and new therapeutic modalities
P071
Management of severe cases of psoriasis:
some interesting cases
XIAO, Ting
The First Affiliated Hospital of China Medical
University, Dermatology, 155 North Nanjing Street,
Shenyang, China
Erythrodermic psoriasis and generalized pustular psoriasis
(GPP) are severe forms of psoriasis. Both forms are
associated with significant morbidities or even
mortality. The management of severe cases of the two
clinical forms of psoriasis is challenging. So far traditional
medications including acitretin and cyclosporine are still
the first-line choices of erythrodermic psoriasis or GPP,
though new biologics are being tried in more and more
cases. The experience of the management of some cases of
severe erythrodermic psoriasis and GPP is shared here.
Some interesting cases are reviewed.
P072
Successful treatment of generalized pustular
psoriasis in an 8 year old male with infliximab
Skrabl- Baumgartner, Andrea1; Salmhofer, Wolfgang2;
Muntean, Wolfgang3; Weger, Wolfgang2
1Medical University of Graz, Pediatric Department,
Graz, Austria; 2Medical University of Graz, Department
of Dermatology, Graz, Austria; 3Medical University of
Graz, Pediatric Department, Graz, Austria
Objective: Psoriasis is a common inflammatory disorder
affecting 2–3% of the population worldwide. Plaque type
psoriasis is the most common form accounting for
approximately 80 percent, whereas generalized pustular
psoriasis (GPP) is rare. Treatment of GPP is still
considered a challenge, especially in children.
Materials and methods: An 8 year old boy presented with
erythematous annular lesions located at the trunk and
extremities which were studded with marginal pustules.
The patient was in otherwise good health and was on no
medications.
Results: A 4 mm punch biopsy was performed and was
compatible with pustular psoriasis. Topical as well as UVB
311 treatment were initiated. Despite this treatment and
due to a gastrointestinal infection the patient’s psoriasis
exacerbated. After recovering from his gastrointestinal
infection treatment with methotrexate was started.
However, GPP tended to exacerbate even while treated
with methotrexate. During exacerbation of his psoriasis
the patient experienced severe malaise and fever.
Therefore treatment with infliximab (5 mg/kg)
combined with low dose methotrexate (15 mg po once
weekly) was initiated. One week after the first infliximab
infusion nearly complete remission of his pustular
psoriasis was noted. Infliximab has been administered
at weeks 0, 2, 6 and every 7 weeks thereafter. GPP has
been well controlled for 16 months. So far no serious
side effects due to infliximab therapy did occur in our
patient.
Conclusion: As data concerning treatment of GPP in children
are still lacking, this case highlights the efficiency and safety
of infliximab in treating childhood GPP.
P073
A randomized, double-blind, placebo-controlled
study of ustekinumab in Chinese patients
with moderate to severe plaque psoriasis:
LOTUS trial results
Zheng, M1; Zhu, X2; Song, M3; Shen, Y-K3; Wang, B4
1Second Affiliated Hospital, Zhejiang University School
of Medicine, Dept of Dermatology, Hangzhou, China;
2Peking University First Hospital, Department of
Dermatology and Venereology, Beijing, China;
3Janssen Research and Development LLC, Spring
House, USA; 4Institute of Dermatology, Chinese
Academy of Medical Sciences, Nanjing, China
Objective: To report LOTUS trial results on the efficacy
and safety of ustekinumab (UST) treatment in Chinese
patients with moderate to severe plaque psoriasis.
Methods: In this double-blind, placebo-controlled trial,
patients with baseline moderate to severe plaque type
psoriasis were randomized to receive subcutaneous
UST45 mg or placebo (PBO) at weeks 0 and 4. Patients
randomized to PBO crossed over to receive UST45 mg at
week 12 and 16 (PBO ? UST). Patients randomized to
UST received an additional UST45 mg at week 16.
Primary endpoint was the proportion of patients who
achieved PASI75 response at week 12. Efficacy was
assessed through week 28 and safety through week 36.
Results: 322 patients were randomized to either UST
45 mg (n = 160), or PBO (n = 162). Baseline
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demographics and disease characteristics were
comparable between groups; majority (77%) were male,
mean (SD) body weight was 69.9 (12.2) kg. At week 12,
82.5% (132/160) and 78.8% of UST-treated patients
achieved PASI75 response and PGA score of clear/
minimal versus 11.1% (18/162) and 14.8% of PBO-
treated patients (p\0.001), respectively. After week 12,
in UST45 mg group, the proportions of patients
achieving PASI75 and PGA clear/minimal continued to
increase and reached maximum at week 24 (91.6%) and
week 20 (86.9%), respectively. The response was
maintained through week 28 at 91.5% [140/153] and
86.3% [132/153], respectively. Similar response rates
were also observed in PBO ? UST group after week 12.
With follow-up through week 36, 48.7% of UST-treated
patients experienced an adverse event (AE) compared
with 42.5% through week 12. Through week 36, there
were no deaths, opportunistic infections, active
tuberculosis, malignancies, or serious cardiovascular
events reported.
Conclusions: UST 45 mg injections at weeks 0, 4 and 16
can significantly improve moderate to severe psoriasis in
Chinese patients. UST was well-tolerated with a
favorable benefit/risk profile through week 36.
P074
Efficacy and safety of secukinumab (a fully human
anti-interleukin-17A antibody) in a phase II
regimen-finding study for the treatment
of moderate-to-severe plaque psoriasis
Rich, PA1; Sigurgeirsson, B2; Guettner, A3;
Machacek, M3; Papavassilis, C3
1Oregon Dermatology and Research Center, Portland,
USA; 2University of Iceland, Department of
Dermatology, Reykjavik, Iceland; 3Novartis Pharma
AG, Basel, Switzerland
Psoriasis is a chronic, immune-mediated skin disorder
associated with increased levels of Interleukin (IL)-17A.
In an earlier study, secukinumab has shown therapeutic
potential in treatment of plaque psoriasis1. This double-
blind, parallel group, placebo-controlled phase II study
evaluated the efficacy and safety of secukinumab in
patients with moderate-to-severe plaque psoriasis.
Patients (n = 404) were randomized (1:1:1:1) to either
one of the three subcutaneous secukinumab 150 mg
regimens: ‘‘Single’’ (at Week 0; n = 66), ‘‘Early’’ (at Weeks
0, 1, 2, 4; n = 133) and ‘‘Monthly’’ (at Weeks 0, 4, 8;
n = 138) or placebo (n = 67). PASI 75 response at Week
12 was the primary efficacy endpoint. After the 12-week
induction period, PASI 75 responders were further
randomized (1:1) to one of the two maintenance
regimens: the fixed-interval regimen (n = 65 patients
received secukinumab 150 mg at Weeks 12 and 24) or
the treatment at start-of-relapse regimen (n = 67
patients received secukinumab 150 mg at visits at
which a start-of-relapse was observed).
Different treatment arms showed comparable baseline
disease characteristics. At week 12, PASI 75 responses
were statistically higher in ‘‘Early’’ and ‘‘Monthly’’
induction regimens compared to placebo (55 and 42%
vs. 2%; p\0.001 for both). Similarly, the ‘‘Early’’ and
‘‘Monthly’’ arms attained significantly greater PASI 90
responses than placebo (32 and 17% vs. 2%; p\0.001
for both). In maintenance period, at week 24, 71% of the
subjects in the fixed-interval regimen maintained their
PASI 75 response. 16 weeks after last secukinumab
administration, 30% of patients had experienced a
start-of-relapse.
Serious adverse events and AE rates (including
infections) were comparable between the secukinumab
regimens and placebo (during the induction period),
and between the fixed-interval and the start-of-relapse
treatment arms (during the maintenance period).
In conclusion the primary efficacy endpoint of this
study was met and the results reported here indicate that
secukinumab may be useful in the treatment of psoriasis
in induction and maintenance and warrant larger phase
III studies.
Reference: 1. Hueber et al. 2010. Sci Transl Med.
2(52):52ra72.
P075
Recombinant bacterial system for local delivery
of anti-TNFa biomolecules
Ravnikar, Matjaz1; Berlec, Ales2; Obermajer, Natasa2;
Lunder, Mojca1; Strukelj, Borut1
1Faculty of Pharmacy, University of Ljubljana,
Ljubljana, Slovenia; 2Jozef Stefan Institute, Ljubljana,
Slovenia
Anti-tumor necrosys factor alpha (TNFa) therapy with
monoclonal antibodies proved to be an efficient
approach for a wide range of chronic inflammatory-
related diseases including psoriasis. Downsides of this
treatment are the enteral application of these TNFa-
binding biomolecules, the risk of side effects due to
systemic immunosupression and high production costs
of such biodrugs.
A new system that enables local delivery of TNFa-binding
biomolecules has been developed. TNFa-binding affibody
has been expressed on the surface of lactic acid bacteria
Lactococcus lactis as a fusion protein containing AcmA
anchor peptide and Usp45 signal peptide. L.lactis is a lactic
acid bacteria widely used in biotechnology that has a status
of a safeorganism (GRAS)and is highly resistant toacidand
enzyme degradation. Surface protein expression has been
determined using SDS page electrophoresys and the
functionality of the recombinant TNFalpha-binding
proteins was determined by using flow-cytomerty. The
maximum binding capacity for TNFa was determined with
ELISA and the acid resistance of the recombinant bacteria
was determined with flow-cytometry after exposure in
simulated gastric juice.
In vitro data confirmed the capability of the
recombinant bacteria to express sufficient amount of
active TNFa-binding molecules on their surface and the
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ability of bacteria to retain most of the TNFa-binding
capacity under simulated gastric conditions.
This represents a promising new delivery system for the
local anti-inflammatory treatment that is patient
friendly due to the topical application and avoids the
risk of systemic side effects. In vivo efficiency and safety
of the delivery system is currently being tested on
animal models.
P076
Psoriasis patients required to discontinue
adalimumab therapy have worsening in their
quality of life out of proportion to worsening
in the objective signs of disease: subanalysis
of REVEAL
Poulin, Yves1; Sheth, Pranav2; Gu, Yihua3;
Okun, Martin3
1Centre Dermatologique du Quebec Metropolitain,
Que´bec, Canada; 2Group Health Associates, Trihealth,
Cincinnati, USA; 3Abbott Laboratories, Abbott Park,
USA
Aims: To compare dermatology life quality index (DLQI)
and psoriasis area and severity index (PASI) scores, while
on therapy versus after discontinuation among
adalimumab-treated psoriasis patients who undergo
protocol-mandated treatment discontinuation.
Methods: REVEAL was a 52-week, placebo-controlled
Phase III trial of patients with moderate to severe
psoriasis (NCT00237887). 240 patients were
randomized to adalimumab at baseline, achieved CPASI
75 responses at week 16 and 33, and were re-randomized
to placebo. This post hoc analysis compares DLQI and
PASI scores at week 4 (early in adalimumab treatment
initiation) and at week 52 (after up to 19 weeks of
treatment discontinuation), using last observation
carried forward (LOCF) to impute missing data.
Results: At baseline, the mean PASI score was 19.5 and
mean DLQI score was 11.6. At week 4, the mean PASI
score was 8.0 and mean DLQI score was 4.3. At week 33,
the mean PASI score was 1.2 and mean DLQI score was
1.0. At week 52, the mean PASI score was 6.7 and mean
DLQI score was 5.3.
Conclusion: For patients who responded to adalimumab
but were required by the study protocol to discontinue
treatment, mean PASI scores were lower yet mean DLQI
scores were higher than they had been early in treatment
(week 4 vs. 52). We hypothesize that this hysteretical
uncoupling of DLQI and PASI scores occurs because
patients are distressed to see their psoriasis recurring
after it had been effectively controlled. These results may
have general implications about the disutility of
discontinuing, even temporarily, effective psoriasis
therapies in patients who have achieved excellent
control of their disease.
P077
Phase IIa randomized, double-blind, placebo-
controlled, sequential dose-escalation study
to evaluate the efficacy and safety of ASP015K,
a novel Janus kinase (JAK) inhibitor, in patients
with moderate-to-severe psoriasis
Papp, Kim1; Pariser, David2; Wierz, Gina3; Ball, Greg3;
Akinlade, Bola3; Zeiher, Bernhardt3
1Probity Medical Research, 135 Union Street, East
Waterloo, Canada; 2Eastern Virginia Medical School
and Virginia Clinical Research, Inc., Norfolk, USA;
3Astellas Pharma Global Development, Inc., Deerfield,
USA
Objective: ASP015 K is an oral Janus Kinase (JAK)
inhibitor with in vitro activity vs. JAK 1, 2, 3 and Tyk2.
JAKs have increased expression and mediate pathogenic
cellular activation in immune-mediated diseases,
including psoriasis. This phase IIa study examined the
efficacy and safety of ASP015 K in moderate-to-severe
psoriasis.
Methods: Adult patients with stable, moderate-to-severe
plaque psoriasis affecting C10% body surface area (BSA)
were randomized in this double-blind, placebo-
controlled, sequential dose-escalation (10, 25, 60,
100 mg BID or 50 mg QD or placebo) 6 week study.
The primary efficacy outcome was change in Psoriasis
Area Severity Index (PASI) score from baseline to end of
treatment (EOT). Secondary outcomes included change
from baseline to EOT in BSA, and Physician Static
Global Assessment (PSGA) score, and proportion of
patients achieving success at EOT (PSGA score, 1 [almost
clear] or 0 [clear]). Overall treatment effect was analyzed
using analysis of covariance for PASI, PSGA, and BSA,
and the Cochran–Mantel–Haenszel test for PGSA
success.
Results: 124 patients were enrolled; mean baseline BSA,
PASI, and PSGA were 20.3, 15.4, and 3.3%, respectively.
The primary analysis, reduction in mean PASI score at
EOT, favored ASP015K (P\0.0001) (range: 10 mg BID,
-6.4; 100 mg BID, -11.9; placebo, -4.2). All secondary
analyses were significant: PSGA score (P = 0.0002)
(range: 50 mg QD, -0.95; 100 mg BID, -1.69; placebo,
-0.44), PSGA success (P = 0.002) (range: 25 mg BID,
14.3%; 60 mg BID, 47.4%; placebo, 0%), and BSA
(P = 0.0003) (range: 25 mg BID, -4.84; 60 mg BID,
-11.16; placebo, -3.02). There were no dose-related
increases in adverse events (AEs) and the incidence of
AEs occurring in C2 patients was similar across all
groups. 3 patients discontinued the study because of
drug-related AEs (decreased neutrophils [60 mg BID],
neutropenia [100 mg BID], vomiting [100 mg BID]).
Conclusions: ASP015K was generally well tolerated (dose
range: 20–200 mg/d) for 6 weeks in patients with
moderate-to-severe psoriasis. Dose-dependent
reductions in mean PASI were noted and similar
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reductions were seen with ASP015K (50 mg/d) whether
dosed QD or using a BID regimen.
P078
Improvement of psoriasis in subjects
with and without prior brodalumab (AMG 827)
treatment in an open-label extension study
Papp, Kim1; Leonardi, Craig2; Menter, Alan3;
Ortonne, Jean-Paul4; Klekotka, Paul5; Aras, Girish5;
Thompson, Elizabeth5; Lin, Shao-Lee5;
Kricorian, Gregory5
1Probity Medical Research, Waterloo ON, Canada;
2St Louis University, St Louis, USA; 3Baylor University
Medical Center, Dallas, USA; 4Hopital de l’Archet, Nice,
France; 5Amgen Inc, Thousand Oaks, USA
Introduction: The pro-inflammatory cytokines
interleukin-17A (IL-17A), IL-17C, and IL-17F are over
expressed in psoriatic skin.
Objective: To compare efficacy and safety of brodalumab
(AMG 827), a human anti-IL-17 receptor monoclonal
antibody, in subjects with moderate to severe plaque
psoriasis with and without prior brodalumab treatment.
Methods: This was a week 48 analysis of an open-label
extension (OLE) study in subjects who had received
brodalumab (70, 140, or 210 mg Q2WK or 280 mg
Q4WK) or placebo in a 16-week phase 2 study (last
dose of brodalumab at week 8 [280 mg Q4WK] or 10 [70,
140, and 210 mg Q2WK]). All subjects who enrolled in
the OLE (n = 33 placebo; n = 148 brodalumab) received
210 mg Q2WK brodalumab. Measurements of efficacy
included % change in PASI and PASI75/90/100 from
parent study baseline. Safety was assessed by monitoring
adverse events (AE).
Results: At baseline of the OLE, mean (SD) PASI in
placebo subjects was 17.3 (8.2), comparable to mean
PASI at parent study baseline in subjects randomized to
receive active treatment. Upon receiving treatment,
prior placebo subjects showed a rapid clinical response
with PASI improvements from parent study baseline
observed as early as week 2 (mean [SD] improvement in
PASI 67% [27]; N = 33) and by week 8 (PASI75/90/100 in
94%/76%/61% of subjects; N = 33) the responses were
comparable to those of subjects originally treated with
brodalumab. All of the subjects achieved PASI75 by week
12 (PASI90/100 in 79%/64% of subjects). The
improvements in PASI were maintained through week
48 (PASI75/90/100 in 95%/90%/63% of subjects; N = 19),
as were the responses in those originally treated with
brodalumab. Serious AEs were reported in 9 subjects with 1
leading to death (aortic aneurysm rupture in 1 subject from
the prior 280 mg Q4WK group). None of the SAEs occurred
in more than 1 subject.
Conclusion: Subjects in the placebo group responded
rapidly to treatment with brodalumab following
initiation of therapy in the OLE study. Their responses
were comparable to those of subjects on active treatment
in the parent study. The risk: benefit ratio of brodalumab
appears to warrant continued development.
P079
Long term efficacy and safety of ustekinumab
in patients with moderate to severe psoriasis
through 5 years of follow-up: results
from the PHOENIX 1 long-term extension
Papp, Kim1; Kimball, A2; Wasfi, Y3; Chan, D3;
Bissonnette, R4; Sofen, H5; Yeilding, N3; Li, S3;
Szapary, P3; Gordon, K6
1Probity Medical Research, Waterloo, Canada;
2Harvard Medical School and Massachusetts General
Hospital, Boston, USA; 3Janssen Research and
Development, LLC, Spring House, USA; 4Innovaderm
Research, Inc, Montreal, Canada; 5Dermatology
Research Associates, Los Angeles, USA; 6North Shore
University Health System and University of Chicago
Pritzker School of Medicine, Chicago, USA
Objective: To report efficacy and safety of ustekinumab
(UST) through 5 years of follow-up in PHOENIX1.
Methods: Pts with moderate to severe PsO (n = 766) were
randomizedtoPBO,UST45 mg,or90 mgat Wk0and Wk4.
UST pts continued with q12wk dosing. PBO pts crossed-
over to UST45 mg or 90 mg at Wk12. PASI75 responders
receiving UST from Wk0 (n = 322) were re-randomized at
Wk40to continuemaintenance ontheiroriginaldoseuntil
end of study, or withdraw from UST and reinitiate
treatment upon loss of 50% of their Wk40 PASI
improvement. Partial responders (Wk28 PASI50\75
orWk40 PASI75) switched to q8wk dosing. Efficacy
(Wk244) and safety (Wk264) evaluations included all pts
who received C1 UST dose. Results:68.7% (517/753) of
treated pts received UST through the last scheduled yr5
dose, with similar high retention rates observed in 45 mg
and 90 mg grps. In overall population analysis, PASI75
responses were 63.4 and72.0% and PASI90 responses were
39.7 and49.0%, for the 45 and 90 mg grps, respectively.
Among Wk40 PASI75 responders randomized to continue
maintenance, efficacy was similarly sustained; PASI75
responses were 79.1 and 80.8% and PASI90 responses
were 47.8 and 58.9%, for the 45 and 90 mg grps,
respectively. Among partial responders switched to q8wk
dosing, PASI75 responses were 57.6 and 55.1% and PASI90
responses were 27.2 and 27.5%, for the 45 and 90 mg grps,
respectively. UST was generally well-tolerated thru 5 years
(3,104 pt yrs of follow-up[PY]). Rates of adverse events
(AEs), serious AEs, and infections per 100PY for the 45 and
90 mggrps, respectively, were 220.9 and 209.0, 5.3 and 5.4,
and 83.7 and 81.6. Rates of serious infection, non-
melanoma skin cancer, other malignancy and
investigator-reported major adverse CV events (CV death,
MI or stroke) per 100PY for the UST grps combined were
1.03, 0.4 (BCC:SCC ratio = 13:1), 0.48, and 0.35,
respectively. No apparent dose effect was observed, and
rates were consistent with those reported at 3 years of
follow-up.
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Conclusion: Consistent with data reported thru yr3,
majority of pts remained on UST thru up to 5 years
and maintained clinical responses. UST was generally
well-tolerated, without evidence of cumulative toxicity
with increased duration of exposure.
P080
Secukinumab for treatment of moderate-to-severe
plaque psoriasis: results of a phase II dose-ranging
study
Papp, K1; Sigurgeirsson, B2; Haemmerle, S3;
Richards, H3; Papavassilis, C3
1Probity Medical Research, Ontario, Canada;
2University of Iceland, Reykjavik, Iceland;
3Novartis Pharma AG, Basel, Switzerland
Interleukin-17A (IL-17A) has been reported to be
upregulated in psoriatic lesional skin. Secukinumab, a
fully human anti-IL-17A antibody, has shown efficacy in
the treatment of psoriasis1. This phase II study assessed
the efficacy and safety of different doses of secukinumab
in patients with moderate-to-severe plaque psoriasis.
Patients (n = 125) were randomized (1:1:1:1:1) to receive
subcutaneously either placebo (n = 22) or secukinumab
[1 9 25 mg (n = 29), 3 9 25 mg (n = 26), 3 9 75 mg
(n = 21), 3 9 150 mg (n = 27)] at Week 0, 4 and 8. At
the end of 12-week treatment period, patients entered a
24-week follow-up period. At Week 12, PASI 75 (primary)
and PASI 90 response (secondary) were assessed as
efficacy endpoints.
Baseline disease characteristics were comparable between
treatment groups. At Week 12, PASI 75 response rates for
secukinumab 3 9 150 and 3 9 75 mg were superior as
compared to placebo (81 and 57% vs. 9%; p\0.001 and
p = 0.002; respectively). Higher PASI 75 response rates
were maintained throughout the follow-up period for
secukinumab vs. placebo (Week 32: 56 and 24% vs. 5%;
Week36: 26and 19% vs. 5%).AtWeek 12, PASI90 response
rate reached statistical significance for only secukinumab
3 9 150 mg versus placebo (52 vs. 5%) and remained
highervs.placeboconsistentlyduring the follow-up period
up to Week 36 (11 vs. 5%).
Secukinumab 3 9 150 mg group reported slightly higher
AEs (89%) compared with the other secukinumab dose
cohorts (73–76%) which were similar to the placebo group
(73%). Most AEs were mild or moderate in severity. 2
patients in secukinumab 3 9 25 mg group, 1 in
secukinumab 3 9 75 mg group and 2 in placebo reported
SAEs. One patient died in the placebo group.
In conclusion, secukinumab 3 9 75 and 3 9 150 mg
cohorts achieved the primary endpoint of PASI 75
response at Week 12 and the higher response vs. placebo
was maintained over 36 weeks. Overall, secukinumab had
a comparable safety profile to placebo. These findings
indicate that secukinumab given every 4 weeks is
efficacious for the treatment of moderate-to-severe
plaque psoriasis and warrant larger phase III studies.
1. Hueber et al. 2010. Sci Transl Med. 2(52):52ra72
P081
Novel EP4 antagonists as a new therapy for auto-
immune diseases
Okumura, Takako; Kanazawa, Kiyoshi; Takahashi,
Nobuyuki; Take, Yukinori
RaQualia Pharma Inc., Research, Aichi, Japan
Helper T cell (Th) subsets, Th1 and Th17 cells, play an
important role in the development of autoimmunity in
human diseases. Recently, prostaglandin E2-EP4 receptor
signaling was demonstrated to induce Th1 cell
differentiation and Th17 cell expansion (Ref). We
investigated the EP4 pharmacology using RQ-00000007
(RQ-7) and RQ-00000008 (RQ-8), potent, selective and
structurallydistinct smallmoleculeEP4antagonists.TheKi
values for RQ-7 and RQ-8 are 13 and\10 nM, respectively,
in a recombinant human EP4 receptor-transfected HEK293
cell assay system. Selectivity for the EP4 was demonstrated
against more than 100 enzymes and receptors that
included the other prostanoid receptors. In vitro, RQ-7
and RQ-8 suppressed PGE2-induced IL-23 production in
human dendritic cells with IC50 values of 3.1 and 5.0 nM,
respectively. RQ-7 also inhibited PGE2 and Con-A-induced
IL-6 production in human peripheral blood mononuclear
cells. In vivo, RQ-7 and RQ-8 demonstrated oral activities
in a variety of autoimmune disease models, i.e., psoriasis,
inflammatory bowel disease and rheumatoid arthritis.
Specifically, RQ-8 demonstrated oral activity in a mouse
picryl chloride-induced contact hypersensitivity model at
3 mg/kg, bid, and a mouse dextran sulfate sodium-induced
colitis model at 30 mg/kg, qd. RQ-7 and RQ-8, significantly
suppressed paw edema, and bone destruction in rat
adjuvant-induced arthritis model at 29, and 0.3 mg/kg
bid, respectively. In conclusion, EP4 antagonist RQ-7 and
RQ-8 are attractive development candidates for the
treatment of a variety of autoimmune diseases with high
unmet medical needs.
Reference: C. Yao, et al., Nat Med. (2009). 15(6):633–40.
P082
Serendipity opens new avenues: a pilot study
to evaluate the efficacy of saxagliptin
in combination with cyclosporine and acitretin
in diabetic psoriasis patients
Narang, Tarun1; Dogra, Sunil2; Handa, Sanjeev2
1Post Graduate Institute of Medical Education and
research, Dermatology, Venereology and Leprology,
sec 12, Chandigarh, Chandigarh, India; 2Post Graduate
Institute of Medical Education and Research,
Chandigarh, India, Dermatology, Venereology and
Leprology, Chandigarh, India
Background: Psoriasis is a chronic inflammatory skin
disease, accompanied by obesity, diabetes mellitus
(DM), or metabolic syndrome. Despite the availability
of several treatments, psoriasis is often a therapeutic
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challenge due to its unpredictable course, adverse
effects and variable response to treatments. Since
dipeptidyl peptidase IV (DPP-IV) dysregulation is
present in DM and psoriasis, DPP-IV inhibitors
(saxagliptin) can be useful for both conditions.
Aim: To assess the efficacy and safety of combination of
saxagliptin with cyclosporine or acitretin in patients
with refractory psoriasis and type 2 DM.
Methods: Ten patients of resistant psoriasis with type 2
DM with severe disease (mean baseline PASI[20) were
randomly divided into two groups; group A received
cyclosporine 3 mg/kg/day and saxagliptin 5 mg/day
whereas group B received acitretin 25 mg daily and
saxagliptin 5 mg/day. In both the groups, patients were
treated for 12 weeks and then followed up for 12 weeks
after stopping cyclosporine or acitretin. The severity of
psoriasis was accessed by the PASI at baseline and 4, 8, 12
and 24 weeks after the initiation of treatment. Quality of
life (QoL) was assessed by DLQI scoring at 0, 12 and
24 weeks.
Results: Seven patients (70%) (4 in group A and 3 in
Group B) attained PASI 50 and three of these (30%)
(2 group A and 1 group B) patients attained PASI 75 at
week 12 of therapy. One patient had exacerbation
4 weeks after starting saxagliptin and treatment was
stopped; 2 patients did not show any improvement. QoL
score improved significantly in both groups. The clinical
response was maintained at week 24 in patients who
improved with therapy after stopping acitretin/
cyclosporin. No serious adverse events were observed
in this study.
Conclusion: We observed that saxaglptin in combination
with cyclosporine and acitretin is an effective treatment
option in patients of severe psoriasis with type 2 DM.
Further long term studies with larger patient cohort are
needed to evaluate the efficacy of saxagliptin in non
diabetics psoriasis patients, as a monotherapy and in
combination with other systemic or topical agents.
P083
Secukinumab, a fully human anti-interleukin-17A
antibody, improves signs and symptoms of psoriatic
arthritis: a 24-week, double-blind, placebo-
controlled, multicenter trial
McInnes, I1; Sieper, J2; Braun, J3; Emery, P4; van der
Heijde, D5; Isaacs, J6; Dahmen, G7; Wollenhaupt, J8;
Schulze-Koops, H9; Gsteiger, S10; Bertolino, AP11;
Hueber, W11; Tak, PP12
1University of Glasgow, Glasgow, UK; 2Charite‘
Campus Benjamin Franklin, Berlin, Germany;
3Rheumazentrum Ruhrgebiet, Herne, Germany;
4University of Leeds, NIHR-Leeds Biomedical Research
Unit and Leeds Institute of Molecular Medicine, Leeds,
UK; 5Leiden University Medical Center, Leiden,
Netherlands; 6Newcastle University and the Freeman
Hospital, Newcastle-upon-Tyne, UK; 7Praxis fuer
klinische Studien, Hamburg, Germany; 8Eilbeck
Hospital, Hamburg, Germany; 9Klinikum Innenstadt
der Ludwig-Maximilians-Universitat, Munich,
Germany; 10Novartis Pharma AG, Basel, Switzerland;
11Novartis Institutes for BioMedical Research, Basel,
Switzerland; 12University of Amsterdam, Amsterdam,
Netherlands
This study assessed the safety and preliminary efficacy of
secukinumab inhibiting Interleukin-17A, a novel target
for the treatment of psoriatic arthritis (PsA). 42 patients
with active PsA who fulfilled CASPAR criteria were
randomized 2:1 to receive two injections of
secukinumab (10 mg/kg) or placebo, given 3 weeks
apart. The primary efficacy endpoint was the
proportion of ACR20 responders at Week 6 in active
versus placebo (one-sided p\0.01).
35 (83.3%) patients (25 on secukinumab, 10 on placebo)
completed the study. 5 patients (4 secukinumab and 1
placebo) were excluded from the efficacy analysis due to
protocol violations and 7 (3 secukinumab and 4 placebo)
discontinued prematurely for lack of efficacy or
withdrawal of consent. Demographics and baseline
characteristics were balanced between groups including
parameters: mean ± SD SJC (secukinumab vs. placebo):
8.3 ± 5.6 vs. 9.5 ± 5.4; TJC 23.5 ± 19.4 vs. 22.6 ± 11.0;
DAS28 4.8 ± 1.2 vs. 4.8 ± 1.2; MASES 3.0 ± 4.1 vs.
3.4 ± 2.3. Co-existing psoriasis, prior TNFi exposure
and co-medication with DMARDS were present in 23,
11 and 21 patients on secukinumab and in 11, 5 and 10
on placebo, respectively. ACR20 responders on
secukinumab versus placebo were 39 versus 23%
(P = 0.27) at Week 6, 39 vs. 15% at Week 12, 43 vs.
18% at Week 28. ACR50 and ACR70 responders on
secukinumab versus placebo were 17 versus 8% and 9
versus 0%, respectively at Week 6. CRP reductions at
Week 6 were greater on secukinumab (median [range]
at baseline versus Week 6: 4.9 [0.3, 43.0] vs. 3.0 [0.2,
15.2]) than on placebo (6.2 [1.3, 39.7] vs. 5.0 [0.8,
29.6]). Overall rate of adverse events (AEs) was
comparable in secukinumab 26 (93%) versus placebo
11 (79%). 7 serious AEs were reported in 4 secukinumab
patients and 1 in placebo. Infections were reported in
16 (57%) patients on secukinumab and 7 (50%) on
placebo. In conclusion, the primary endpoint was not
met, though patients showed rapid and sustained
improvements of clinical scores and CRP levels up to
Week 28. The safety profile of secukinumab was
favorable. These findings warrant further larger phase
III clinical trials in PsA.
P084
Combined treatment of psoriasis with methotrexate
and narrowband UVB phototherapy compared
with methotrexate alone and narrowband UVB
alone
Mashhadani, Sabeeh; Al-Hamamy, Haider;
Nazar, Ihsan
College of Medicine/Baghdad University,
Dermatology, Baghdad, Iraq
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Background: Wide spread psoriasis has significant
negative effects on the quality of life. Effective and
rapid response in treatment of psoriasis is needed.
Objectives: To compare the efficacy of combined
methotrexate and NBUVB with NBUVB and
methotrexate each one alone in the treatment of wide
spread plaque-type psoriasis.
Patients and methods: A total of (120) patients with wide
spread plaque-type psoriasis were enrolled but only (113)
patients completed the study. These (113) patients were
divided into three groups, group MN (n = 38) received
methotrexate plus NBUVB, and group N (n = 38)
received NBUVB alone, and group M (n = 37) received
methotrexate alone.
End point of treatment was 90% reduction in PASI Score
(clearance), or up to 8 month. Follow-up was performed
for 1 year after clearance for assessment of relapse rate,
and the relapse was defined as PASI scores returned to
50% of the original ones.
Results: The mean number of weeks (wks) required for
clearance was 6.11 ± 1.28 wk in group (MN), and
11.42 ± 2.36 wk in group (N), and 20.87 ± 4.21 wk in
group (M) (P = 0.0001). The mean number of
phototherapy sessions was 17.86 ± 3.74 sessions in
group (MN), and 33.51 ± 6.9 sessions in group
(N) (P = 0.0001). The mean total cumulative dose of
NBUVB for clearance was 12.13 ± 4.02 J/cm2 in group
(MN), compared with 34.48 ± 13.13 J/cm2 in group
(N) (p = 0.0001). The mean total cumulative dose of
methotrexate for clearance was 116.04 ± 20.47 mg in
group (MN) compared with 298.63 ± 60.26 mg in group
(M) (p = 0.0001). The percentage of patients relapsed
during follow-up period was 8.33% in group (MN), and
14.28% in group (N), and 21.62% in group
(M) (p = 0.314).
Conclusions:
1 -Methotrexate and NBUVB phototherapy provides
more rapid clinical improvement with shorter
duration of therapy, and less cumulative doses of
both therapy. Compared with NBUVB monotherapy
and methotrexate alone in the treatment of wide
spread plaque-type psoriasis.
2 -NBUVB monotherapy was superior to methotrexate
alone in treatment of wide spread plaque-type
psoriasis.
3 -The combination of methotrexate and NBUVB lead
to decrease in percentage of relapsed patients
P085
Treatment in mono-/oligo- and polyarthritic
patients: a 5 year study on the Swedish early
psoriatic arthritis cohort (SwePsA)
Lindqvist, Ulla Ruth Kristina1; Husmark, Tomas2;
Alenius, Gerd-Marie3; Larsson, PT4; Teleman,
Annika5; Geijer, Mats6; Theander, E7
1Department of Medical Sciences, Rheumatology,
Ent. 40 5th floor, Uppsala, Sweden; 2Department of
Rheumatology, Falu Hospital, Falun, Sweden;
3Department of Public Health and Clinical Medicine,
Rheumatology, University of Umea˚, Umea˚, Sweden;
4Department of Rheumatology, Karolinska University
Hospital Huddinge, Huddinge, Sweden; 5Spenshult
Hospital, Oskarstro¨m, Sweden; 6Center of medical
imaging and physiology, Lund University, Lund,
Sweden; 7Department of Rheumatology, Ska˚ne
University Hospital, Malmo¨, Sweden
Background: The diverse features of psoriatic arthritis
(PsA) with clinical classification changes over time and
with difficulties to outline treatment recommendations
cause suboptimal assessment in many patients.
Objectives: Patients with symptoms of PsA have been
documented in SwePsA since 1999. This is a presentation
of classification, medical assessment and outcome in six
rheumatologic clinics.
Methods: Patients referred to the clinics within 2 years of
onset were followed up according to the program by the
same rheumatologist. Classification according to
CASPAR was done.
Results: On inclusion patients with mono- or oligoarticular
(MO) disease were most frequent with 47% of 208 patients.
Forty-two percent were classified as polyarticular
(P) patients. Nine percent had axial involvement, 2%
were in remission defined as no tender or swollen joints
and with E-SR and CRP within the reference range. One-
third of patients with MO disease were treated with
DMARD. At reclassification 80% remained MO patients
and 18% were in remission. Fifty-five % of the patients with
P disease were treated with DMARD or anti-TNF-alpha and
at reclassification 40% had MO disease and 8% were in
remission. Significantly more MO patients were in
remission at 5-year followup compared to P patients
(p = 0.041). Minimal disease activity (MDA) was assessed
and patients with MO disease had more frequent MDA
compared to P patients at 5-year followup (p = 0.047) and
treatment with DMARD in MO patients did not improve
the number of patients reaching MDA. Neither was there
any significant difference between numbers of treated and
untreated MO patients reaching remission at 5-year
followup. Treatment with DMARD and/or TNF-alpha did
not increase the number of P patients that reached MDA or
remission. On the contrary all P patients that reached
remission were non-treated patients (p = 0.006). There was
a gender difference with more men reaching MDA
(p = 0.006) and remission (p = 0.043) at 5-year followup,
more frequent in patients before 40 years of age.
Conclusions: The effects of treatment in early PsA
patients in clinical practice are not clear-cut and need
to be further evaluated.
P086
Content validity of a novel patient-reported
psoriasis symptom diary for patients with
moderate-to-severe plaque psoriasis
Lebwohl, Mark1; Nyirady, J2; Gwaltney, C.J.3;
Strober, B.E.4
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Connecticut, Farmington, USA
Moderate-to-severe plaque psoriasis significantly
impacts the daily life of patients. There are no
currently available psoriasis symptom-based patient-
reported instruments consistent with current
regulatory expectations. Using instrument
development methods recommended by regulatory
agencies, the specific aims of this study were to
(a) highlight which concepts are important and
relevant to patients with chronic plaque psoriasis, and
(b) describe methods of this work and how the results
may be utilized for evaluating perceived patient benefit
associated with treatments designed for moderate-to-
severe plaque psoriasis.
Qualitative patient interviews with moderate-to-severe
psoriasis patients were utilized to develop a 20 item
patient reported Psoriasis Symptom Diary. The key
elements in measure development included (1)
conducting patient interviews to identify key plaque
psoriasis-related symptoms and impacts (N = 29); (2)
development of an initial set of items capturing the key
patient experiences; and (3) conducting cognitive
interviews to test patient understanding of the items
selected for inclusion in the new psoriasis symptom
measure (N = 16). A variety of symptoms were noted by
the patients, with plaque-related pain (including related
sensations of burning and stinging), changes in skin
appearance, and itching being reported by all patients.
Patients also expressed notable embarrassment and
avoidance of social situations, due to the appearance of
plaques, and limited mobility. The Psoriasis Symptom
Diary assesses the severity and impact of symptoms
using a 24-h recall period, in order to reduce recall bias
and error.
In conclusion, qualitative evidence-based research in
this disease indicates that itching, pain, scaling, skin
color, stinging and burning, and pain due to skin-
cracking are the most important and relevant psoriasis
related symptoms. The Psoriasis Symptom Diary assesses
important symptoms and disease-related impact in a
manner that is consistent with guidelines for
establishing the content validity of new PRO
instruments. Following quantitative psychometric
testing, the Psoriasis Symptom Diary may support
efficacy endpoints in clinical trials.
P087
Safety and efficacy of adding topical therapy
to etanercept in patients with moderate to severe
plaque psoriasis
Lebwohl, Mark G.1; Kircik, Leon2; Callis Duffin,
Kristina3; Pariser, David4; Hooper, Michele5; Wenkert,
Deborah5; Thompson, Elizabeth HZ5; Yang, Jun5;
John, Koo6
1Mount Sinai Medical Center, New York, NY, USA;
2Derm Research, PLLC, Louisville, KY, USA; 3University
of Utah, Salt Lake City, UT, USA; 4Virginia Cliical
Research, Inc., Norfolk, VA, USA; 5Amgen Inc.,
Thousand Oaks, CA, USA; 6University of California at
San Francisco, San Francisco, CA, USA
Background: This study examined efficacy and safety of
addition of clobetasol propionate (CP) foam to
etanercept (ETN) compared with ETN monotherapy in
patients (pts) with moderate to severe plaque psoriasis.
Methods: This phase 3b study enrolled adults with
Psoriasis Area and Severity Index (PASI) C10 and
affected body surface area C10%. Pts were randomized
(1:1) to ETN 50 mg twice weekly (wkly) for 12 wks
followed by ETN once wkly for 12 wks or ETN (same dose
schedule) +CP as needed to clear for two up-to-2-wk
courses (wks 11–12, 23–24). Outcomes included PASI 75
at wk 12 (primary endpoint), static Physician Global
Assessment (sPGA), pt satisfaction with treatment, and
adverse events (AEs). Last-observation-carried-forward
imputation was used for missing data. Significance
testing for primary/secondary endpoints was based on
sequential testing and Hommel procedure.
Results: 592 pts enrolled; 295 and 297 were randomized
to ETN + CP and ETN arms, respectively. PASI 75 was
achieved at wk 12 by 65.2 and 48.3% of pts in ETN + CP
and ETN arms (P\0.001), respectively, and 69.3 and
63.6% at wk 24 (P = 0.135). At wk 12, sPGA of clear/
almost clear (score 0/1) was achieved by 63.1 and 47.3%
of pts in ETN + CP and ETN arms (P\0.001),
respectively, and 61.7 and 54.8% at wk 24 (P = 0.135).
At wk 12, pt satisfaction with treatment was significantly
greater in ETN + CP arm than in ETN arm (P = 0.006). Pt
satisfaction also favored ETN + CP at wk 24 (exploratory
endpoint; nominal P value\0.05, without multiplicity
adjustment). Comparable numbers of AEs were reported
in the ETN + CP (56.6%) and ETN (60.5%) arms. 16
serious AEs in 13 pts were reported: 7 (2.4%) in the
ETN + CP arm and 6 (2.0%) in the ETN arm. 3 fatal AEs
occurred in the ETN + CP arm: death unknown; gunshot
wound; cardiorespiratory arrest and pneumonia. No
imbalances in infections and skin events were observed.
Conclusions: Addition of CP to ETN yielded increased
efficacy compared with ETN alone in pts with moderate
to severe psoriasis as measured by wk 12 PASI 75, sPGA,
and pt satisfaction. Wk 24 PASI 75 and sPGA response
rates were numerically higher in the ETN + CP arm but
differences were not statistically significant.
P088
Secukinumab for treatment of moderate-to-severe
plaque psoriasis: Results of a double-blind, parallel-
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Interleukin (IL)-17A has been reported to be upregulated
in psoriatic lesional skin. Secukinumab, a fully human
anti-IL-17A antibody, has shown efficacy in the
treatment of psoriasis1. This phase II study assessed the
efficacy and safety of different doses of secukinumab in
patients with moderate-to-severe plaque psoriasis.
Patients (n = 125) were randomized (1:1:1:1:1) to receive
subcutaneously either placebo (n = 22) or secukinumab
[1 9 25 mg (n = 29), 3 9 25 mg (n = 26), 3 9 75 mg
(n = 21), 3 9 150 mg (n = 27)] at Week 0, 4 and 8. At
the end of 12-week treatment period, patients entered a
24-week follow-up period. At Week 12, PASI 75 (primary)
and PASI 90 response (secondary) were assessed as
efficacy endpoints.
Baseline disease characteristics were comparable
between treatment groups. At Week 12, PASI 75
response rates for secukinumab 3 9 150 and 3 9 75 mg
were superior as compared to placebo (81 and 57% vs.
9%; p\0.001 and p = 0.002; respectively). Higher PASI
75 response rates were maintained throughout the
follow-up period for secukinumab vs. placebo (Week
32: 56 and 24% vs. 5%; Week 36: 26 and 19% vs. 5%). At
Week 12, PASI 90 response rate reached statistical
significance for only secukinumab 3 9 150 vs. placebo
(52 vs. 5%) and remained higher versus placebo
consistently during the follow-up period up to Week
36 (11 vs. 5%). Secukinumab 3 9 150 mg group reported
slightly higher AEs (89%) compared with the other
secukinumab cohorts (73–76%) which were similar to
the placebo group (73%). Most AEs were mild or
moderate in severity. 2 patients in secukinumab
3 9 25 mg group, 1 in secukinumab 3 9 75 mg group
and 2 in placebo reported SAEs. One patient died in the
placebo group. In conclusion, secukinumab 3 9 75 and
3 9 150 mg cohorts achieved the primary endpoint of
PASI 75 response at Week 12 and the higher response vs.
placebo was maintained over 36 weeks. Overall,
secukinumab had a comparable safety profile to
placebo. These findings indicate that secukinumab
given every 4 weeks is efficacious for the treatment of
moderate-to-severe plaque psoriasis and warrant larger
phase III studies.
Reference: 1. Hueber et al. 2010. Sci Transl Med.
2(52):52ra72.
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Our experience with naphtalan therapy in Danish
psoriasis patients
Krnjevic Pezic, Gordana1; Pasic, Aida2;
Ceovic, Romana2; Stanimirovic, Andrija3;
Ivkovic, Jakov1; Ceovic, Romana2
1Naftalan, Special Hospital for Medical rehabilitation,
Ivanic, Grad, Croatia; 2Zagreb University Hospital
Center, Dermatology and Venerology, Zagreb, Croatia;
3School of Health Studies, Zagreb, Croatia
Introduction: The Naftalan Special Hospital for Medical
Rehabilitation is a unique institution both in Europe and
worldwide for the management of psoriasis, psoriatic
arthritis and rheumatic diseases. Naphthalan as a
specific form of medicinal earth oil is rare, and
naphthalan found at the Kriz oil field near Ivanic Grad
in Croatia is the only one in Europe.
Subjects and methods: During the 2006–2011 period, 63
psoriasis patients (25 female and 38 male) from
Denmark were referred by Denmark insurance
company for treatment at Naftalan Hospital. The mean
patient age was 46.3 (range 15–78) years; 43.9 (15–76)
years in female and 48.8 (18–78) years in male patients.
The mean length of treatment was 21 (18–28) days.
During their stay at Naftalan Hospital, the patients
received baths in naphthalan oil tubs for 15 min/day for
6 days, naphthalan oil temperature 38 C. Naphthalan
cream was applied once daily. During their stay at
Naftalan Hospital, three female and two male patients
continued taking methotrexate and one male patient
cyclosporine, initiated in Denmark. The effect of
naphthalan oil therapy was monitored by PASI score
and photo documentation.
Results: PASI score at the beginning and at the end of
treatment in 63 Danish patients (25 female and 38 male)
is reported. The mean initial PASI score was 16 (female
15 and male 17), while the mean final PASI score was 4.5
(female 3.6 and male 5.4). PASI 90 was achieved in six
(24%) female and three (7.9%) male patients; PASI 75 in
eight (32%) female and 11 (28.9%) male patients; PASI
50 in seven (28%) female and 18 (47.4%) male patients;
and PASI\50 in four (16%) female and six (15.8%) male
patients. Naphthalan oil therapy was well tolerated by
the patients and no side effects were observed.
Conclusion: Naphthalan is a useful topical agent for the
treatment of mild to moderate psoriasis.
P090
Investigator-initiated, open-label trial
of ustekinumab for the treatment of moderate
to severe palmoplantar psoriasis
Kim MD, Noori; Au MD, Shiu-Chung; Goldminz,
Ari; Dumont, Nicole; Michelon MD, Melissa; Volf
MD, Eva; Hession MD, Meghan; Lizzul MD PhD MBA
MPH, Paul; Andrews MD, Israel; Kerensky MD, Todd;
Wang MD, Andrew; Yaniv, Shimrat; Gottlieb MD
PhD, Alice
Tufts Medical Center, Dermatology, Boston, MA, USA
Background: Palmoplantar psoriasis (PP) is a variant of
psoriasis resistant to many forms of treatment. There is
no standard management for PP with only small studies
and case reports showing varied responses to topical and
systemic treatments as well as phototherapy. The Th17/
interleukin (IL)-23 pathway is thought to play an
important role in the pathogenesis of psoriasis, and
ustekinumab, an IL-12/23 inhibitor, is FDA-approved for
the treatment of plaque-type psoriasis. Yet, there is
limited data on its use and efficacy for the treatment of
PP.
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Methods: Twenty subjects with moderate-to-severe
psoriasis of the palms and soles, 50% with pustules at
baseline, were treated with ustekinumab at weeks 0, 4, 16.
All subjects had previously failed topical corticosteroids.
During the treatment phase, subjects were restricted from
concomitant use of other systemic psoriasis therapies,
including PUVA, UVB, systemic corticosteroids,
methotrexate, cyclosporine, oral retinoids, and biologic
therapies. Dosing was 45 milligrams (mg) subcutaneously
for subjects weighing\100 kilograms (kg) and 90 mg for
subjects weighing C100 kg. The primary endpoint was
the percent of subjects achieving clinical clearance at
week 16, defined as Palm-Sole Physician’s Global
Assessment B1.
Results: After 16 weeks of treatment, 35% (7/20) of
subjects achieved clinical clearance. 60% (12/20)
improved two or more points on the Palm-Sole
Physician’s Global Assessment scale. 67% (6/9) of those
receiving the 90 mg ustekinumab dose achieved clinical
clearance compared to 9% (1/11) receiving 45 mg
(p = 0.02). At 24 weeks, mean values showed 56%
improvement in Dermatology Life Quality Index, and
34% improvement in pain Visual Analogue Score (all
p\0.05).
Limitations: Assessment tools for palmoplantar psoriasis
are not yet validated. Five subjects withdrew or were lost
to follow up.
Conclusion: This study demonstrates that ustekinumab
dosed at 90 mg is effective in controlling signs and
symptoms of palmoplantar psoriasis. This may suggest
higher dosing may be required to achieve clinical
clearance in patients with PP compared to current
recommendations for plaque-type psoriasis.
P091
Ustekinumab in patients with active psoriatic
arthritis: results of the phase 3, multicenter, double-
blind, placebo-controlled PSUMMIT I study
McInnes, I1; Kavanaugh, A2; Gottlieb, A3; Puig, L4;
Rahman, P5; Ritchlin, C6; Li, S7; Wang, Y7;
Mendelsohn, A7; Doyle, M8
1University of Glasgow, Glasgow, UK; 2University of
California-San Diego, La Jolla, USA; 3Tufts Medical
Center, Boston, USA; 4Universitat Auto`noma de
Barcelona, Barcelona, Spain; 5Memorial University,
Newfoundland, Canada; 6University of Rochester,
Rochester, USA; 7Janssen Research and Development,
LLC, Spring House, USA; 8Janssen Research and
Development, LLC/University of Pennsylvania, Spring
House/Philadelphia, USA
Objective: To assess efficacy and safety of ustekinumab
(UST) in PsA.
Methods: Adult PsA pts (n = 615) with active disease (C5
SJC and C5 TJC; CRP C 0.3 mg/dL) despite DMARD and/
or NSAIDs were randomized to UST45, 90 mg, or PBO at
wks 0.4, and q12wks. At wk16, pts with\5%
improvement in TJC and SJC entered blinded early
escape (PBO ? UST45 mg; UST 45 ? 90 mg;
90 ? 90 mg). Stable concomitant MTX was permitted
but not mandated. Pts treated with prior anti-TNF agents
were excluded. Primary endpoint was ACR20 response at
wk24; secondary endpoints: ACR 50/70, DAS28-CRP
response, change from baseline (BL) in HAQ-DI, PASI75
response (in pts with C3% BSA), and % change from BL
in enthesitis and dactylitis scores (in pts affected at BL).
Results: At wk24, ACR20 responses were 42.4, 49.5, and
22.8% for the UST 45 mg, UST 90 mg, and PBO grps, resp
(p\0.001). Significant (sig) improvements were also
observed with UST45 mg and 90 mg versus PBO for
ACR50/70 responses and DAS28-CRP responses.
Changes from BL in HAQ-DI at wk24 were sig greater
in the UST versus PBO, and sig greater proportions of
UST-treated pts had a clinically meaningful change from
BL in HAQ-DI (C0.3). Nearly half used concomitant
MTX at BL; this did not alter likelihood of benefit of UST
versus PBO. While ACR responses were greater with UST
than PBO regardless of MTX use, differences were
numerically larger among pts not taking MTX. Of 440
pts with C3% BSA involvement at BL, PASI75 was
achieved in 57.2, 62.4, and 11.0% of UST45 mg, UST
90 mg, and PBO, resp (p\0.001). Among pts with
enthesitis (n = 425) or dactylitis (n = 286) at BL,
greater improvements in enthesitis and dactylitis were
observed at wk24 in the UST grps versus PBO (p\0.001,
each). Through wk16 (PBO-controlled period), prop of
pts with C1 AE was similar between pts receiving UST
(41.8%) and PBO (42.0%), with infections being the
most common AE; 1.7% (UST) and 2.0% (PBO) had C1
SAE. No malignancies, SIE, TB, opportunistic infections,
or deaths occurred through wk24.
Conclusions: UST sig reduced signs and symptoms of
arthritis, improved physical function, enthesitis and
dactylitis, and plaque psoriasis vs. PBO-treated pts at
wk24. Safety profiles were similar between UST and PBO.
P093
ASP015K: a novel JAK inhibitor demonstrated
potent efficacy in a chronic oxazolone-induced
dermatitis model in rats
Higashi, Yasuyuki1; Inami, Masamichi2; Ito, Misato2;
Chida, Noboru2; Nakanishi, Tomonori3; Ooshima,
Shinsuke2; Hanaoka, Kaori2; Ookubo, Keiko4;
Shirakami, Shohei5; Inoue, Takayuki5; Fujii,
Yasutomo6; Yamazaki, Shunji6
1Pharmacology Research Labs, Astellas Pharma Inc., 21
Miyukigaoka, Ibaraki, Japan; 2Pharmacology Research
Labs, Astellas Pharma Inc., Ibaraki, Japan; 3Astellas
Research Institute of America LLC, Skokie, USA;
4Astellas Research Technology Co., Ltd., Osaka, Japan;
5Chemistry Research Labs, Astellas Pharma Inc.,
Ibaraki, Japan; 6Applied Pharmacology Research Labs,
Astellas Pharma Inc., Ibaraki, Japan
Background: The janus kinase (JAK) family of enzymes
play a key role in cytokine signaling, which are involved
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in the pathogenic events of immune-mediated disorders
such as psoriasis.
Methods: In vitro enzyme inhibition assays and cell-
based assays were performed to evaluate the potency and
selectivity of ASP015K against JAK and tyrosine kinase 2
(TYK2) enzymes. Cell-based assays were also performed
to assess the selectivity of ASP015K for signaling via
JAK3/JAK1 over JAK2/JAK2. The efficacy of orally
administered ASP015K was explored in a repeated
oxazolone-induced contact dermatitis model in rats.
Results: ASP015K inhibited JAK1, JAK2, JAK3 and TYK2
enzyme activities with IC50 values of 3.9, 5.0, 0.71 and
4.8 nM, respectively. ASP015K inhibited the IL-2-
induced proliferation (JAK3/JAK1-mediated reaction) of
human T cells with an IC50 value of 18 nM. Moreover,
ASP015 K was 14-fold more potent against JAK3/JAK1
than JAK2/JAK2 on the basis of erythropoietin-induced
proliferation of human leukemia cells (JAK2/JAK2-
mediated reaction). This selectivity suggests that
ASP015 K has the potential to demonstrate JAK3/JAK1-
mediated immunomodulatory effects without the
occurrence of JAK2-mediated hematopoietic effects
such as anemia. The efficacy of ASP015K was examined
in a rat ear model of chronic oxazolone-induced
dermatitis, in which sustained ear swelling and marked
epidermal hyperplasia were observed in control animals.
By contrast, oral administration of ASP015K at doses of
3, 10 and 30 mg/kg suppressed ear swelling in a dose-
related fashion. Histopathological studies revealed that
ASP015K suppressed the infiltration of inflammatory
cells and suppressed epidermal thickening, one of the
most prominent features of psoriasis.
Conclusion: ASP015K is a novel, orally administered JAK
inhibitor with selectivity for JAK3/JAK1 over JAK2/JAK2
that demonstrated dose-dependent efficacy in a rat ear
model of oxazolone-induced dermatitis. These data
suggest that ASP015K may have potential for the oral
treatment of psoriasis as well as other autoimmune
disorders. Early clinical studies in patients with moderate
to severe psoriasis showed improvement indisease activity.
P094
Efficacy and safety of topical combination
treatments in chronic plaque psoriasis:
a systematic literature review
Hendriks, Anke; Keijsers, Romy; de Jong, Elke;
Seyger, Marieke; van de Kerkhof, Peter
Radboud University Nijmegen Medical Centre,
Dermatology, Nijmegen, Netherlands
Background: Most psoriasis patients suffer from mild to
moderate disease and are treated with topical therapies.
Although evidence based guidelines on combinations of
topical therapies are lacking, the majority of patients
will be treated with these combinations at some point
during their life-long treatment.
Objectives: To systematically review all available
literature on the efficacy and safety of combinations of
topical treatments in chronic plaque psoriasis, and
ultimately, to propose recommendations for
combination treatment.
Methods: According to standardized procedures a
literature search from January 1985 to May 2011 in
PubMed, EMBASE, and the Cochrane Controlled
Clinical Trial Register was carried out, and a level of
evidence according to the Oxford Center for Evidence-
based Medicine Levels of Evidence was determined.
Results: Literature search revealed 2,787 studies, of which
61 studies on combinations with topical treatments were
included. The majority of combination regimens are at
least as effective as monotherapies, and are generally
well tolerated.
Conclusions:
1. Methods of classical treatments are not standardized
and different protocols in different treatment
settings were used. Therefore the interpretation of
results of studies cannot be generalized and
conclusions should be drawn with caution.
2. The combination of topical corticosteroids and the
penetration enhancer salicylic acid proved to be
more effective as compared to monotherapy with
either component, and can be recommended
(Grade B).
3. The combination of dithranol with superpotent
corticosteroids may be preferred above both
monotherapies and the combination of dithranol
and coal tar above coal tar monotherapy (Grade C).
4. The highest level of evidence was found for the
combination of potent and superpotent
corticosteroids with vitamin D analogues, and this
combination proved to be more efficacious and
faster than monotherapy with either active
component (Grade A).
5. Combinations of corticosteroids/tazarotene and
corticosteroids/calcineurin inhibitors do not
provide an advantage above corticosteroid
monotherapy (Grade B–C).
P095
Psoriasis treatment expectations and healthcare
provider relationships for patients in Europe,
the USA and Canada
Hansen, Mikkel1; Bewley, Anthony2; Ersser, Steven3;
Ward, Corinne4
1LEO Pharma A/S, Corporate Medical Affairs,
Industriparken 55, Ballerup, Denmark; 2Whipps Cross
University Hospital, Dermatology Service, London, UK;
3University of Hull, Faculty of Health and Social Care,
Hull, UK; 4Mater Dei Hospital, Administration
Department, Msida, Malta
Background: Psoriasis can have a serious impact on
patients’ quality of life. Adherence to therapies is often
poor, which has been associated with low treatment
satisfaction. Effective treatment adherence depends on a
Page S42 of S67 Dermatol Ther (2012) 2:10
123
concordance process, based on a collaborative patient-
health care professional (HCP) relationship. We
explored factors that could affect adherence; including
patient factors, symptom burden, beliefs about
treatment and HCP relationships, to inform a holistic
understanding and approaches to disease management.
Methods: A quantitative questionnaire was developed
based on the results of a previous in-depth qualitative
study involving 56 patients with psoriasis, from seven
countries (data on file), to enhance validity. The 68-part
questionnaire survey was completed on-line by 3,822
adult patients with psoriasis and/or psoriatic arthritis,
also from seven countries in Europe and North America.
Results: The impact of psoriasis on life was scored as
moderate–high for 73% of patients and 49% were
prescribed medication(s) for their psoriasis. Most
patients saw either a GP (34%) or dermatologist (39%)
most often. Many felt knowledgeable about their
psoriasis (61%) and familiar with treatment options
(56%). However, 70% stated that they expect a cure
when trying a new treatment and 78% said that they
expect fast results. Of patients seeing a doctor for their
psoriasis, most (79%) felt that they do not find it difficult
to discuss their psoriasis with their doctor, 83% said that
they follow their doctor’s recommendations and 80%
felt that their doctor gives clear instructions.
Conclusions: To date, this is the largest multinational
study to investigate these patient-centric issues. It
indicates that the vast majority of patients have a
positive, collaborative relationship with their doctor.
However, although many patients feel knowledgeable
about treatments, many appear to have unrealistic
expectations of the effectiveness and speed of action of
current treatments, which could impact on adherence.
We plan further analysis of this data set, ultimately
aiming to help optimise treatment adherence and
outcomes through informing individualised care
strategies.
P097
Use of modern psychometric techniques
to demonstrate improvement in fatigue in RA
patients treated with secukinumab
Gnanasakthy, A.1; Kosinski, M.2; Durez, P.3;
Mallya, U.G.1; Mpofu, S.4
1Novartis Pharmaceuticals Corporation, East Hanover,
USA; 2Quality Metric Incorporated, Lincoln, RI, USA;
3Universite´ Catholique de Louvain, Brussels, Belgium;
4Novartis Pharma AG, Basel, Switzerland
Background: Fatigue is recognized as a clinically and
patient relevant treatment outcome in RA. A large
proportion (40–80%) of RA patients report significant
levels of fatigue and absence of this symptom is
included in the characterization of disease remission.
As such, EULAR and the ACR expert panels have
added fatigue to the core set of recommended
endpoints for RA clinical trials. The FACIT-F and the
SF-36v2 vitality (VT) scale have been used to measure
fatigue in RA.
Objective: To improve the sensitivity of detecting treatment
effects on fatigue in RA.
Methods: 237 adults with RA on methotrexate were
randomized to receive s.c. injections of secukinumab 25,
75, 150, 300 mg or placebo. The SF-36v2 and FACIT-F
were administered at baseline, weeks 2, 4, 8, 12, and 16.
A generalized partial credit IRT model was used to cross-
calibrate the items of the SF-36 VT and FACIT-F scales
and weighted maximum likelihood estimation was used
to score a composite index. Change scores for the
composite index and the SF-36 VT and FACIT-F scales
were calculated. Analysis of variance and effect sizes
were used to evaluate and compare the sensitivity of
each measure. A ratio of F-statistics was calculated to
determine the relative validity of each measure in
responding to treatment in both a within groups and
between groups analysis.
Results: The composite index was found to be the most
responsive to treatment across dose groups (effect size
for composite index was 11–93% larger than the effect
sizes observed for the SF-36 VT and FACIT-F scales).
F-statistics testing the difference in change score from 0
within each of the dose groups was largest for the
composite fatigue index, indicating a greater response.
The 75 mg (mean difference of 3.3, F = 3.9, p\0.05)
and the 150 mg (mean difference of 3.5 points, F = 5.1,
p\0.05) doses showed significantly greater
improvement on the composite index compared to
placebo. No significant differences in change scores
between the 75 and 150 mg doses and placebo was
observed with either the SF-36 VT or FACIT-F scales
alone.
Conclusion: A fatigue composite index offers more
sensitive assessment of fatigue in patients with RA.
P098
Association between reduction in disease activity,
pain severity and health-related quality of life
(HRQoL) among rheumatoid arthritis (RA) patients
treated with secukinumab
Gnanasakthy, A.1; Kosinski, M.2; Genovese, M.3;
Mallya, U.G.1; Mpofu, S.4
1Novartis Pharmaceuticals Corporation, East Hanover,
USA; 2Quality Metric Incorporated, Lincoln, RI, USA;
3Stanford University School of Medicine, California,
USA; 4Novartis Pharma AG, Basel, Switzerland
Objective: Evaluate the HRQoL benefits associated with
reductions in disease activity and pain among RA
patients treated with secukinumab in a phase 2
randomized controlled trial.
Method: RA patients (n = 237) on methotrexate were
randomized equally to receive monthly injections of
secukinumab or placebo. Secondary efficacy endpoints
consisted of physician (PH-GADA) and patient (PT-
GADA) global ratings of disease activity and VAS pain
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severity, each measured using a 0–100 scale. HRQoL was
assessed using the SF-36v2 Health Survey, the Health
Assessment Questionnaire-Disability Index (HAQ-DI),
and the Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F). Changes from baseline to
week 16 were calculated for secondary endpoints and
HRQoL measures. Patients treated with secukinumab
were categorized into responder (improvement of[10
points) and non-responder groups (improvement\10
points) on each secondary endpoint measure. ANOVA
was used to test differences in mean changes in HRQoL
scores across responder and non-responder groups.
Results: Significant changes in HRQoL scores were
observed among responders on each secondary efficacy
measure. Among PT-GADA responders, relatively small
improvements of 11–20 points was associated with
significant improvements on most HRQoL scales
ranging from 1.4–4.9 points across SF-36v2 scales, 5.9
points on FACIT-F, and -0.32 points on HAQ-DI.
Patients showing greater improvement ([20 points) on
the PT-GADA showed incrementally larger improvement
in HRQoL scores. Larger improvement in PH-GADA ([20
points) were required to see significant improvement in
HRQoL. The range of score improvement was 1.7–5.9
points across SF-36 scales, 4.1 points on FACIT-F, and
-0.28 points on HAQ-DI. Lastly, significant
improvement in HRQoL scores was observed among
patients showing clinically meaningful reduction in
pain. Mean score improvement ranged from 3.8 to 8.9
points across SF-36v2 scales, 7.2 points on FACIT-F, and
-0.47 points on HAQ-DI among pain responders.
Conclusion: Greater reduction in disease activity and pain
severity was associated with significant HRQoL benefits
among patients treated with secukinumab.
P099
Evaluation of high and low intensity physical
functioning in secukinumab treated RA patients:
an application of IRT methodology
Gnanasakthy, A1; Kosinski, M2; Kellner, H3;
Mallya, UG1; Mpofu, S4
1Novartis Pharmaceuticals Corporation, East Hanover,
USA; 2QualityMetric Incorporated, Lincoln, USA;
3Praxis Mu¨nchen Nymphemburg, Germany, Germany;
4Novartis Pharma AG, Basel, Switzerland
To fully evaluate the impact of RA treatment on physical
functioning, two scales are typically employed: HAQ-DI
and SF-36v2 physical functioning (PF) scales. Items of the
HAQ-DI assess lower intensity functioning, such as eating,
dressing, and reaching, while SF-36 PF scale assesses
relatively higher intensity, such as lifting or climbing
stairs. Utilization of a combination of these scales may
improve the ability to detect treatment effects by
extending the range of physical functioning measured.
To create a single composite index of physical functioning
and evaluate the ability of such index to detect treatment
effects utilizing modern psychometric methods. 237
adult RA patients on methotrexate were randomized to
receive injections of secukinumab 25, 75, 150, 300 mg or
placebo. The SF-36v2 and HAQ-DI were administered at
baseline, weeks 2, 4, 8, 12, and 16. A generalized partial
credit IRT model was used to cross-calibrate the items of
SF-36 PF and HAQ-DI scale and weighted maximum
likelihood estimation was used to score a composite PF
index. Change scores were calculated. Response to
treatment was assessed using ANOVA and effect sizes for
each measure. A ratio of F-statistics was calculated to
determine the relative validity of each measure in within
groups and between groups analysis.
The composite PF index was found to be the most
responsive to treatment for the 25, 75 and 150 mg
groups. The effect size for the composite index was
10–40% larger than observed for the SF-36 PF and HAQ-
DI scales for each dose group. The F-statistic was largest
for the composite PF index, indicating a greater
response to treatment. In the between groups
analyses, the 150 mg dose group showed significant
improvement in physical functioning. The composite
PF index was most sensitive (effect size of 0.49 vs. 0.43
for the HAQ-DI and 0.32 for the SF-36 PF). The
F-statistic was largest for the composite PF Index
(F = 6.6, p\0.01, RV = 1.0) compared to the HAQ-DI
(F = 4.4, p\0.05, RV = 0.67) and SF-36 PF (non-
significant).
Physical functioning may be more fully measured in RA
patients utilizing composite PF index.
P100
Etanercept in psoriasis and psoriatic arthritis:
an Indian experience
Ghosh, Sanjay1; Prasad, Balaram2
1MGM Medical College and LSK Hospital, Department
of Dermatology, Kishanganj, India; 2Institute of
Allergic and Immunologic Skin Diseases, Department
of Dermatology and Internal Medicine, Kolkata, India
Background: Psoriasis has been increasing rapidly in
India especially in urban set up in recent decades due
to life pattern changes. One-fifth of Indian patients
have BSA more than 26–50%. Interestingly PASI score
has no positive correlation with quality of life in
them. Many psoriatics are refractory to conventional
drugs or develop toxicity to these agents due to high
incidence of alcoholism, fatty liver and dyslipidemia
in Indians. Thus need for biologics become really
true in the scenario of psoriasis management in
India. Our object was to assess clinical outcome
of Indian psoriasis patients to etanercept, an anti-
TNFa not requiring in-house admission, in this open
trial.
Method: Patients were chosen as per BAD guideline for
biologics in psoriasis and screened for pre-therapy
investigations especially to exclude tuberculosis. They
were given etanercept injection 25 mg S/C twice in a
week for 3–6 months with proper monitoring.
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Results: Among total 14 patients (10 M 4F), age ranging
from 17 to 68 year, suffering from psoriasis for 8 to
15 years, 4 had erythroderma, 4 pustular psoriasis, 4
plaque psoriatic associated with psoriatic arthritis, 1
extensive (BSA[50%) refractory plaques, 1 limited
involvement on cosmetically disfiguring area with high
DLQI. Impressive therapeutic response was seen 85.7%
(n = 12) patients. Rest 2 overweight patients having
erythroderma did not adequately respond. No
tuberculosis flare or other adverse effect was seen in any
one. However 2 previously negative patients showed
positive TB gold test after 6 months treatment; one
showed non-specific axillary lymph gland swelling. After
three months post-therapy 57.1% (n = 8) had moderate
relapse being controlled by methotrexate or acetretin with
UVB NB, 14.3% (n = 2) had severe relapse responding
only to cyclosporine and 14.3% (n = 2) had no relapse at
all. Rebound flare was not seen in anyone.
Conclusion: Etanercept in Indian psoriasis perspective is
quite effective and safe if patients are properly chosen
and screened. Moderate post-therapy relapse, however,
can occur in good number of patients.
Keywords: Psoriasis, Psoriatic arthritis, Etanercept, PASI,
Biologics, Quality of life.
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Secukinumab improves signs and symptoms
in patients with active rheumatoid arthritis: results
of dose-finding, double blind, randomized, placebo
controlled, phase II study
Genovese, Mark1; Durez, Patrick2; Richards, Hanno3;
Supronik, Jerzy4; Dokoupilova, Eva5; Aelion,
Jacob A.6; Lee, Sang-Heon7; Codding, Christine E.8;
Kellner, Herbert9; Ikawa, Takashi10; Hugot,
Sophie3; Ligozio, Gregory11; Mpofu, Shephard3
1Stanford University, Palo Alto, Canada; 2Universite0
Catholique de Louvain, Brussels, Belgium; 3Novartis
Pharma AG, Basel, Swaziland; 4NZOZ Centrum
Medyczne Artur Racewicz, Bialystok, Poland; 5Medical
Plus s.r.o, Uherske Hradiste, Czech Republic; 6Arthritis
Clinic, Jackson, Tanzania; 7Konkuk University Medical
Center, Seoul, Republic of Korea; 8Health Research of
Oklahoma, Oklahoma, USA; 9Centre for Inflammatory
Joint Diseases, Munich, Germany; 10Kobe–Konan
Yamate Clinic, Kobe, Japan; 11Novartis
Pharmaceuticals Corporation, East Hanover, USA
The interim analysis results of this study presented
earlier suggested that secukinumab improved clinical
outcomes in active rheumatoid arthritis (RA) patients.
Herein, we report the long term results up to Week (wk)
52 of the same study.
In this study (NCT00928512), RA patients (C18 years;
n = 237) with inadequate response to methotrexate
(MTX) were randomized (1:1:1:1:1) to receive monthly
s.c injections of secukinumab 25, 75, 150, 300 or
placebo. After wk16, secukinumab responders remained
on the same dose, while doses were escalated in
non-responders at wk20 (except in patients initially on
300 mg). All placebo patients were switched to
secukinumab 150 mg. Primary endpoint was the
proportion of patients achieving ACR20 at wk16
followed through wk52.
Demographics and baseline characteristics were
comparable across all groups. ACR20 responders at
wk16 were higher (but not statistically significant) with
secukinumab 75 mg (47%), 150 mg (47%) and 300 mg
(54%) versus placebo (36%) and maintained their ACR
responses through wk52 [75 mg (57%), 150 mg (90%),
300 mg (71%)]. ACR50/70 responses at wk24 and wk52
were highest in patients who remained on secukinumab
150 mg (ACR50/70: wk24 = 50/20%, wk52 = 55/40%),
as did responders who switched from placebo to
secukinumab 150 mg (ACR50/70: wk24 = 39/6%,
wk52 = 50/22%). In secukinumab responders, DAS28-
CRP reductions were sustained up to wk52 along with
improved HAQ scores (wk24 = 0.6, wk52 = 0.8). Non-
responders did not gain much additional efficacy after
dose escalation as assessed by ACR20/50/70 and DAS28-
CRP. The overall rates of AEs from wk20¨C60 were
comparable to those observed up to wk20 (60—70%).
Most AEs were mild to moderate in severity and did not
lead to study discontinuation. From wk20—60, infection
rate was 31.9% with six infections reported as SAEs. In
total, 28 SAEs were reported in 21 patients. There were 3
malignancies reported and no deaths.
RA patients on secukinumab who achieved an ACR20
response at week 16 maintained their response and
demonstrated a reduction in disease activity over time.
There were no safety signals with secukinumab related to
specific organ class and the frequency of AEs remained
stable over time.
P102
Effect of secukinumab treatment on ACR50, HAQ-DI
and EULAR remission rates in patients
with rheumatoid arthritis
Genovese, Mark1; Kellner, Herbert2; Durez, Patrick3;
Codding, Christine E.4; Ligozio, Gregory5;
Richards, Hanno B.6; Escrig, Cesar6;
Mpofu, Shephard6
1Stanford University, Palo Alto, USA; 2Centre for
Inflammatory Joint Diseases, Munich, Germany;
3Universite´ Catholique de Louvain, Brussels, Belgium;
4Health Research of Oklahoma, Oklahoma City, USA;
5Novartis Pharmaceuticals Corporation, East Hanover,
USA; 6Novartis Pharma AG, Basel, Switzerland
Secukinumab, a fully human anti-IL-17A monoclonal
antibody has shown improvement in signs and
symptoms of patients (pts) with active rheumatoid
arthritis (RA) in this phase II trial. Here we report the
effect of secukinumab on disease activity in pts with
active RA despite stable methotrexate (MTX) treatment.
Adult RA pts (n = 237) on MTX were equally
randomized to receive monthly subcutaneous
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secukinumab 25, 75, 150, 300 mg or placebo. After Week
(wk) 16, responders on secukinumab remained on the
same dose whereas doses were escalated in non-
responders at wk20 (except pts initially on 300 mg
who remained on the same dose). At wk20, all placebo
pts were switched to secukinumab 150 mg. All pts were
followed up to wk52. Primary endpoint was proportion
of pts achieving ACR20 at wk16. Secondary endpoints
include ACR50, HAQ-DI and EULAR remission rate
(DAS28-CRP B2.6). Demographics and baseline
characteristics were comparable between groups. The
primary endpoint was not achieved. ACR50 response
rates at wk24 (50%) and wk52 (55%) were highest in pts
who remained on secukinumab 150 mg for the entire
study. HAQ scores improved over time in responders on
secukinumab 150 mg (wk24 = -0.6; wk52 = -0.8). At
wk16, the EULAR remission rates were higher with
secukinumab vs. placebo (25 mg-11.3%, 75 mg-6.1%,
150 mg-11.6%, 300 mg-14.6 vs. 6% placebo) which
increased overtime and was highest in pts on
secukinumab 150 mg (wk24 = 30%, wk52 = 40%). Pts
who responded to placebo but switched to secukinumab
150 mg at wk20 had similar EULAR remission response
rate (wk24 = 29.4%; wk52 = 38.9%). No additional
efficacy benefits were observed with non-responders even
afterdoseescalation. Overall rates ofadverse events (AEs) at
wk52werecomparable to wk20data.MostAEsweremild to
moderate in severity and did not led to study
discontinuation. In conclusion, this study did not meet
its primary objective. Substantial proportion of pts who
either remained on or escalated to secukinumab 150 mg
achieved ACR50, HAQ-DI and EULAR remission rates and
showed consistent improvement till wk52. These results
suggest the potential role of secukinumab in RA and
warrant larger phase III studies.
P103
Maintenance therapy of psoriasis with cyclosporine:
comparison between continuous and weekend
therapy
Fernandes, Iolanda1; Torres, Tiago2; Selores, Manuela2
1Centro Hospitalar do Porto, Hospital de Santo
Anto´nio, Dermatology, Edifı´cio das Consultas
Externas, Rua D. Manuel II, s/n, Porto, Portugal;
2Centro Hospitalar do Porto, Hospital de Santo
Anto´nio, Porto, Portugal
Introduction: Many reports have confirmed that
cyclosporine (CsA) is effective in both induction and
maintenance regimen for the treatment of moderate-to-
severe psoriasis. Intermittent therapy is used in order to
minimize the risks without loss of clinical benefits.
Objectives: Evaluate the efficacy, safety and tolerability of
CsA in the maintenance treatment of psoriasis. Two
different treatment methods were compared: continuous
therapy (low-dose ranging from 2 to 3 mg/Kg/day) and
intermittent therapy (5 mg/kg/day for two consecutive
days/week), during 20 weeks.
Methods: Twenty-one patients with psoriasis (PASI[15)
were submitted to induction treatment with
cyclosporine (4 mg/Kg/day) for 12 weeks. The patients
who achieved clinical remission (PASI 75) following
continuous CsA therapy were divided into the two
different groups described above, for maintenance
therapy.
Results: After 12 weeks of continuous therapy with CsA
(induction treatment), 19 patients achieved PASI 75. Of
these, 9 patients started the continuous low-dose
regimen and the remaining 10 were submitted to
intermittent therapy with CsA. Before starting the
maintenance therapy, there was no significant
difference in the mean PASI between the 2 groups.
Also, at the end of the study, no statistically significant
difference in the mean PASI score was found between
the regimens. However, adverse effects and drop-outs
were more frequent in patients under continuous
maintenance therapy. The mean daily dose was higher
in the latter and the twice-weekly dosing schedule was
more convenient for patients.
Discussion and results: Both treatment regimens showed
comparable efficacy. However, patients treated with
intermittent regimen received lower daily CsA doses
and had fewer side effects. Thus, the use of weekend
maintenance treatment seems to be reasonable.
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Formulation of anthralin in liquid solution
for the treatment of scalp psoriasis
Farshi, Susan1; Farshi, Hooman2;
Saghazadeh, Mojgan3
1Tehran University of Medical Sciences, Dermatology,
Tehran, Islamic Republic of Iran; 2Azad University,
Chemistry, Tehran, Islamic Republic of Iran; 3Qom
Branch, Islamic Azad University, Microbiology,
Tehran, Islamic Republic of Iran
Anthralin is one of the effective drugs in the treatment
of psoriasis. The efficacy of anthralin as a topical
treatment of psoriasis has been repeatedly established
over a half century of use. The drugs available so far are
either ointment or O/W type cream. This form of drug is
not suitable to be applied in the treatment of scalp
psoriasis. For this purpose we have done some researches
about the preparation of anthralin solutions which have
had considerable results. Anthralin ointment and cream
suffer from two clinical disadvantages: (1) Since the
formulation has high viscosity, it is not rapidly
penetrated into the skin, most of the application
remains on the surface. (2) It is not easy to remove the
ointment or cream from the scalp hairs with just soap
and water. The advantages of applying anthralin
solution are as follows: (1) It is more penetrable than
ointment and cream. (2) Easily applicable and washable.
(3) The stability of anthralin is low in cream form and
most of the drug in ointment and cream equivalents
remains in the form of small scattered insoluble
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particles, therefore anthralin solution is more potent
than the equivalent strengths of ointment and cream. In
recent study, many anthralin derivatives have been
developed and formulated as solution forms which are
suitable for the treatment of psoriasis with SCAT (short
contact anthralin therapy) method. In this method the
treatment must be started with low concentration of
anthralin and then it should be increased little by little.
These solutions were tested in ten patients with scalp
psoriasis as a pilot study. The duration of treatment was
21 days. Modified psoriasis area severity index (PASI)
scores were determined before and after treatment. PASI
scores were significantly lowered where the formulated
solutions had been applied. In determining PASI scores,
three factors, erythema scaling and thickness, were
evaluated; all were significantly lower where the
formulated solutions had been applied (P = 0.002,
P = 0.001, P = 0.001).
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Secukinumab induces higher assessment
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over placebo in patients with moderate-to-severe
ankylosing spondylitis: Results of 28-week,
double blind, randomized, placebo-controlled
trial
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IL-17 may play a role in the inflammatory process of
ankylosing spondylitis (AS). This proof-of-concept study
assessed the preliminary efficacy and safety of
secukinumab, a fully human monoclonal antibody, for
targeted IL-17A blockade as a novel therapeutic strategy
in the treatment of moderate-to-severe AS.
In this study (NCT00809159), 30 patients (pts) with
active AS randomly (4:1) received two i.v. infusions of
secukinumab 10 mg/kg or placebo, given 3 weeks (wk)
apart (at days 1 and 22). Primary endpoint was the
proportion of pts achieving Assessment of
SpondyloArthritis international Society (ASAS) 20
response at wk 6. Historical placebo information from
8 representative AS trials was included in a Bayesian
analysis of the primary endpoint.
Demographics and baseline characteristics were
comparable between groups. 5 pts (placebo 3 and
secukinumab 2) discontinued the study before wk 6. At
wk 6, 61% (14/23) pts on secukinumab achieved ASAS20
responses vs. 17% (1/6) pts on placebo (99.8%
probability that secukinumab response rate larger than
placebo rate; 95% credible interval of response difference
[12, 56%]). At wk 6, ASAS40 and ASAS5/6 response of pts
on secukinumab were 30 and 35%, respectively and
mean (range) BASDAI change from baseline was -1.8 (-
5.6-0.8). ASAS response rates were greater at wk 6, and
gradually declined thereafter out to wk 28, consistent
with the preliminary dose regimen. Post hoc subgroup
analyses showed TNFi naive pts have greater ASAS20
response rates (85%; 11/13) vs. TNFi pre-exposed (30%;
3/10) pts. Secukinumab PK profile was as expected for
an IgG1 mAb and similar to those seen with
secukinumab in other indications. Overall, 30
infections (22 mild, 7 moderate, 1 severe) were
reported in 18 pts. 2 SAEs (placebo: BP increased;
secukinumab: subcutaneous abscess) and no death were
reported in this study.
The primary endpoint of this study was met, as the
treatment with secukinumab significantly improved the
signs and symptoms of AS as measured by ASAS20 at wk
6 compared to placebo. No early safety signals were
noted in this study population. These findings warrant
larger long term trials on safety and efficacy of
secukinumab in AS.
P106
Secukinumab treatment has no effect on the lipid
profile in patients with rheumatoid arthritis: results
from a randomized, double-blind, placebo-
controlled, phase II study
Durez, Patric1; Genovese, M2; Kellner, H3;
Codding, C4; Ligozio, G5; Richards, H6;
Escrig, C6; Mpofu, S6
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Active rheumatoid arthritis (RA) is associated with an
unfavorable lipid profile leading to higher atherogenic
index. Secukinumab, a fully human anti-IL-17A
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monoclonal antibody improved signs and symptoms of
patients with active RA in this phase II trial. Efficacy and
safety of this study group did not report any
cardiovascular event. Here, we report the effect of
secukinumab on the lipid profile and atherogenic
indices in patients with active RA, despite stable
methotrexate (MTX) treatment.
Adult RA patients (n = 237) on MTX were randomized
equally to receive monthly s.c injections of secukinumab
25, 75, 150, 300 mg or placebo. After Week (wk) 16,
responders on secukinumab remained on the same dose.
At wk20, secukinumab doses were escalated for non-
responders (except for patients on 300 mg) and placebo
patients were switched to 150 mg and followed up to
wk52. Demographics, baseline characteristics and lipid
parameters were normal and comparable across all
treatment arms. There was no effect of secukinumab
on the lipid profile (total cholesterol [TC], high-density
lipoprotein cholesterol [HDLc], low-DLc [LDLc],
triglycerides [TG], apolipoprotein (Apo) A-I and Apo B)
during the first 16 wks compared to placebo. Mean
change ± SD (mmol/L) from baseline to wk16 were,
for TC: 0.092 ± 1.02, 0.015 ± 0.56, 0.212 ± 0.83,
0.017 ± 0.73; -0.093 ± 0.66; HDLc: 0.053 ± 0.24,
-0.051 ± 0.24, 0.063 ± 0.24, 0.026 ± 0.23; 0.055 ± 0.23;
LDLc: -0.158 ± 0.89, 0.01 ± 0.5, 0.12 ± 0.74, -0.008 ±
0.61; 0.082 ± 0.58; TG: 0.028 ± 0.47, 0.122 ± 0.48,
0.062 ± 0.58, -0.002 ± 0.62; 0.147 ± 0.56 for
secukinumab 25, 75, 150, 300 mg and placebo
respectively. Atherogenic indices (mean change ± SD;
TC/HDLc: -0.133 ± 0.64, 0.095 ± 0.5, -0.021 ± 0.58,
0.068 ± 0.53; -0.216 ± 0.67; ApoB/Apo A-1: -0.041 ±
0.15, -0.023 ± 0.1, -0.022 ± 0.13, -0.012 ± 0.1;
-0.042 ± 0.12 for secukinumab 25, 75, 150, 300 mg and
placebo respectively). TC/HDLc and Apo B/Apo A-I ratios
remainedunchanged during thefirst16 wks of therapyand
throughout the study period (wk0–52) in patients
switching to secukinumab150 mg from placebo at wk20.
Secukinumab treatment was not associated with changes
in the lipid profile or atherogenic risk in patients with
RA.
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Phototherapy of psoriasis in the era of biologics:
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Introduction: Biologics have temporarily shifted the
conventional systemic antipsoriatic therapy including
phototherapy aside. However, because of its efficacy,
cost, availability and minimal side effects, phototherapy
remains the therapy of choice for a large number of
psoriatic patients. Phototherapy is known to be
frequently combined with various local and systemic
therapeutic options to improve overall efficacy.
Methods: In the last 3 years, 1,208 patients were treated
at our Phototherapy Unit. Narrow band UVB (NBUVB)
was the first choice among the phototherapy methods
used, whereas photochemotherapy (PUVA) was applied
in cases of low clinical response to NBUVB.
Results: PASI 75 was achieved by 72 and 88% of patients
after 4–6 weeks of NBUVB and PUVA, respectively. No
maintenance phototherapy was used, but the majority
of the patients combined various topical therapies to
enhance clinical response to phototherapy. Patients
mostly combined NBUVB with dithranol as a so-called
‘short contact therapy’ and calcipotriol. In patients
responding with inadequate disease clearance,
phototherapy and photochemotherapy were combined
with systemic drugs, mainly retinoids, (acitretin). In 8
patients having received methotrexate for a longer
period due to psoriatic arthritis and skin psoriasis and
showing favorable effect on the joints and skin, NBUVB
was applied in the phases of skin psoriasis exacerbation.
Considering the geographical position of our country
and the possibility for our patients to stay at seaside
during summer, natural UV therapy combined with sea
bath (heliomarinotherapy) is recommended. As biologic
therapy has to date been used in a relatively small
number of our patients, we have not acquired much
experience in combining photo- and biologic therapy.
Conclusion: Even in the era of biologics, phototherapy
remains an important modality of treating psoriasis,
especially in combination with various local and systemic
therapeutic options. The advantage of combination
therapy is the possibility of decreasing the UV irradiation
dosage to reduce its side effects, while at the same time
achieving an additive or synergistic effect.
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Utilization of narrow-band UVB light therapy
and etanercept for the treatment of psoriasis/
characteristics of PASI responders
Belaus, Monica
Hospital Nacional De Clinicas, Cordoba, Argentina
Clinical trials in psoriasis often use the psoriasis area and
severety index (PASI) 75 (indicating a 75% or greater
improvement from baseline in PASI score), as a measure
of response to therapy. PASI scores range from 0 to 72 on
a severety scale, whit higher score indicatting, worse
disease. Because of the high rate complete psoriasis
clearance-as measured by attaimment of PASI 100
responses-in the utilization of NB-UVB light therapy and
Etanercept for the treatment ofpsoriasis (unite) trial, we are
able to examine the characteristics of patients with severe
psoriasis who achieeved these response rates when
receiving the combination of etanercept with NB-UVB.
Adult patients with chronic plaque psoriasis and PASI
score of 15 or greater at baseline received 50 mg
etanercept twice-weekly (BIW) in combination with
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NB-UVB 3 times- weckly (TIW) for 12 weeks in this open-
label, single-arm study the primary endpoint was the
proportion of patients achieving PASI 90 and 100.
Analyses included all patients who received at least 1
dose of etanercept and NB-UVB phototherapy; analyses
were conducted using a last-observation-carried-forwad
approach, of the 86 patients who received at least 1 dose
of etanercept and NB-UVB phototherapy, analyses were
conducted using a last-observation-carried-forwad
aproach, of the 86 patients who recieved treatment-
20% achieved a PASI 100 response at weeck 12.58%
achieved PASI 90, and 85%, achieved PASI 75, potential
relation ships between patient characteristcs and the
likelihood of achieving a PASI 100 in this study will be
presented, including comparisons of baseline and
treatment of patients in the top quartile of PASI,
responders through 12 weeks of treatment with the
bottom quartile of responders. Data from study offer a
unique opportunity to examine the characteristics of
patients, whith psoriasis who achieved a complete
psoriasis clearance with a combination of etanercept
BIW and NB-UVB therapy TIW.
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as detected by magnetic resonance imaging—results
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phase II proof-of-concept study
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In this proof-of-concept study, secukinumab induced
higher Assessment of SpondyloArthritis international
Society (ASAS) 20 response rates than placebo (PL) at
Week (wk) 61. Herein, we evaluated the effects of
secukinumab on bone marrow edema as detected by
magnetic resonance imaging (MRI) in Ankylosing
Spondylitis (AS) patients.
30 patients with active AS (as per 1984 modified New
York criteria) were randomized (4:1) to receive two i.v.
infusions of secukinumab (10 mg/kg) or PL, given 3 wks
apart. Primary endpoint was the proportion of patients
achieving ASAS20 response at wk6. Sagittal MR images of
the spine were performed including T1- and short tau
inversion recovery sequences at baseline, wk6 and wk28.
Images were analyzed by an independent reader, who
was blinded to treatment allocation and chronology of
images, using the Berlin modification of the AS spinal
MRI (ASspiMRI-a2) scoring system. Changes in MRI
scores between baseline and followup visits in each
treatment arm were evaluated by Wilcoxon signed-rank
test.
In total, MR images of 27 patients (22 secukinumab; 5
PL) were evaluable at baseline. Due to early
discontinuation, few patients (wk6: 2 secukinumab, 3
PL; wk28: 6 secukinumab, 1 PL) were not analyzed for
MRIs. Improvement in MRI scores from baseline with
secukimunab was noticed as early as wk6 and sustained
up to wk28 (Berlin MRI scores [mean ± SD]: Baseline:
9.2 ± 8.9; wk6: 6.7 ± 6.6; wk28: 5.7 ± 6.2). This
improvement in MRI scores at wk6 was especially
noted in patients with higher baseline scores. In
contrast, changes in MRI scores were minimal in the
placebo group.
This study suggests that treatment with only 2
infusions of secukinumab reduces spinal
inflammation as detected by MRI in patients with
active AS. Improvements in MRI scores were seen as
early as 6 wks after start of secukinumab treatment and
sustained up to wk28. Results are consonant with MRI
findings obtained in previous AS trials with TNF
blockers. These results further support the notion that
secukinumab may be a potential treatment for patients
with active AS.
References: 1. Baeten D et al., EULAR 2011, OP0174. 2.




Wnt pathway inhibitors in patients with psoriatic
and rheumatoid arthritis treated with anti-TNF
therapy
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Dublin, Ireland; 2Medical and Health Science Center
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Background: Both rheumatoid and psoriatic arthritis
(RA, PsA) are characterised by erosion but bone
formation is also a feature in PsA. Wnt proteins are
key promoters of osteoblastogenesis in inflammatory
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arthritis. Dickkopf-1 (Dkk-1) and sclerostin are natural
inhibitors of Wnt signaling. Dkk-1 induces sclerostin
expression and promotes osteoclastogenesis by
suppressing osteoprotegerin (OPG). TNFalpha inhibits
bone formation by inducing Dkk-1 and sclerostin
expression. The effect of anti-TNF on Wnt inhibitors in
RA and PsA has not been studied previously.
Objectives: To study serum levels of Dkk-1 and sclerostin
in RA and PsA; to compare the early and long-term
effects of anti-TNF on Wnt inhibitors and to explore
associations between serum levels of Dkk-1, sclerostin
and acute phase responses.
Methods: RA and PsA patients were recruited prior to start
anti-TNF. Serum levels of Dkk-1 and sclerostin were
measured by ELISA at baseline, 1 and 12 months and
were related to CRP. OPG/Dkk-1 and OPG/sclerostin
ratios were calculated from previously measured OPG
levels.
Results: We recruited 62 patients (35 RA, 27 PsA). Dkk-1
and sclerostin levels did not change significantly in
either group. No significant difference was observed in
Dkk-1 and sclerostin levels between RA and PsA, while
Dkk-1 levels were lower in PsA at 12 months
approaching significance (p = 0.08). There was no
correlation between Dkk-1 or sclerostin and CRP. OPG/
Dkk-1 ratio reflecting remodeling balance was similar
and did not change in either group. OPG/sclerostin ratio
was significantly higher at 12 months compared to
baseline in both groups (RA p = 0.002, PsA p\0.0001).
OPG/sclerostin ratio was significantly higher in PsA than
in RA at 12 months (p = 0.038).
Conclusion: This study provides data suggesting
differences in the cross-talk between TNFalpha, Dkk-1
and sclerostin between RA and PsA. After 12 months of
anti-TNF therapy Dkk-1 levels were lower, OPG/
sclerostin ratio was higher in PsA compared to RA. This
may contribute to the imbalance of bone remodeling in
favour of bone formation in PsA. Neither Dkk-1 nor
sclerostin correlated with CRP indicating that these Wnt
inhibitors may not linked to inflammation.
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Serum IL-23 does not correlate with disease activity
in psoriatic arthritis and SAPHO syndrome
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There are some data that IL-23 play an important role in
pathogenesis of psoriatic arthritis.
Objectives: The aim of the study was to assess the
association between serum concentrations of IL-23 and
disease activity in psoriatic arthritis (PsA) and SAPHO
syndrome.
Materials and methods: We studied 82 PsA patients, 22
SAPHO syndrome patients and 20 healthy persons. We
recorded: age, sex, disease duration. We assessed: BASFI,
BASDAI, BASG, BASMI, VAS, SF-36, PASI scores. Blood
was collected for analysis of serum IL-23, EGF, FGFb and
FGFc by ELISA method. We assessed also CRP, ESR, WBC.
Results: Mean age of patients was: 52.8 years in PsA
group and 54.8 years in SAPHO group. Mean disease
duration was 8.6 years in PsA group and 6 years in
SAPHO group. Mean serum IL-23 levels were: 4.1 pg/ml
in PsA group and 3.5 pg/ml in SAPHO group. There was
no correlation between IL-23 and disease activity
assessed by CRP and ESR in PsA and SAPHO patients.
There was also no correlation between serum IL-23 and
disease activity assessed by BASMI, BASDAI, BASFI and
BASG. There was no correlation between serum IL-23
and EGF and FGF. There was negative correlation
between VAS score and serum IL-23 in SAPHO group
(R = -0.46; p = 0.04). There was positive correlation
between SF-36 and IL-23 in PsA group (R = 0.42;
p = 0.003).
Conclusion: There is no association of serum
concentrations of IL-23 with disease activity in
psoriatic arthritis and SAPHO syndrome.
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Molecular signature and new perspective markers
of psoriasis
Mezentsev, Alexandre1; Sobolev, Vladimir2;
Soboleva, Anna2; Bruskin, Sergey2
1Institute of General Genetics, Functional Genomics,
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Introduction: Identification of new biomarkers is
beneficial for reliable diagnosis and monitoring of
psoriasis. In this paper, we suggest two new groups of
biomarkers and report of a groups of genes those
expression is characteristic for the lesional skin.
Aim of this study was to propose a compact gene set that
can be used as a molecular signature of psoriasis and
suggest new biomarkers via comparative analysis of
microarray and proteomic data.
Methods: Using a global approach we examined 84
individual arrays and proteomic data represented skin
of healthy, uninvolved and lesional skin. The data were
analyzed by qPCR, and mass spectrophotometry, gene
ontology and networking tools.
Results: We discovered a set of 114 genes differentially
and unidirectionally expressed under transition from
normal to either uninvolved or lesional epidermis. The
followed comparative study demonstrated that their
expression was characteristic for psoriatic skin and
could be used to distinguish psoriasis from atopic
dermatitis, different forms of skin cancer and mycosis
fungoides. Analyzing skin samples taken from patients
treated with PUVA and interferential therapy we
found that expression of some AP-1 contributors such
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as FRA-1, JUND, JUNB, C-JUN, C-FOS and FRA-2
correlated with flow of the disease and suggested
these genes as biomarkers for tracing psoriasis. Using
proteomic analysis we also revealed ten differentially
expressed proteins: KRT14, KRT16, KRT17, SERPINB3,
SERPINB4, ENO1, SOD2, LGALS7, S100A7, S100A9 that
distinguished uninvolved and lesional psoriatic skin.
Moreover, we showed that differential expression of
these proteins could be a part of a coordinated response
orchestrated by receptor for advanced glycation end
products, RAGE.
In conclusion: we report of two new groups of biomarkers
and set of genes characteristic for the lesional skin. We
propose a role of RAGE and transcription factor, AP-1, in
eruption of the disease.
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MicroRNAs (miRNAs) are a class of small non-coding RNA
molecules that modulate gene expression at the post-
transcriptional level. MicroRNAs have been shown to be
differentially expressed in psoriasis and other
inflammatory skin diseases and may potentially play an
important role in psoriasis by regulating inflammation and
keratinocyte proliferation. Increasing evidence shows that
miRNAs are not only present in tissues but also in human
blood in a stable form. This makes miRNAs potentially
useful as biomarkers for the diagnosis and monitoring of
disease severity. Using miRNA qPCR panels we
investigated the global miRNA expression in peripheral
blood mononuclear cells (PBMCs) from patients with
psoriasis (N = 6) and healthy controls (N = 6). The disease
severity of patients with psoriasis was measured by PASI
score (9.1–22.1). We identified a list of miRNAs which were
significantly deregulated in the PBMCs of patients with
psoriasis compared with healthy controls. Among those
were miR-21, -125b and miR-107 which previously have
been shown to be deregulated in psoriatic skin. Our results
demonstrate that miRNA signatures derived from PBMCs,
could be valuable novel biomarkers for psoriasis and likely
represent a novel strategy to aid unravelling the disease
mechanisms involved in psoriasis.
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Clinical examination versus magnetic resonance
imaging of the hand and foot: its usefullness in early
detection of psoriatic arthritis among patients
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Background: At its earliest stages, clinical symptoms of
psoriatic arthritis (PsA) may not be detectable.
Objectives: the aim of the study was to determine the
agreement between clinical examination (CE) and
magnetic resonance imaging (MRI) of the hand and
foot in early peripheral PsA.
Methods: 60 pts (M/F—23/37) with new onset PsA,
according to the CASPAR criteria, the mean age
41.25 ± 13.6 years, (from 18 to 72 years), the average
duration of PsA being 0.87 year [0.5;1.5] (from 0.16 to 2
years), the average duration of psoriasis being 7.5 year
[2;20] (from 0.3 to 47 years.), the mean DAS 3.69 ± 1.34,
DMARD naı¨ve were recruited. All pts underwent
standard CE of the joints on 78/76-joint manikin
including evaluation of the clinical signs (tender/
swelling) of the flexor tenosynovitis of the fingers and
toes and MRI of the same regions via ‘‘Artoscan C’’ (0.2 T)
(‘‘Esaote’’ Italy). Degree of agreement was tested by
Cohen‘s kappa.
Results: According to CE and MRI arthritis of the hands/
foot were found in 45 (75%)/43 (72%) pts and in 43
(72%)/42 (70%) pts accordingly. According to CE
tenosynovitis of the flexor fingers were found in 9 pts
(15%) and the flexor toes in 6 pts (10%). Via MRI
tenosynovitis of flexor fingers and flexor toes were
determinate more often—in 27 pts (45%) and in 31 pts
(52%) accordingly. In the diagnosis of peripheral
arthritis the results of the CE and MRI of the hands
were in agreement in 46 pts (77% of cases) and of the
foot in 49 pts (82%). For tenosynovitis of the flexor
fingers and toes the results of the CE and MRI were in
agreement in 38 pts (63% of cases) and in 31 pts (52%)
accordingly. A moderate level of agreement was found in
the diagnosis of arthritis of the hand and foot through
CE and MRI (Cohen‘s kappa—0.41/0.56 accordingly).
We detected slight level of agreement for the test results
for tenosynovitis of the hand and especially of the foot
by way of CE and MRI (Cohen‘s kappa—0.21/0.06
accordingly).
Conclusions: MRI is more accurate in diagnostics of
tenosynovitis than CE. In order to completely
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understand all early peripheral PsA symptoms among
psoriasis pts both CE and MRI should be done.
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The relative activity of anti-TNF-rar agents,
etanercept, infliximab, adalimumab
and golimumab, evaluated by a stable IL-8 reporter
cell line, THP-G8
Kimura, Yutaka; Takahashi, Toshiya; Yamasaki,
Kenshi; Aiba, Setsuya
Tohoku University Graduate School of Medicine,
Department of Dermatology, Sendai, Japan
Now the biologics become an essential component of
psoriasis therapy. In particular, anti-TNF-rar antibodies
(Abs) are a mainstream among them. There are several
anti-TNF-rar agents available in the clinics. However, we
do not necessarily know the difference of them.
Recently, we have established an IL-8 reporter cell line,
THP-G8, which is derived from a human monocyte cell
line and harbors SLO and SLR luciferase genes under the
control of IL-8 and glyceraldehyde 3-phosphate
dehydrogenase promoters, respectively (1). This stable
cell line responds with TNF-rar in a dose-dependent
manner in a wide range of the concentration. Therefore,
we hypothesized that this cell line enables us to easily
compare the relative activity among different anti-TNF-
rar agents. So, we treated 10 ng/ml of human
recombinant TNF-rar with increasing concentrations
of anti-TNF-rar agents, Etanercept, Infliximab,
Adalimumab, Golimumab, or control human IgG1 Ab
for 30 min, and stimulated THP-G8 cells with them for
6 h. As expected, all anti-TNF-rar agents significantly
and dose-dependently suppressed TNF-rar-induced IL-8
reporter activity indicated as SLO-luciferase activity of
THP-G8 cells, while control IgG1 Ab had no effects.
Moreover, by serial titration of anti-TNF-rar agents, we
could estimate the relative activity of anti-TNF-rar
agents that was determined by calculating the
concentration of each reagent required to neutralize
50% of soluble TNF-rar in the assay (IC50). The IC50 of
Etanercept, Infliximab, Adalimumab and Golimumab,
were 100, 81.3, 19.3 and 52.4 ng/ml, respectively. These
data were confirmed by quantitative real-time PCR.
Since anti-TNF-rar agents can react with soluble and
membrane-bound TNF-rar, it is not enough to examine
their effects on soluble TNF-rar. However, considering
that serum IL-8 concentration is significantly elevated in
psoriatic patients and decreased after effective
treatment, it is important to know the inhibitory
effects of each anti-TNF-rar agent on IL-8 expression
by monocytes in selecting anti-TNF-rar agent for
psoriatic patients.
Reference: (1) Takahashi T et al. Toxicol Sci. 124:359–369,
2011.
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Predictive biomarkers for high responsiveness
to treatment, and biomarkers associated
with clinical response to treatment, in psoriasis
patients treated with the anti-IL-17A monoclonal
antibody, ixekizumab
Hoffman, Robert1; Krueger, James2; Fretzin, Scott3;
Dow, Ernst1; Nantz, Eric1; Komocsar, Wendy1;
Cameron, Gregory1; Phipps, Krista1; McColm, Juliet1;
Banerjee, Subhashis1
1Eli Lilly and Company, Indianapolis, USA;
2Rockefeller University, New York, USA; 3Dawes-
Fretzin Dermatology Group, Indianapolis, USA
The goal of the present study was to identify biomarkers
that correlate with clinical response to therapy. We
performed a comprehensive survey, using whole blood
mRNA and serum from patients with moderate-to-severe
plaque psoriasis treated with an anti-IL-17A monoclonal
antibody, ixekizumab (previously, LY2439821). A total
of 40 subjects were enrolled in a phase 1, randomized,
double-blind trial of ixekizumab, receiving
subcutaneous injections of 5 mg (n = 8), 15 mg
(n = 8), 50 mg (n = 8), 150 mg (n = 8) ixekizumab or
placebo (n = 8) at Weeks 0, 2 and 4. Lesional skin
biopsies and blood samples were obtained at Weeks 0, 2
and 6. The psoriasis area and severity index (PASI)
scores were also assessed at Weeks 0, 2, 6 and 12. By
Week 2, there were significant dose-dependent
reductions from baseline in histologic scoring, and in
numbers of infiltrating T cells and dendritic cells
present. Also, by Week 2, there was a significant
reduction from baseline in IL-17 mRNA expression in
lesional skin. By Week 6 in the 150 mg group, all
subjects achieved a PASI 75, and skin appeared
clinically normal. Analysis of whole blood mRNA
expression of IL-17 pathway genes demonstrated
significant correlations with PASI score, including
N-GAL (p\0.01). We found that there was also a
significant correlation between PASI scores and serum
N-GAL concentration (p\0.01). In addition, a marker
of inflammation, soluble E-selectin, was highly
correlated with PASI scores (p\0.00001). In the 3
highest dose groups patients achieving a PASI 90 at
12 weeks had lower baseline IL-17F and IL-17 receptor
C subunit (IL-17RC) gene expression compared to
other subjects (p\0.01). These data support the
hypotheses that there are biomarkers in peripheral
blood which demonstrate statistically significant
correlations with clinical response to therapy with
ixekizumab and some may have utility in predicting
response to therapy at baseline. The biomarkers
reported here may assist in monitoring disease
activity and in predicting response to therapy, and
need to be validated in larger studies.
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The Swedish Early Psoriatic Arthritis (SwePsA)
Registry 5-year follow-up: Slow radiographic
progression of bone destruction in the hands
without correlation to clinical disease activity
Geijer, Mats1; Lindqvist, Ulla2; Husmark, Tomas3;
Alenius, Gerd-Marie4; Larsson, Per T5;
Teleman, Annika6; Theander, Elke7
1Ska˚ne University Hospital, Lund, Center for Medical
Imaging and Physiology, Lund, Sweden; 2Uppsala
University, Rheumatology, Department Of Medical
Sciences, Uppsala, Sweden; 3Falu Hospital,
Rheumatology, Falun, Sweden; 4Umea˚ University,
Public Health and Clinical Medicine/Rheumatology,
Umea˚, Sweden; 5Karolinska University Hospital
Huddinge, Rheumatology, Stockholm, Sweden;
6Spenshult AB, Oskarstrom, Sweden; 7Ska˚ne University
Hospital, Rheumatology, Malmo¨, Sweden
Objective: To describe early X-ray findings in the hands
and evaluate progression of destructions after 5 years,
correlated to clinical parameters in early psoriatic
arthritis (PsA).
Method: In 31 men and 46 women with PsA fulfilling the
CASPAR criteria hand X-rays were available from the
5-year follow-up and either inclusion or the 2-year visit.
Disease activity was measured by DAS-28 and DAPSA.
X-rays were scored by the Wassenberg scoring system for
PsA (Wassenberg, et al., 2001). In the hands, all DIP, PIP
and MCP joints and the carpus (30 joints), in the feet,
the IP joint I and MCP joints 2–5 are scored for
destructive and proliferative changes typical for PsA
(total score: 0–360).
Results: Median symptom duration at inclusion was
12 months. Median DAS-28, DAPSA, HAQ and PASI at
baseline were 3.86, 20.25, 0.69 and 1.45 respectively,
58% had polyarticular and 38% mono/oligoarticular
PsA.
At the first evaluation 60% had a zero score (mean 2.0,
SD 4.07, range 0–22). At the 5-year visit median score
was 2 (mean 3.99, SD 7.6, range 0–42). In 34 patients
(44%) the score was still 0, in 28 between 1 and 5, in 5
between 6 and 10, in 6 between 11 and 15, and 1 patient
each had a score of 19, 22, 39, and 42.
At baseline women had significantly higher disease
activity and HAQ than men, but similar X-ray score. At
5 years men had improved considerably in function and
DAS, but showed more often X-ray progression (58 vs.
28%, p = 0.009). Male gender was a significant predictor
of X-ray progression (OR 3.52, 95% CI 1.35–9.18).
Longer symptom duration at entry predicted X-ray
progression (p = 0.038) and prevented minimal disease
activity (p\0.001). Lower baseline HAQ score predicted
no X-ray progression (p = 0.02). Baseline DAS-28/DAPSA
did not predict X-ray damage.
Conclusion: After 5 years of PsA, most patients still have
no or very little hand joint destruction. Symptom
duration at inclusion and male gender were the main
predictors of X-ray progression, preserved function at
baseline was protective. Despite worse clinical outcome
with higher HAQ and DAS/DAPSA, women had less
X-ray progression than men.
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A screening tool that includes key clinical features
and biomarkers discriminates patients
with psoriatic arthritis (PsA) from those
with psoriasis without PsA
Chandran, Vinod1; Cook, Richard2; Lee, Ker-Ai2;
Pellett, Fawnda3; Gladman, Dafna3
1Toronto Western Hospital, Division of Rheumatology,
1E416, 399 Bathurst Street, Toronto, Canada;
2University of Waterloo, Department of Statistics and
Actuarial Science, Waterloo, Canada; 3Toronto
Western Hospital, Division of Rheumatology, Toronto,
Canada
Purpose: There is high prevalence of PsA among
patients with psoriasis. We have shown that hsCRP,
OPG, MMP-3 and CPII: C2C are biomarkers for PsA.
Our purpose was to determine whether a screening
tool that includes key clinical features and these
biomarkers distinguishes PsA from psoriasis without
PsA (PsC).
Methods: 26 patients with PsA and 26 PsC patients were
recruited. Subjects were group matched for age, sex and
psoriasis duration. Serum drawn at the time of
assessments was analyzed for: MMP-3, OPG, CPII, C2C
and hsCRP. Cut off values for biomarker levels that best
distinguished PsA from PsC was determined by
Classification and Regression Tree (CART) analysis.
Data were analyzed using logistic regression with
disease status as the outcome (PsA versus PsC) to
develop a risk score. Predictive accuracy was assessed
using Receiver Operating Characteristic curves.
Results: PsA patients (mean age 47 years, psoriasis
duration 17 years, PsA duration 13 years) had an
average 16 tender and 5 swollen joints and mean PASI
score of 4, whereas PsC patients (mean age 45 years,
psoriasis duration 17 years) had mean PASI score of 5.
Among the PsA patients, 25/26 had nail psoriasis
whereas only 14/26 PsC patients had nail psoriasis.
20/26 patients in both groups had scalp psoriasis. CART
analysis identified that the following cut-offs best
distinguished PsA from PsC: MMP-3- 20 ng/mL, OPG-
760 pg/mL, hsCRP- 1,750 mg/L, CPII/C2C ratio- 4.
Logistic regression analysis using dichotomized
biomarker levels and clinical features showed that
MMP-3 (OR 13.5, p = 0.09), OPG (OR 26.1, p = 0.02),
hsCRP (OR 3.2, p = 0.27), CPII/C2C (OR 10.5, p = 0.07),
scalp psoriasis (OR 3.8, p = 0.34) and nail psoriasis (OR
31.9, p = 0.13) were associated with PsA. ROC curve
based on this logistic regression model had an area
under the curve of 0.95 demonstrating that a tool
incorporating these variables is likely to be clinically
useful for screening for.
Conclusion: This pilot study indicates that a tool that
includes hsCRP, OPG, MMP-3 and the ratio CPII/C2C
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along with nail and scalp psoriasis distinguishes patients
with PsA from PsC.
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Treg profile of psoriasis patients: preliminary data
Boca, Andreea; Tataru, Alexandru; Orasan, Remus;
Krausz, Tibor; Buzoianu, Anca
University of Medicine and Pharmacy ‘‘Iuliu
Hatieganu’’, Cluj-Napoca, Romania, Cluj-Napoca,
Romania
Psoriasis, a chronic inflammatory skin disorder, has
plurifactorial determinism including autoimmune,
genetic and environmental factors. A key position in
its pathogenesis is held by T lymphocytes. A subset of T
lymphocytes, T regulatory (Treg) cells are responsible for
suppressing and terminating the immune response, and
therefore could be deficient in psoriasis patients. A Treg
cell normally expresses all CD25, GITR and FoxP3, but
other combinations of these molecules can also code for
it.
The aim of the present study was to determine if
psoriasis patients show any differences in circulating
Treg cells, compared to apparently healthy people.
For the assessment of CD4+ and CD8+ T lymphocytes
isolated from peripheral blood mononuclear cells
(PBMCs) we used flow cytometry. We analyzed the
expression of the imunomodulatory molecules CD25+,
FoxP3 and GITR in eleven psoriasis patients and
compared it to six apparently healthy volunteers (no
self or family history of psoriasis-control group). The
psoriasis group included only patients with PASI
score[12. We assessed the frequency of CD4+CD25+,
CD4+FoxP3+, CD4+GITR+, CD8+CD25+, CD8+FoxP3+,
CD8+GITR+ and by triple staining Treg cells
CD4+CD25+FoxP3+GITR+ and CD8+CD25+FoxP3+GITR+.
The frequencies in the psoriasis group were compared to
the control group.
Flow cytometry assessment showed an increased
frequency of CD4+CD25+ and CD4+FoXP3+ in the
psoriasis group, compared to the controls. Psoriasis
patients had also a higher percentage of CD8+CD25+
and CD8+GITR+. The opposite was noticed for
CD8+FoxP3+, which were less frequent in psoriasis
patients compared to the healthy volunteers. The Treg
cells in the psoriasis group vere increased both for CD4+
and CD8+, compared to the control group.
Psoriasis patients showed differences in circulating T
cells, according to the surface molecules which they
expressed (possibly Treg cells). These preliminary
results will be followed by a larger study, aiming to
assess both frequency and function of CD4+ and CD8+
Treg cells, which appear to be involved in the
pathogenesis of psoriasis. These cells represent a




Health-related quality of life (HRQOL)
improvement with secukinumab in patients
with rheumatoid arthritis: results from a dose-
finding study
Vibeke, Strand1; Genovese, M2; Mallya, UG3;
Richards, H4; Mpofu, S4
1Stanford University, Division of Immunology/
Rheumatology, Office: 306 Ramona Road, Portola
Valley, Canada; 2Stanford University School of
Medicine, California, USA; 3Novartis Pharmaceuticals
Corporation, East Hanover, USA; 4Novartis Pharma AG,
Basel, Switzerland
Interleukin (IL)-17A is a key inflammatory mediator in
pathogenesis of rheumatoid arthritis (RA). Secukinumab is
a fully human monoclonal antibody selectively targets IL-
17A. This phase 2 randomized controlled trial (RCT)
evaluated the effect of secukinumab on patient reported
HRQoL by SF-36v2. Adult RA patients (n = 237) failing
methotrexate were randomized equally to receive monthly
s.c. injections of secukinumab 25, 75, 150, 300 mg or
placebo.ACR 20and HRQoL responses were assessed at wks
0, 2, 4, 8, 12 and 16 and SF-6D scores were derived based on
mean changes across all 8 domains of SF-36v2. Data was
analyzed using descriptive statistics and mean
changes C minimum clinically important differences
(MCID). Baseline physical component scores (PCS) and
physical domain scores were low across all treatment
groups: C1.5 SD and 26–40 points less than age/gender
matched norms; mental component scores (MCS)
approximately 1 SD\norms, reflecting large impact of
active RA on HRQoL. ACR 20 responders at wk 16 in
secukinumab 75, 150 and 300 mg treatment groups (46.9,
46.5 and 53.7%) was higher than 25 mg (34%) and placebo
(36%) groups. Median PCS scores increased from baseline
in all secukinumab groups (change from baseline in 25, 75,
150 and 300 mg groups at wk 16: 1.44, 2.40, 3.62, 3.73) and
placebo group (1.85). Similar increase in median MCS
scores was reported for all secukinumab groups 25, 75,
150 mg groups (1.17, 0.59, 1.64) except 300 mg group
(-1.68) and placebo group (0.44). Improvements in PCS
and MCS scores and 7 of 8 domains in 75 mg and all 8
domains in 150 mg treatment groups met or exceeded
MCID and SF-6D well exceeded MID = 0.041. Mean
changes in 300 mg were of less magnitude than 75 or
150 mg but CMCID in PCS and 3 of 8 domain scores.
Improvements with 25 mg were not different from
placebo, consistent with earlier findings of a ‘‘no effect’’
dose. Secukinumab showed dose dependent improvement
in HRQoL in all dose groups (25, 75, 150, 300 mg). Greater
improvement in HRQoL was observed with 75 and 150 mg
dose groups than 25 mg and placebo groups. These
findings support the selection of secukinumab 75 mg and
150 mg doses for future phase 3 RCTs in RA.
Page S54 of S67 Dermatol Ther (2012) 2:10
123
P122
Use of clinical trial data to compare psoriasis area
and severity index, static physician’s global
assessment, and lattice system-physician’s
global assessment in assessing severity
of psoriasis
Tejasvi, Trilokraj1; Chow, Conroy1;
Simpson, Matthew J.2; Ellis, Charles N.1
1University of Michigan Medical School,
Department of Dermatology, Ann Arbor,
Michigan, USA; 2University of Michigan
School of Public Health, Department
of Epidemiology, Ann Arbor,
Michigan, USA
Reduction of 75 or 90% in the Psoriasis Area and Severity
Index (PASI-75, PASI-90, respectively) historically has
been a measure of treatment success in psoriasis trials.
However, European and US regulatory agencies do not
use PASI in Phase III trials. Therefore, we investigated the
changes over the course of treatment in PASI, along with
other measures, namely Static Physician’s Global
Assessment (sPGA) and the Lattice System-Physician’s
Global Assessment (LS-PGA), in a randomized,
multicenter, 24-week study of chronic plaque psoriasis.
Of 652 enrolled patients, 455 completed the study and
were included in our analyses. The treatment group
had 366 patients who received oral calcineurin
inhibitors, either cyclosporine or voclosporin. In this
group at trial entry, the Spearman correlation
coefficients showed poorer correlation of sPGA with
PASI (r = 0.45) or LS-PGA (0.39) than between PASI
and LS-PGA (0.68). After therapy, all correlations were
stronger; however, sPGA continued to be less well
correlated (with PASI, 0.85, with LS-PGA, 0.79)
compared to PASI with LS-PGA (0.90). Mean scores at
pretherapy and after 12 and 24 weeks of active therapy
were 18.5, 6.3, and 5.4 for PASI (maximum possible
score 72), 3.5, 1.8, 1.7 for sPGA (max 5), and 5.9, 3.2,
2.8 for LS-PGA (max 7). When placebo patients crossed
over to active therapy, the scores showed the same
pattern.
In this first comparison of PASI, sPGA, and LS-PGA in
an actual clinical trial, all 3 measurement methods
demonstrated efficacy of treatment compared to
placebo and for change from before to end of active
treatment (all P \0.05). With treatment, PASI, sPGA
and LS-PGA reflected changes in the Dermatology Life
Quality Index (DLQI), further indicating validity of
these measures in clinical trials. At all time points, LS-
PGA has stronger correlations with PASI than does
sPGA. PASI and LS-PGA are highly correlated
measures of change in psoriasis severity. After
effective therapy, sPGA does not detect the
difference between PASI-75 and PASI-90. The LS-PGA
more readily detects such changes in psoriasis severity
during treatment.
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Psychiatric disorders in psoriatic patients
in Semnan city during the first 6 months of 2006:
a survey
Taheri, Ramin1; Behnam, Behnaz2
1Fatemie hospital/Semnan University of Medical
Science, Internal Medicine, Semnan, Islamic Republic
of Iran; 2Fatemie hospital/Semnan University of
Medical Science, Psychiatry, Semnan, Islamic Republic
of Iran
Introduction: Psoriasis is a common, genetically
determined, inflammatory and proliferative disease of the
skin In this research, we tried to investigate the prevalence
of psychiatric disorders in psoriatic patients.
Methods: During the first half of the year 2006, the
psoriatic patients who were referred to the skin clinics in
Semnan city have been investigated. The researcher used
two questionnaires: S.C.L. 90 for the survey of psychosis,
paranoia, phobia, aggression, anxiety, depression,
obsessive compulsive disorder (O.C.D), interpersonal
sensitivity, hypochondriasis. The other questionnaire
consisted of age, sex, severity and duration of psoriasis
and the lack of history of psychiatric disorders in family.
Findings: In this study,57.1%of thesampleswere femaleand
42.9% were male. The most common finding (31.4%) was
depression. With increasing the duration of the psoriasis,
the prevalence of depression and its treatment increased;
also this increase was noted in paranoia and phobia. With
increasing of the severity of the psoriasis, the prevalence of
the patients who suffered from depression requiring
treatment and consultation also increased. The prevalence
of O.C.D, anxiety, interpersonal sensitivity, hypo-
chondriasis, and psychosis also increased with increasing
the severity of psoriasis but this increase was not observed in
paranoia, phobia and aggression.
Discussion and conclusion: The most common disorder was
depressionwhichwas inaccordance with theother studies.
The prevalence of psychiatric disorders increased with
growing the severity of the psoriasis which was compatible
with other studies. In the depressed patient who suffered
from severe psoriasis, it was very important to be cured and
consulted. As depression has a negative effect on the
compliance of the patients for the treatment of the skin
disease, it is necessary for these sufferers being referred to
the psychiatric clinics for assessment treatment and
probable consultation.
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Significant effects of patient educative training
on psoriasis disease
Kling, Heidrun; Jahn, Julia; Sticherling, Michael
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The impact of chronic skin diseases on patients is
generally appreciated. Apart from sufficient drug
treatment with regard to efficiency and tolerability,
coping of patients is a major concern and needs
educational support. Appropriate training will help
patients to learn about their disease, its pathogenic
and clinical background as well as treatment and will
improve the cooperation of patients and their doctors as
well as patients’ well-being. Standardized training
formats for psoriasis have neither been established nor
evaluated yet. Therefore, in this study a 5 week 2 h per
week modular training covering medical, psychological,
dietary and topic treatment issues has been followed up
in 100 patients. Patients were dermatologically (PASI,
DLQI) and psychologically (knowledge of their disease,
behavior, self expectations, resilience) monitored before
and immediately as well as 12 months after the training.
Results were compared to patients without training.
Whereas the PASI was grossly unchanged before and
after training, DLQI improved significantly from eight to
four points. This study demonstrates significant effects
of a standardized and comprehensive training of
patients and will definitely support and improve
somatic drug treatment of psoriatic patients.
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Percentage of suicidal ideation and suicidal
attempts in adult patients diagnosed
with psoriasis
Sison, Antonio1; Verallo-Rowell, Verme´n2
1Skin and Cancer Foundation, Inc, Dermatology,
Unit 1611, Medical Plaza Ortigas, San Miguel Avenue,
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Philippines; 2Skin and Cancer Foundation, Inc,
Dermatology, Pasig City, Philippines
Background: Psoriasis is a chronic inflammatory whose
natural history of flares and remissions may impact
negatively on the patients’ psychological, social, and
occupational well being. Several studies have shown that
patients with psoriasis have suicidal ideation whose
percentage range between 3.2 and 8.6%.
Objective: To describe the percentage of patients
diagnosed with psoriasis who report to have suicidal
ideation and suicide attempt.
Methods: The mailing list of Psorphil, an organization of
patients with psoriasis, was sent invitations to answer an
on-line survey.
Results: A total of 699 members were emailed invitations
for the on-line survey. One hundred twenty-seven
responses were received; however duplicate or
incomplete entries were excluded making a total of
120 entries included in the study.
Sociodemographic profile of 120 patients are as follows:
average age is 29 years old (range: 18–59 years old),
majority are female (60%) and Roman Catholic (72%),
less than half are single (42%), majority are college
graduate and/or postgraduate (62%). Almost half were
employed fulltime (48%) Seventeen patients (14%) of
patients reported suicidal ideation and 9 (7%) of patient
reported suicidal attempt, and one patient (0.8%) was
referred to a psychiatrist.
Majority of patients who had suicidal ideation and
attempts self reported to have moderate to severe
psoriasis. All patients reported to be depressed due to
psoriasis. One-third of patients did not talk to anyone
regarding suicide. One patient disclosed to suicide to a
doctor and was referred to a psychiatrist. One patient
disclosed to a dermatologist but was not referred to a
psychiatrist.
Conclusion: The suicide ideation percentage (14%) was
highest compared to other international studies
(3.2–8.6%). However the referral to a psychiatrist was
low at 0.8%.
Recommendations: It is recommended that dermatologists
regularly elicit depressive and suicidal symptoms among
patients; to evaluate psychological difficulty and suicidal
risk and to refer to a psychiatrist or mental health
professional.
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A descriptive study on the knowledge and beliefs
of adult patients diagnosed with psoriasis
Sison, Antonio1; Verallo-Rowell, Verme´n2
1Skin and Cancer Foundation, Inc, Dermatology, Unit
1611, Medical Plaza Ortigas, San Miguel Avenue, Pasig
City, Metro Manila, Philippines, Pasig City,
Philippines; 2Skin and Cancer Foundation, Inc,
Dermatology, Pasig City, Philippines
Introduction: Psoriasis is a chronic inflammatory
dermatological condition whose natural history of
flares and remissions may adversely impact on the
patients’ psychological, social, and occupational well
being. Objective: To describe the knowledge, beliefs and
treatment practices of adult patients diagnosed with
psoriasis Method: An invitation to answer an on-line
survey Questionnaire was sent to the patient list of
Psorphil, (an organization of patients with psoriasis in
the Philippines).
Results: A total of 699 members were emailed invitations
for the on-line survey. One hundred twenty-seven
responses were received, of which duplicate or
incomplete entries were excluded to make a total of
120 included entries. Average age is 29 years old (range:
18–59 years old), majority are female (60%) and Roman
Catholic (72%), less than half are single (42%), majority
are college graduate and/or postgraduate (62%). Almost
half were employed fulltime (48%) A total of 81
respondents answered the psoriasis knowledge
questionnaire. Mean score of knowledge is 69.73 which
indicate good knowledge of psoriasis. A total of 81
respondents answered the psoriasis belief questionnaire.
The mean score of belief is 2.82 which show that the
patients have neutral or neither favourable nor
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unfavourable attitude towards psoriasis. A total of 81
respondents answered the psoriasis treatment practices.
Majority were compliant with medications (64%
responded to be always or are often compliant with
medications). Majority were not compliant with regular
follow-ups (65% responded to sometimes, occasionally
or never go to scheduled follow-ups).
Conclusion: Adult patients diagnosed with psoriasis had
good knowledge of psoriasis and neutral beliefs on
psoriasis which may be a contributing factor on good
compliance with medications and poor compliance with
follow-up.
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Quality of life and health-state utilities in psoriasis
patients
Pan, Jiun Yit; Theng, Colin; Tan, Suat Hoon
National Skin Centre, Singapore
Psoriasis is a chronic skin disease affecting a significant
proportion of our Singaporean population. We
measured the quality of life of psoriasis patients using
a general scale (SF-36), a disease-specific scale (Psoriasis
Disability Index—PDI) and a visual analogue scale. Two
health-state utilities, namely the time trade-off and
willingness to pay indices, were assessed. Health-state
utilities are important and sensitive indicators of QOL in
patients with acute and chronic diseases, and are
important to health economists for cost-utility
analysis. The PASI score was also obtained during
clinical examination.
We recruited 254 patients—70.6% patients were male
and 29.4% were female, comprising 71.6% Chinese,
14.4% Malays, 12.6% Indians and 1.4% Eurasians. The
average age was 49.4 years. 72.1% of patients had
monthly income of less than $2,000. The mean
duration of disease was 13.6 years, with chronic
plaque psoriasis (91.6%) being the most common
clinical subtype.
Hypertension, hyperlipidaemia and diabetes mellitus were
the most commonly found co-morbidities, occurring in
31.6, 20.9 and 19.1% of patients respectively. Psoriatic skin
lesions were present in areas unable to be concealed by
clothing in almost all patients (98.1%), and arthropathy
was present in almost a quarter (27.4%). Almost all the
patients were on topical steroids, topical coal tar
preparations and moisturizers. Other treatments received
are as follows: methotrexate in 40.4% of patients,
phototherapy 23.3%, acitretin 16.2%, cyclosporine 7.0
and 5.1% biologic agents.
The mean PASI score was 14.79 and the mean PDI 9.35.
The SF-36 assessment showed the lowest scores for the
energy/fatigue levels and the general health category in
our group of psoriasis patients. The average time-trade
off was 3.74 years of life, with 6 patients willing to give
up their entire lifespan for an immediate cure. The
patients were willing to give up 34% of their income/
savings, on average, for an immediate cure for their
condition. This study illustrates that psoriasis can
significantly affect patients to the extent that they are
willing to trade their years of life or income in search of a
cure.
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The psoriatic school, education for patients
with psoriasis, psoriatic arthrithis and pustulosis
palmoplantaris
Naslund, Anja1; Stymne, Birgitta2; Stiernquist, Anne1
1The Swedish Psoriasis Association, Stockholm,
Sweden; 2University Hospital Linkoping, Dermatology
department, Linkoping, Sweden
Background The Psoriasis School (PS) is a model for
patient education for patients with psoriasis, psoriatic
arthritis and PPP. It includes 40 h of education, split
into three areas: knowledge of disease and treatments,
lifestyle and health, and ‘‘living and coping with
the disease’’. Different types of training adjusted
for people with joint disease are also included. All
the lectures are given by health care professionals
such as dermatologists, rheumatologists and health
educationists.
Aim The aim was to give evidence for this kind of patient
education, to investigate if knowledge of the disease and
the quality of life increases after the classes.
Method We used the following validated questionnaires:
DLQI, SF-36, EQ-5D, HAQ and AHI. In addition we
included questions about the disease, treatments and
effects on life, questions about the self-estimated
knowledge and questions about lifestyle in separate
questionnaires. All participants in the PS filled in the
questionnaires before the PS started and after four, eight
and 12 months after taking part in the class. For
evaluation purposes there was also a controlgroup,
people with psoriasis that did not participate in the
classes but voluntary filled out the forms.
Results In DLQI (0 = best result) the participants
(N = 22) went from 4.8 to 3.2 and the controls
(N = 34) from 4.1 to 4.8. The SF-36 (high result the
best) shows the highest changes in mental health, where
the participants (N = 21) went from 44.0 to 50.4
whereas the controls (N = 34) went from 49.4 to 47.0.
Initially the participants (N = 22) estimated their
average knowledge to 4.9 in 10-grade scale. Four
month later the average was 8.0. The controls (N = 33)
went from 6.6 to 6.8. In coping skills the participants
(N = 21) went from 6.0 to 7.8 and the controls (N = 33)
from 7.2 to 7.0. At the start the participants had less
knowledge about the disease than the controls. The
conclusion of this study is that the PS increases both
perceived knowledge of the disease and quality of life, as
well as mental health.
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Perceived disadvantages in leisure time activities
among patients with psoriasis
Leino, M1; Mattila, K1; Mustonen, A1; Koulu, L1;
Tuominen, R2
1Turku University Hospital, Dermatology, Turku,
Finland; 2University of Turku, Public Health, Turku,
Finland
Objectives: The aim of the study was to estimate the
experienced disadvantage in leisure-time activities due
to psoriasis.
Materials and methods: A questionnaire was mailed to 489
patients with moderate or severe psoriasis who visited
the dermatology outpatient clinic in Turku University
Hospital during the period 1.10.2009–30.9.2010. Using
one reminder, the final sample size was 262 patients
(52.6%). The patients were asked to list their hobbies
and leisure-time activities, the time spent on these
activities, how well they perform in leisure-time
activities and any activities they had reduced or given
up completely because of psoriasis. Using a visual
analogue scale (VAS) of 0–100, the patients assessed
how well they could perform in their leisure time
activities with psoriasis and in a hypothetical situation
without it. The difference between the VAS scores
depicted the level of disadvantage caused by psoriasis.
Results: The average VAS score for the disadvantage in
leisure time activities caused by psoriasis was 16.9, with
minor differences between sexes. Because of psoriasis,
32.0% of the subjects had reduced some of their leisure-
time activities, and 34.7% had completely given up at
least one leisure-time activity. On average, women had
reduced leisure time activities by 129 min per week and
men by 64 min (NS). Many patients had completely
given up (30.2%) or reduced (23.7%) sports activities;
psoriasis had slightly more influence on sports activities
among men than women (NS). Social activities and
other activities where psoriasis could be considered to
cause cosmetic disadvantage were given up by 29.0%
and reduced by 21.4% of the patients.
Conclusion: A significant proportion of patients with
psoriasis had reduced leisure time activities, or given up
completely, because of their disease. When estimating
the overall burden of psoriasis, the influence on leisure
time activities should be taken into account.
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Quality-of-life effects of psoriasis skin symptoms
affecting different body regions
Kimball, Alexa B.1; Sundaram, Murali2;
Signorovitch, James3; Yang, Min3; Mulani, Parvez M.2
1Harvard Medical School, Department of Dermatology,
Boston, MA, USA; 2Abbott Laboratories, Global Health
Economics and Outcomes Research, Abbott Park, IL,
USA; 3Analysis Group, Inc., Boston, MA, USA
Aims: Component scores for head (H), trunk (T), and
upper (U) and lower (L) extremities contribute to total
Psoriasis Area and Severity Index (PASI) scores
proportionately to each region’s body surface area
(BSA). We assessed whether region-specific symptom
effects on Dermatology Life Quality Index (DLQI) scores
were disproportionate to respective BSAs.
Methods: All assessments of PASI and DLQI scores were
included from trials of adalimumab (REVEAL, BELIEVE,
CHAMPION, and PROGRESS) and ABT-874 (all 4 Phase
III trials). The effects of region-specific PASI component
scores on total DLQI scores were assessed in regression
analyses stratified by median age of 45 years and sex.
Region-specific effects were expressed as percentages of
the overall effect of total PASI on total DLQI and were
assessed for proportionality to their respective BSAs.
Results: Analyses included 15,280 assessments of 4,988
patients. The effects of region-specific PASI component
scores on total DLQI scores were significantly
disproportionate to respective BSAs and varied
significantly by age and sex (all P\0.05). Among
younger women, H and U had disproportionately large
effects on DLQI (H: 22.8%, U: 32.6%) versus their
respective BSAs (H: 10%, U: 20%), driven primarily by
DLQI items for embarrassment, clothing, social
activities, partner relations, and sexual difficulty. The
relative impact of H and U PASI component scores on
total DLQI scores in older women was lesser, similar to
that in men.
Conclusions: Along with severity and area, skin symptom
location can significantly impact health-related quality
of life for patients with psoriasis. Relative to their
respective BSAs, psoriasis skin symptoms affecting the
head and upper extremities had disproportionately large
effects on dermatology-specific health-related quality of
life in younger women.
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The use of an Apple iPad-based health assessment
questionnaire (HAQ) application in psoriatic
and rheumatoid arthritis
Khraishi, Majed; Aslanov, Rana
Newfoundland Labrador Research Technologies,
St. John’s, Canada
Objectives: 1. To compare the validity, accuracy and
reproducibility of an iPad-based version of the HAQ to
the paper version in patients with psoriatic and
rheumatoid arthritis.
2. To assess patients’ acceptability, convenience,
preference and ease of administration of the electronic
version.
Methods: Patients with PsA and RA were randomly
selected from a rheumatology clinic. The subjects
completed both electronic touch screen and paper
versions of the HAQ. The order of completing the
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tools (electronic vs. paper) was reversed for every
second patient. All patients have been asked to
complete a questionnaire documenting their
demographics, time to complete the tool, preferences
and computer expertise. The scores of the electronic
and the paper versions were evaluated by comparing
differences in the HAQ scores, the time taken to
complete the tools using t test.
Result(s): Thirty-two patients were included. Twenty
(62.5%) were females. Eleven aged 30–49 years; 19 (59.4%)
50–69 years.There was not a significant difference in the
Reported HAQ Scores between the tools (95%CI -0.159-
0.345; p = 0.459). There was not a significant difference in
the time taken for patients to complete either version
(95%CI -0.397-1.882; p = 0.193). 75% (24) found that the
electronic version of HAQ was easier to perform and 72%
(23) found that the electronic questionnaire took less time
to perform as compared to the paper version. 63% (20)
preferred iPad to the paper. 91% (29) concluded that the
electronic version was more beneficial than the paper
version. The evaluation of the acceptability, convenience
and preference of both tools was not statistically significant
between genders.
Conclusion: The iPad version of the HAQ is valid as a
measure of health assessment for psoriatic arthritis
patients as scores are near identical to the paper
version. Patients of all ages and computer literacy
levels preferred the electronic version of the test and
found it more beneficial.
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Psoriasis: a model for chronic diseases
in dermatology
Gupta, Monisha1; Gupta, Monisha2
1Skin and Cancer Foundation Australia, NSW, 2/88-94
Redmyre Road, Strathfield, Australia; 2Skin and Cancer
Foundation Australia, NSW, Darlinghurst, Australia
Psoriasis is the best studied chronic disease in
dermatology and can serve as a model for study of
other similar diseases in dermatology.
Chronic diseases are characteristically defined by
prolonged course, frequent relapse/recurrence, severe
psychological impact etc. Acne vulgaris, eczema and
vitiligo are other conditions which share these
characteristics. Other dermatoses like connective tissue
diseases, immune—bullous disorders, hidradenitis
suppurativa, chronic urticaria can also be included under
the umbrella term.
We need to recognise the hidden burden of chronic
diseases to patients and the health service. There are
economic, psychological, occupational, social and
health implications from chronic diseases. The Health
Care Professionals need to be sensitised to these issues by
‘treating the person’ rather than ‘treating the disease’.
There is a need for a Special Interest Group within
dermatology to clearly set definitions for ‘chronic
diseases in dermatology’, devise common tools to
evaluate the impact across all the diseases and finally
devise measures to alleviate these. Psoriasis has clearly
set the trend for recognising the systemic impact of
inflammatory diseases.
We now also recognise that tools for assessing severity of
the disease e.g. PASI fail to assess the impact of the
disease on the individual e.g. patients with a PASI
score\5 can still demonstrate a high DLQI and vice
versa. Unmet patient expectations remain a persistent
problem with chronic diseases.
We have come a long way from when ‘no treatment’ was
a reasonable option for management of early Psoriasis,
guttate psoriasis was always allowed to self resolve
(although up to one-third are now known to progress
to Chronic Plaque Psoriasis).
Chronic diseases persist, changing in distribution and
severity. Our role as Health Care Providers has to be of
support and hope. A review of Quality of Life measures
in Psoriasis, Acne, Eczema and Vitiligo is an attempt at
initiating the process.
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Association between ACR improvement and health-
related quality of life (HRQoL) among rheumatoid
arthritis (RA) patients treated with secukinumab
Gnanasakthy, A1; Kosinski, M2; Genovese, M3;
Mallya, UG1; Mpofu, S4
1Novartis Pharmaceuticals Corporation, East Hanover,
USA; 2QualityMetric Incorporated, Lincoln, USA;
3Stanford University School of Medicine, California,
USA; 4Novartis Pharma AG, Basel, Switzerland
Background: Secukinumab demonstrated improvement
of signs and symptoms in RA patients in a phase 2 RCT.
In this analysis of the same study, we assessed the
association between signs and symptoms of RA and
HRQoL.
Objective: To evaluate the HRQoL benefits associated
with American College of Rheumatology (ACR)
improvement among RA patients treated with
secukinumab.
Method: RA patients (n = 237) on methotrexate were
randomized equally to receive monthly s.c. injections of
secukinumab 25, 75, 150, 300 mg or placebo. Primary
efficacy endpoint consisted of the proportion of patients
achieving the ACR 20 response at week (wk) 16. HRQoL
was measured at baseline, 2, 4, 8, 12 and 16 wks using SF-
36v2 and FACIT-Fatigue. At wk 16, all patients treated
with secukinumab combined were categorized into 4
groups based on their ACR-N scores (\20, 20–49, 50–69,
and C70). Analysis of variance methods were used to
evaluate differences in mean changes in HRQoL scores
from baseline to wk 16 across the 4 groups of patients.
Results: Nearly one-half (45%) of all patients treated with
secukinumab achieved ACR 20 response, while 18 and
5% of patients reached ACR 50 and ACR 70, respectively.
Statistically significant and clinically meaningful
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improvement in HRQoL scores were observed across all
SF-36v2 and FACIT-Fatigue scales among patients who
achieved ACR 20. Mean SF-36v2 and FACIT-Fatigue
scores improved incrementally across the ACR-N
categories. Among patients who were assigned to ACR-
N category 20–49, mean score improvement ranged
from 2.2 to 7.5 points across SF-36v2 and FACIT-Fatigue
scales. Mean score improvement ranged from 3.4 to 10.0
points across SF-36v2 and FACIT-Fatigue scales among
patients assigned to the ACR-N 50–69 category. Lastly,
mean score improvement ranged from 8.8 to 16.3 points
across SF-36v2 and FACIT-Fatigue scales among patients
assigned to the ACR-N C70 category. Patients in the
ACR-N category of \20 showed no significant
improvement in HRQoL scores.
Conclusion: In patients on secukinumab with greater
ACR responses there were associated relevant benefits in
patients’ overall physical, social, role functioning and
psychological well-being.
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Sex differences in health-related quality of life
in patients with moderate to severe psoriasis
Cather, Jennifer C.1; Horn, Elizabeth J.2;
Sundaram, Murali3; Yang, Min4; Farooqui, Saif4;
Mulani, Parvez M.3
1Modern Dermatology, a Baylor Health Texas Affiliate,
and Modern Research Associates, Dallas, Texas, USA;
2Modern Research Associates, Dallas, Texas, USA;
3Abbott Laboratories, Global Health Economics and
Outcomes Research, Abbott Park, IL, USA; 4Analysis
Group, Inc., Boston, MA, USA
Aims: To evaluate sex differences in health-related
quality of life (HRQOL) in patients with moderate to
severe psoriasis.
Methods: Baseline assessments of the Dermatology Life
Quality Index (DLQI), the Short Form 36 Health Survey
Mental and Physical Component Summary scores (MCS
and PCS), and the Work Productivity and Activity
Impairment Questionnaire were assessed using data
from REVEAL (Randomized Controlled EValuation of
Adalimumab Every Other Week Dosing in Moderate to
Severe Psoriasis TriAL) regarding adalimumab use by
patients with moderate to severe psoriasis. Scores were
compared for men versus women overall and for women
by age quartiles (B32, 32–44, 45–54, and[54 years).
Results: Female patients (n = 408) had significantly
(P\0.05) worse mean (±SD) scores than male patients
(n = 802) for DLQI (12.9 ± 6.9 vs. 10.6 ± 6.5), MCS
(45.7 ± 11.9 vs. 48.4 ± 10.9), PCS (48.1 ± 10.5 vs.
48.4 ± 10.9), presenteeism (20.5 ± 24.2% vs.
16.6 ± 22.5%), total work productivity impairment
(21.8 ± 25.5% vs. 17.0 ± 23.3%), and total activity
impairment (32.3 ± 30.4% vs. 24.0 ± 26.0%). Women
in the youngest versus oldest age quartiles had
significantly (P\0.05) worse DLQI (14.0 vs. 11.3) and
MCS (42.9 vs. 48.0) but significantly better PCS (50.7 vs.
43.6).
Conclusions: Female patients with moderate to severe
psoriasis had significantly greater HRQOL and work
productivity impairment compared with male patients.
Whereas dermatologic and mental HRQOL were
significantly more impaired among younger versus
older female patients, physical HRQOL was
significantly less impaired among younger versus older
female patients.
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Colors of psoriasis: the lived experiences of middle
aged adults with moderate to severe psoriasis
Bustos, John Patrick1; Burgos, Gem Angeli2; Burgos,
Mikaela3; Butic, Kiel Lara4; Caballes, Ana Angela5;
Caboboy, Jessica Louise6; Maravilla, Susan2
1University of Santo Tomas, Manila, Nursing, 8 Paseo
De Eduardo, Villa Angela, Angeles city, Pampanga,
Angeles city, Philippines; 2University of Santo Tomas,
Manila, Nursing, Manila, Philippines; 3University of
Santo Tomas, Manila, Nursing, Novaliches,
Philippines; 4University of Santo Tomas, Manila,
Nursing, Ifugao, Philippines; 5University of Santo
Tomas, Manila, Nursing, Rizal, Philippines; 6University
of Santo Tomas, Manila, Nursing, Quezon, Philippines
This study aims to explore and expound the
understanding about the lived experiences of middle
aged adults with psoriasis. Specifically, this study seeks
to discover the individual perception of the illness, the
hindrances and limitations imposed by the illness and
the variety of coping mechanisms employed by the
afflicted population. Exploring these areas will
eventually lead to a more extensive understanding of
their meaning of quality of life and thriving with
psoriasis. With this understanding, an improved
approach of holistic care may be given to these middle
aged adults with moderate to severe psoriasis whilst
considering the various aspects of health and not just
limited to the physical facet.
Purposeful or judgmental sampling and the convenience
sampling methods were employed in selecting the
participants. The gathered data were recorded,
transcribed and presented to the interviewed
respondents for validation. The written transcription
was then analyzed and examined to formulate codes to
describe the verbal statements of the participants. These
level I codes were examined and analyzed by the
researchers. Subsequently, these initial codes with
similar implications were put into same groups, thus,
formulating clusters of codes called level II codes. Then
finally, these clusters were then examined and analyzed
to formulate the emerging themes or the level III codes.
The themes derived were: Suffering, Seeking and
Accepting. There are different adversities arising from
having psoriasis as experienced by the respondents. These
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have great impact on them physically, emotionally,
psychologically, socially, and financially. Nevertheless,
the respondents exhibit the will to be accepted by the
public and their families and to rise beyond the
limitations imposed by psoriasis. With all the learning
they have acquired in encountering this disease, they
continue to struggle for freedom and acceptance and
overcome all the challenges stringed with this illness in
order to attain a meaningful life with psoriasis.
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The global challenge of stigmatization
and discrimination for people with psoriasis:
Preliminary results of a survey carried
out by the International Federation of Psoriasis
Associations and 15 national member associations
Bohannan, Barbra1; Gallant, Kathleen2
1IFPA, Stockholm, Sweden; 2IFPA Executive
Committee/Chair of IFPA Task Force on NCDs
Committee, Pittsburgh, USA
Background: Psoriasis is a chronic, inflammatory disease,
affecting approximately three per cent of the world’s
population. Due to its highly visual and, in severe cases,
even disfiguring nature, psoriasis can place a large
psychosocial burden on its sufferers.
Aim: This survey was carried out by IFPA and 15 of its
member associations to investigate and map how stigma
and discrimination affect people with psoriasis in
different parts of the world, and also in which areas of
society these problems most frequently occur.
Method: The questionnaire was supplied by IFPA in 2011
to its member associations. The questionnaire contained
questions on whether or not the respondent had ever
experienced stigmatization and/or discrimination and, if
so, in what areas of society. Areas given were school,
work, family and social relations, and amenities.
Multiple choices were possible.
Results: The total number of respondents to the survey
was 5,176. The preliminary results show that of the
respondents to the question on stigmatization
(N = 5,167) 77% answered that they have experienced
stigmatization. For the respondents to the question on
discrimination (N = 5,137), the share is at 65%. The
areas where the respondents reported experiencing
stigmatization were primarily at work (36.5% of total),
followed by amenities (21%) and school (20.5%); for
discrimination: at work (45%), followed by school and
amenities (19% respectively). These results confirm that
a majority of people with psoriasis at some time suffer
from the difficult social problems of stigmatization and
discrimination, and also indicate within which areas of
society the need for preventive measures is the greatest.
*Participating IFPA members: Argentina, Belgium,
Canada, China, Czech Republic, Denmark, Finland,
Israel, Mexico, Norway, Slovakia, South Africa, Spain,
Sweden, Singapore.
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Psoriasis uncovered: the results of two quantitative
surveys of psoriasis patients in Australia
Baker, Christopher; Foley, Peter; Braue, Anna
Skin and Cancer Foundation Inc, Carlton, Australia
Background: Psoriasis is a multifaceted, systemic chronic
inflammatory skin disease that affects 1–3% of the
world’s population and a similar prevalence in
Australia. However, data measuring the impact of
psoriasis on Australians is lacking.
Method: Two national quantitative surveys were
conducted during 2010 and 2011 among adult
Australian psoriasis patients. The 2010 survey assessed
medical and physical symptoms; life consequences; and
psychosocial impact, while 2011 survey evaluated
comorbidities; satisfaction with treatment; cost of
treatment; health care resource utilisation; and impact
on domains of Health Related Quality of Life (HRQoL).
Results: Thirty-seven percent of patients described their
psoriasis as severe, unstable, deteriorating or rapidly
deteriorating, with 43% experiencing flare-ups daily.
The majority (73%) reported hiding their disease due to
feelings of embarrassment and stigmatisation. Psoriasis
affected perceptions of sexual attractiveness and resulted
in reduced desire for sexual intimacy. Patients’ mood
changes during flare-ups adversely affected their general
health, well-being and personal relationships. Treatment
with phototherapy and injectable medications provided
highest patient satisfaction. Commonly reported
concomitant medical conditions—including joint pain
(46%) weight problems (46%) stress (44%) fatigue (37%)
depression (32%) and anxiety (31%)—were not treated
in most cases. Approximately one-third (34%) of
patients with psoriatic arthritis (prevalence: 28%)
reported they were not being not treated for their
condition.
Conclusions: Survey results confirm that psoriasis greatly
affects personal relationships and general well-being,
with concomitant conditions often left untreated. This
suggests that management strategies must account for
the disease’s emotional and social impact as well as its
physical manifestations. Non-pharmacological therapies
such as education, cognitive intervention and
psychological support may be worthwhile adjunctive
therapies.
Acknowledgement: This study was conducted in
consultation with the patient representative group
Psoriasis Australia.




Erectile dysfunction: a rare side effect
of methotrexate
Yayli, Savaþ; Akþan, Burak; Aksu Ary´ca, Deniz;
Bahady´r, Sevgi
Karadeniz Technical University School of Medicine,
Department of Dermatology, Trabzon, Turkey
Methotrexate (MTX) is widely used for severe chronic
plaquepsoriasis.The mostcommonside-effectsofMTXare
hair loss, nausea, fatigue, vomiting, and transaminase
increase. We report a psoriasis patient with recent onset
erectile dysfunction while he was on MTX therapy.
Patient: A 39-year-old man with 10-years history of
chronic plaque psoriasis was examined for regular
follow-up. He was on weekly oral MTX therapy for
4 months. The current dose was 15 mg/week. On
examination, he had no psoriatic lesions. His actual
complaint was a 2-week history of impotence without
any loss of libido. He had no similar problems before,
and no other relevant systemic diseases such as diabetes
or medications. All blood parameters were normal for
regular control of MTX.
We discontinued MTX, and started low-dose
cyclosporine therapy. Within 3 weeks, there was no
sign of erectile dysfunction.
Discussion: Reduced libido and erectile dysfunction due
directly to MTX was reported in very few numbers of
case reports. However, reduced libido, defective
spermatogenesis, and infertility, with the onset of
within days to months are among the side-effects of
MTX which manufacturers list.
Although the exact mechanism is not known, it has
been shown that MTX blocks the activity of interleukin-
1 and interleukin-2 which influence pituitary hormone
secretion including prolactin. MTX may also show an
inhibitory effect on the production of nitric oxide with
reduced activity against vascular smooth muscle. The
side effects on sexual functions may be easily forgotten
due to many common adverse effects of the drug at the
management of the patients on MTX therapy. Clinicians
should keep in mind this rare side effect of the drug for
their patients currently on that therapy.
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Anti-TNF-alpha treatment in a psoriatic patient
with concurrent HCV infection
Santos Paim de Oliveira, Maria de Fa´tima1;
de Oliveira Rocha, Bruno2; Follador, Ivonise2;
Pedreira de Almeida Reˆgo, Vito´ria Regina2
1Federal University of Bahia, Dermatology, Augusto
Viana Street, Canela, Salvador, Brazil; 2Federal
University of Bahia, Dermatology, Salvador, Brazil
Background: Treatment of psoriasis with concurrent
hepatitis C is a major challenge, since most of systemic
treatments are potentially hepatotoxic/
immunosuppressants and the treatment for HCV tends
to worse psoriasis. We report a case of a patient with
hepatitis C, psoriasis and psoriatic arthritis (PsA)
successfully treated with anti-TNF-alpha agents.
Case Report: A 72-years-old man with psoriasis since
1983, PsA since 2002 and hepatitis C since 2004 was
referred to our outpatient service. Liver biopsy revealed
moderate chronic hepatitis with moderate fibrosis, mild
activity, without cirrhosis (Metavir A1F3). AST and ALT
was respectively 318 and 335 IU/mL. Viral load was
199,277 IU/mL. His PASI was 16.5 and it had already
been tried all the topical treatments available, so we
started nbUVB. His hepatologist started antiviral
treatment (pegylated IFN/ribavirin) which was not
successful (viral load of 2,343,289 IU/mL after
6 months), and he had worsening of arthritis and skin
lesions. We decided to start treatment with infliximab. He
experienced a complete improvement of psoriasis/PsA.
After 2 years, due to recurrence of the lesions, we opted to
switch infliximab for etanercept. Currently, the patient is
in his 3rd year of treatment with etanercept, and in the 5th
year with anti-TNF-alpha therapy, without skin lesions and
joint pain. Complementary examination showed no
significant changes (AST = 42 IU/mL, ALT = 53 IU/mL
and viral load of 3,215,440 IU/mL) and it was not
reported any side effects.
Discussion: Immunobiologicals agents have been referred
as a safe option for treating psoriatic patients infected by
HCV. A recent trial conducted by Zein et al.
demonstrated that etanercept is effective, safe and well
tolerated in those ones. There are also many case reports
suggesting that both etanercept and infliximab are
effective/safe in these patients, at the recommended
doses for healthy ones. The refractory to other
treatments and these data encouraged us to try anti-
TNF-alpha therapy in our patient. However, one should
be aware that current evidence does not allow us to
affirm the long-term safety profile of these drugs in
patients with chronic HCV infection.
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Tinea capitis in two sisters of a ‘‘wooly hair’’ family
Ozyurt, Kemal; Ozturk, Perihan; Karakas, Tugba;
Dokur, Neslihan
KSU Medicine Faculty, Dermatology, Kahramanmaras,
Turkey
Wooly hair is a hereditary condition, usually presented at
birth or infancy. This condition occurs with a genetic
linkage of autosomal dominant or recessive, in which there
are curly, thick, often heavily pigmented hairs.
Microscopically, the hairs are tightly coiled. The condition
have been reported with eye, teeth, cardiac anomalies,
keratosis pilaris atrophicans, ihtiyosis and deafness,
palmoplantar keratoderma and Noonan syndrome.
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We report two sisters with wooly hair. They preferred to
our clinic at the same time with the same complaints.
Engrossingly, both patients simultaneously developed
an inflammatory tinea capitis. Our patients have neither
a systemic disease nor eye, dental and other skin
disorders. In their family, their mother and two sisters
and one brother have also wooly hair without any other
clinical associations.
To our knowledge, this is the second, describes the
association of wooly hair with Tinea capitis. However, in
the first report, patients also had other clinical disorders. As
a result, we think, presence of tinea capitis in both patients
may be explained by the enhanced susceptibility to fungal
infection in keratinizing disorders.
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Concurrent of progressive macular hypomelanosis
and port-wine stain nevus in the same patient
Ozturk, Perihan; Ozyurt, Kemal; Dokur, Neslihan
KSU Medicine Faculty, Dermatology, Kahramanmaras,
Turkey
Progressivemacularhypomelanosis isanunder-recognized
disorder characterized by the presence of numerous ill-
defined hypopigmented macules and patches on the trunk
of young adults. Although being a common condition,
particularly in Fitzpatrick skin types IV-VI, frequently
misdiagnosed and treated inadequately with antifungals
or topical steroids without any benefit. Port-wine stains
result from a progressive ectasia of the cutaneous
superficial vascular plexus. This type of birthmark is
commonly seen on the face, arms or legs but can also
affect other parts of the body. Although not fatal, the
psychological impact of having a port wine stain can leave
a person shying away from the crowd because of their
unique appearance. No case report has been published,
simultaneously of both disease in the same person. We
report a 25-year-old healthy male, who presented with
slowly progressive asymptomatic multiple hypopigmente
macules and red lesions on different upper limb.
Examination showed erythematous indurated macules
and nodules on his left upper limb and several
hypopigmente macules on his right upper limb.
Histopathological examination of hypopigmented tissue
biopsy showed progeressive macular hypomelanosis. This
case was presented because of he was first in literature.
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A case of multiple cutaneous leismaniasis cured
with intramuscular sodium stibogluconate
Ozturk, Perihan; Ozyurt, Kemal; Dokur, Neslihan;
Karakas, Tugba
KSU Medicine Faculty, Dermatology, Kahramanmaras,
Turkey
Leishmaniasis is a clinically heterogeneous group of
diseases, caused by infection with protozoa of the genus
Leishmania. Usually lesions are solitary, rarely may be
multiple. We report a 44-year-old healty male, resident of
Eastern Mediterranean Region of Turkey, who presented
with slowly progressive asymptomatic multiple red lesions
on different parts of body. Examination showed 15 crusted
erythematous indurated plaques and nodules over
forearms, left leg, right index finger, left wrist and
dorsum of both feet. Histopathological examination of
tissue biopsy showed multiple intracellular as well as
extracellular leishmania donovan bodies. We treated this
patient with intramuscular Sodium Stibogluconate
750 mg per day for a period of 15 days and the lesions
showed complete resolution over 2 months of therapy.
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Successful treatment of a paradoxical palmoplantar
pustulosis with ustekinumab in a patient
with psoriatic arthritis
Morales Mu´nera, Caridad Elena1; Lo´pez Ferrer, Anna2;
Puig Sanz, Lluis2
1Hospital de la Santa Creu i Sant Pau, Dermatology,
Sant Antoni Maria Claret 167, Barcelona, Spain;
2Hospital de la Santa Creu i Sant Pau, Dermatology,
Barcelona, Spain
The anti-TNFs are monoclonal antibodies that are used in
the treatment of moderate and severe psoriasis.
Paradoxically, there have been reported hundreds of
dermatological side effects such as eczema, lymphomatoid
papulosis, erythema multiforme, lichenoid reactions and
onset of psoriasis or worsening of a previous psoriasis.
We report the case of a 47-year-old woman with a 5 years
history of psoriatic arthritis that had been treated with
NSAID, methotrexate and prednisone. One year later,
cutaneous psoriasis was diagnosed and treated with
topical calcipotriol-bethametasone.
Because of worsening of rheumatologic symptoms her
rheumatologist decided to start adalimumab 40 mg each
2 weeks. One year later, the patient was sent to our
dermatology clinics because of the recent onset of
pustules and vesicles in palms and soles, which spread
to the trunk and the legs two weeks later. The decision to
stop adalimumab was made due to the possibility of a
paradoxical pustular psoriasis and we started
Ustekinumab 45 mg each 12 weeks. Three months later
cutaneous and rheumatologic symptoms were clearly
reduced and 1 year later the patient continues with a
good response.
Palmoplantar pustulosis (PPP) is a challenging disease for
dermatologists for which no therapeutic standard has been
defined yet, either when this is associated to an anti-TNF
treatment. Until now, several paradoxical reactions to anti-
TNF treatment have been reported, and there is not an
standarized treatment to follow. In our case, we decided to
stop adalimumab to begun ustekinumab. There was good
response since week 10 and complete clearence of the
Dermatol Ther (2012) 2:10 Page S63 of S67
123
patient at week16. Nowadays,ustekinumab is not autorized
to be used in psoriatic arthritis but several successful cases
have been described. In a phase II trial, the use of
ustekinumab versus placebo has been compared. The
primary endpoint was ACR20 at week 12, achieved by
42% of patients treated with ustekinumab and 14% of
patients with placebo. These data opens to the clinics the
oportunity to use ustekinumab in psoriatic arthritis, but
phase III trialareneededtoconfirmthephase II trials results.
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Annular pustular psoriasis in a patient
with pemphigus foliaceus
Kato, Kenichi; Tatsumi, Motohiro; Takahashi, Yuji;
Yamanaka, Takashi
Kansai Rosai Hospital, Department of Dermatology,
Amagasaki city, Hyogo Prefecture, Japan
Annular pustular psoriasis (APP) is a rare form of psoriasis,
characterized by gyrate, annular, or polycyclic lesions with
an erythematous, scaly, pustular margin. Many cases of
APP have followed benign, low graded, subacute or chronic
course. Herein, we report a severe case of APP in a patient
with pemphigus foliates. A 56-year-old woman with a
history of psoriasis vulgaris and pemphigus foliaceus was
admitted to our hospital because of erythema on her trunk,
fever, and nausea. The fever was 40 C, systolic blood
pressure was 70 mmHg and she couldn’t eat and drink.
Some anuular and linear erythemas were localized on her
trunk. Histological examination revealed the typical
features of pustular psoriasis, consisting of the large
spongiform pustules with the migration of neutrophils,
parakeratosis and elongation of the rete ridge. She was
diagnosed with APP from the characteristic eruptions, the
result of biopsy and the other examinations. The annular
erythema locally spread outerward and gradually spread to
extremities, neck and face with a normal appearance in
their centers, and macular scales developed on their
margins. The skin lesions were much improved by
systemic etretinate (40 mg/day), cyclosporine (200 mg/
day)and topical steroid ointment within2 weeks. Whereas
there are many case reports of psoriasis vulgaris with
pemphigoid, but to our knowledge, no previous reports of
APP withpemphigus foliaceus.This is thefirst reportofAPP
in a patient with pemphigus foliaceus.
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Psoriatic arthritis and Degos diseases: a clinical case
Iandoli, Raffaele
S. G. Moscati Hospital, Dermatology, Avellino, Italy.
We report the clinical and histopathologic features of
Degos’ disease in a patient also affected by psoriatic
arthritis and hepatitis B. The patient was admitted to the
Hospital for the occurrence of erythematous papules
evolving in central necrosis, followed by scleroatrophic
lesions with depressed and porcellaneous aspect. The
result of hystological studies were in agreement with the
suspected Degos disease (DD). This disease is also known
as malignant atrophic papulosis or Kohlmeier-Degos-
Delort-Tricort syndrome. It was described by Kohlmeier
and Degos in 1941 and afterward recognized as a distinct
entity (1). The disease has genetic etiology with
autosomal dominant inheritance and is characterized
by multiple porcelain white atrophic papules, infarctive
lesions surrounded by telangiectatic borders, intestinal
haemorrhage, pleural effusion. May also be involved the
CNS and occasionally other structures. Variants of DD
with only cutaneous involvement and associated with
collagen vascular disease have been reported. Degos
disease has young/adult onset and male prevalence. The
gene mutation is unknown (2).
References: 1) Black MM. Malignant atrophic papulosis
(Degos disease). Int J Dermatol 1976;5:405–411. 2)
Mendelian Inheritance in Man (OMIM 602248).
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Coexisting of psoriasis and lupus erythematosus:
a diagnostic and therapeutic challenges
Elsherif, Nadia A1; Elmatardi, Marada A1;
Eldahumi, Ahlam S2; Elmangush, Ibtisam M1
1Benghazi university, dermatology department,
Benghazi, Libyan Arab Jamahiriya; 2Jamhoria hospital,
dermatology department, Benghazi, Libyan Arab
Jamahiriya
A large number of auto-immune diseases associated with
either lupus erythematosus (LE) or psoriasis have been
reported, and LE patient may develop skin lesions of
subacute lupus erythematosus which are clinically similar
to psoriasis. However, the coexistence of these two diseases
is uncommon and may be explained by immunological
factors or trauma. Here, we report five patients suffering
from both lupus erythematosus and psoriasis. The
coexistence of these two diseases causes difficulty in
choosing the right treatment as phototherapy, which is a
prime therapeutic option in psoriasis, may exacerbate
lupus erythematosus. On the other hand, antimalarial
drugs used in the treatment of LE are responsible for
psoriatic flares. Dermatologist and rheumatologist should
be aware of such association with regard of the diagnosis
and choosing the appropriated treatment.
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Successful treatment of a patient
with undifferentiated connective tissue disease
and psoriasis with ustekinumab
Brown-Maher, Tracey; Astani, Roxanna;
Gulliver, Wayne
Memorial University of Newfoundland, Faculty of
Medicine, St. John’s, NL, Canada
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There are few reports of patients having both psoriasis
and CTD (connective tissue disease). Lupus is most
frequently described. Treating both may present a
challenge, as some treatments for psoriasis may flare
CTD (i.e. phototherapy), and some treatments for
psoriasis may associate with an onset or flare of CTD
(TNF-alpha antagonists). Recently the IL17/23 axis has
been reported to play a role in the pathogenesis of lupus.
It is postulated that IL-23 and IL-23R are necessary for
expansion of pathogenic IL-17-producing T
lymphocytes. Increased levels of IL-23 and IL-17 have
been noted in patients with SLE, and IL-17 is increased
in patients with DLE, SCLE, and SLE.
Ustekinumabisamonoclonalantibodythat targets Il-12/IL-
23 and has been shown to reduce inflammatory activity and
signs and symptoms of psoriasis. It has been approved to
treat psoriasis in Canada since 2008. There has been one
recent case report of ustekinumab being used to treat
subacute cutaneous lupus. We present an additional case of
a 20 year-old female with refractory undifferentiated
connective tissue disease and psoriasis that has responded
to ustekinumab in combination with hydroxychloroquine,
mycophenolate mofetil, and prednisone. She had failed
methotrexate in the past and developed cyclosporine
toxicity requiring hospitalization just prior to the addition
of ustekinumab. Ustekinumab has allowed tapering of
prednisone and mycophenolate mofetil. It has improved
not only her cutaneous and systemic signs of SCLE
(subacute cutaneous lupus) including arthritis, headaches,
fatigue, and mood. Also significant improvement in many
aspects of her psoriasis has been approved with a decrease in
DLQI from 15 to 0, %BSA from 10 to 0 and PASI from 5.4 to
0. Prednisone dose has been tapered from 40 mg to 5 mg
and mycophenolate mofetil dose decreased to 1,500 mg
from 1,750 mg.
Ustekinumab should be considered as a viable
alternative treatment for connective tissue disease that
is refractory to conventional management, especially in
the setting of co-existent psoriasis.
Health economics and health policies
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Cost of psoriasis and psoriatic arthritis in Denmark
Sætterstrøm, Bjørn1; Gniadecki, Robert2; Kragballe,
Knud3; Zachariae, Claus4; Lindkvist, Rose-Marie5;
Qvitzau, Susanne6; Olsen, Jens1
1University of Southern Denmark, Centre for Applied
Health Services Research and Technology Assessment
(CAST), Odense, Denmark; 2Bispebjerg Hospital,
Department of Dermatology, Copenhagen, Denmark;
3Aarhus University Hospital, Department of
Dermatology, Aarhus, Denmark; 4Gentofte Hospital,
Department of Dermatology, Copenhagen, Denmark;
5Pfizer, Medical and Access, Ballerup, Denmark; 6Pfizer,
Medical, Ballerup, Denmark
Introduction: Few studies have analysed the costs of
psoriasis and psoriatic arthritis to society. The purpose of
this study is to estimate the societal costs of psoriasis and
psoriatic arthritis in Denmark.
Methods: The study was set up as a register-based study
applying data from Danish registers which hold
exhaustive and detailed registrations on citizens’ use of
healthcare, medicine, socio-demographics etc. Patients
with psoriasis and/or psoriatic arthritis were identified
both in the National Patient register using ICD10-codes
and in the Register of Medicinal Product Statistics ([1
purchase of calcipotriol or betamethason/calcipotriol).
The difference in healthcare costs (i.e. costs in the
primary and secondary health care sector and use of
prescribed medicine) and loss of productivity between
the cohort of patients with psoriasis/psoriatic arthritis
and a matched cohort free of psoriasis/psoriatic arthritis
was regarded as attributable to the disease. Costs to non-
prescribed medicine are not included.
Results: Given the applied approach a total of 66,564
patients were identified. Overall, the total average
healthcare costs per patient was estimated to EUR 214
(mild), EUR 1,014 (moderate) and EUR 1,873 (severe) per
year corresponding to EUR 32.6 mill. per year in
Denmark. Prescribed medicine constitute
approximately 26% of these costs.
We found no loss of productivity attributable to
psoriasis/psoriatic arthritis for mild disease. However,
we found a significant loss of productivity attributable to
psoriasis/psoriatic arthritis of EUR 440 per year for
moderate and EUR 1,097 per year for severe disease
corresponding to EUR 9.3 mill. per year. Adjusting for
confounders, the yearly increase in individual gross
income did not differ significantly for patients with
psoriasis compared to matched controls in the labour
market.
Conclusion: The total costs per psoriasis/psoriatic arthritis
patient per year are moderate. However, given the
relative large number of patients the total costs to
society amount to a notable cost level.
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One-year cost-efectiveness analysis of etanercept
versus adalimumab for moderate-to-severe plaque
psoriasis
Ruano, Juan1; Isla-Tejera, Beatriz2; Jime´nez-Puya,
Rafael1; Ca´rdenas, Manuel2; Go´mez, Francisco1; Velez
Garcia-Nieto, Antonio1; Del Prado-Llergo, Jose-
Ramo´n2; Moreno-Gime´nez, Jose-Carlos1
1Reina Sofı´a University Hospital, Department of
Dermatology, Co´rdoba, Spain; 2Reina Sofı´a University
Hospital, Department of Pharmacy, Co´rdoba, Spain
Purpose: Biologic therapy has become established as an
expensive treatment option in patients with moderate to
severe psoriasis. Relatively little is known about the total
healthcare cost of treating severe psoriasis with these
drugs in daily clinical practice. The aim of this analysis
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was to compare the incremental cost effectiveness, from
a societal perspective, of etanercept versus adalimumab
in patients with moderate to severe psoriasis without
associated arthritis attending a reference hospital in
Spain.
Methods: Cost-effectiveness analysis was performed on a
sequential historical cohort of psoriasic patients
attending a tertiary referral severe psoriasis service from
2005 to 2010. Data on hospital resource use (doses,
intervals, concomitant treatments, inpatient/outpatient
unitary costs, emergency visits, diagnosis hospital
resources), drug usage (systemic nonbiologic and biologic
psoriasis therapies and supportive drugs), and patient’s
travel expenses and costs of lost productive work time were
extracted from patients’ digital histories. Hospital resource
use and drug usage (systemic nonbiologic and biologic
psoriasis therapies and supportive drugs) were collected for
a variablepatient-centered periodof time frominitiationof
biologic therapy till the date of drug discontinuation.
Effectiveness was measured using the Psoriasis Area and
Severity Index (PASI) achieved after 52th-weeks of
treatment. Direct and indirect cost analysis, from a
societal perspective, were performed. Differences in
resource use and associated costs and outcomes were
tested using Kruskall–Wallis test for quantitative variables
and the X2 with Yates correction for categorical variables.
Results: The primary analysis population comprised 138
patients for etanercept group and 28 patients for
adalimumab group. No statistical differences were
observed for efficacy nor drug-associated and total
healthcare costs between both drugs.
Conclusion: Under the conditions of daily clinical
practice in our hospital, treatment of moderate-severe
psoriasis with etanercept appear to be as cost-effective as
with adalimumab in the first year of treatment.
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Impact of psoriasis on work performance
Mattila, Kalle1; Leino, Mauri1; Koulu, Leena1;
Tuominen, Risto2
1University Hospital, Turku, Dermatology, Turku,
Finland; 2University of Turku, Department of Public
Health, Turku, Finland
Objectives: The aim of the study was to evaluate the
disadvantages in work caused by psoriasis.
Materials and methods: The sample was based on patients
visiting the dermatology outpatient clinic in Turku
University Hospital. Out of 498 patients with moderate
or severe psoriasis who attended the clinic during the
period 1.10.2009–30.9.2010, 262 (52.6%) returned a
mailed questionnaire. The subjects were asked how
many hours they were on a sick leave (absenteeism)
and working while sick (presenteeism) due to
(a) psoriasis and (b) other health reasons during the
last 4 weeks. They were also asked to list all work tasks
negatively affected and job modifications due to
psoriasis. The patients assessed their ability to perform
in their daily work using visual analogue scale of 0–100.
They were asked to assess their ability to perform at
work with psoriasis at the time of the questionnaire
and estimate their expected performance in a
hypothetical situation if they did not have psoriasis.
The differences between the scores with and without
psoriasis depicted the level of disadvantage at work
caused by psoriasis.
Results: Of the retired (48.9% of the sample), 17.0% felt
they were retired due to psoriasis. Those in active work
force (51.1% of the sample) reported on average 4.5 h
absenteeism and 8.3 h of presenteeism because of
psoriasis during the last 4 weeks. Psoriasis caused
27.0% of the total absenteeism and 39.0% of
presenteeism. The most frequently mentioned work
tasks negatively affected by psoriasis were connected to
cosmetic or mental aspect of work, e.g. face-to-face
customer contacts. More than a quarter (28.9%) had
been forced to modify their work due to psoriasis, most
frequently to make the work less irritating for the skin.
The average disadvantage score was 15. There was a
significant (p\0.05) correlation (r = 0.253) between
sick leave days and presenteeism and also (p\0.01)
with perceived disadvantage and presenteeism
(r = 0.345). Almost half (48.2%) of workers reported
that psoriasis did not affect their performance in work at
all.
Conclusion: Psoriasis has a significant, though moderate,
adverse effect on the working life of patients.
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Important of psoriasis severity index
in social-medical expertise
Chijavadze, Nino1; Tsagareishvili, Konstantine2;
Datuashvili, Maia1
1Psoriasis Association of Georgia: PSO Georgia,
Dermatology, Kutaisi, Georgia; 2Psoriasis Association of
Georgia—PSO Georgia, Kutaisi, Georgia
Clinical severity of psoriasis and patient’s disability
status isn’t evaluated with international criteria for
assessment of this disorder in Georgia. The aim of our
study was to conduct the repeated social-medical
expertise for objective assessment of psoriasis clinical
severity among patients with this dermatosis in Western
Georgia. There were recalled 37 patients with diagnosis
of ‘‘generalized psoriasis’’ who had given status of
important disability before. Commission assessed
patients with PASI, BSA, DLQI, there was taken into
consideration severe forms of psoriasis, location of
eruption, psoriatic arthritis, comorbidity, psychosocial
condition, effectiveness of conducted therapy. On based
of the received data 24 (65%) patients were kept the
status of disability (I group), 13 (35%), were withdrawn
this one (II group).
In first group PASI was ranged from 17 to 72 and BSA
from 10 to 100%. Erythrodermy was revealed in 3 (12%)
patients, eruption on face -12 (50%), on genital organs
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7 (29%), psoriatic arthritis -9 (37%), nail injury -17
(71%). DLQI was ranged from 19 to 30.
In second group PASI was ranged from 0.9 to 3.9. BSA
wasn’t more than 10%, erythrodermy—0, arthralgia—8
(61.5%), psoriatic arthritis—0, nail injury—8 (61, 5%).
DLQI was ranged from 13 to 23. Unfortunately 50%
from both groups were treated with steroids, 40%—with
alternative medicine. Only 8% was treated adequately
(PUVA, retinoids, cytostatics).
The social-medical expertise revealed the necessity of
international criteria for assessment of clinical severity
of psoriasis not only for monitoring of effectiveness of
conducted therapy but also for identify of degree of
patient’s disability status.
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Studying the calcium serum level in patients
suffering from psoriasis
Goldust, Mohamad
Tabriz University of medical sciences, Tabriz, Islamic
Republic of Iran
Objective: The recent success of vitamin D and its
analogues in the treatment of psoriasis has generated
extensive research into the role of vitamin D and
calcium in this hyperproliferative skin disease. This
study aimed at studying the calcium serum level in
patients suffering from psoriasis.
Methods: In this case control study, 98 hospitalized cases
with psoriasis were compared with 100 patients who
were hospitalized due to other diseases. Two groups were
matched for age and gender. The type of psoriasis, age
and sex of patients and serum calcium and albumin
levels in two groups were documented in a especial
questionnaire.
Results: Of all 98 patients with psoriasis, 37.2% were
hypocalcemic and 63.7% had normal serum calcium.
There was no hypercalcemia. In other group 9% were
hypocalcemic, 89 and 2% were normocalcemic and
hypercalcemic respectively. In 64.9% of hypocalcemic
psoriatic patients, low serum albumin was noted. But all
of control group had normal levels.
Conclusion: Hypocalcemia is a risk factor of psoriasis. It is
better to include dairy as calcium resource in daily diet
of patients suffering from psoriasis.
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